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Zebrafish, Danio Rerio as a Replacement
Alternative Model Useful in CKDu
Experiments
Mangala Gunatilake(&)
Faculty of Medicine, Department of Physiology, University of Colombo,
Colombo, Sri Lanka
mangalagunatilake@hotmail.com
Abstract. Zebrafish (Danio rerio) and its embryo has become a popular
replacement alternative among the scientists because of many scientific attri-
butes. As it is a model commonly used in ecotoxicology, our plan is to use this
model to identify causative factors leading to chronic renal disease of unknown
origin prevailing among poor, farming communities in Sri Lanka. This paper
describes briefly the training underwent at University of Antwerp, Belgium and
how zebrafish model could be used to address an important public health issue
in Sri Lanka.
Keywords: Zebrafish  Danio rerio  Replacement alternative models
CKDu
Introduction
The Concept of Replacement Alternative
Interest of scientists has been deviating since 20th century, from the use of animals in
their experimental work towards substituting with ‘Alternatives’, thus reducing the use
of live animals in experiments. This ‘Alternative’ concept is principally the
‘Replacement’ alternative that was indicated in the book; ‘The Principles of Humane
Experimental Technique’ written by Russell and Burch in 1959. Although many
methods of replacement have been developed and used by researchers, most of these
are not absolute replacement models. As absolute replacement models should not
involve whole animals and animal tissues, in many instances models used by
researchers are relative. Relative replacement models include lower vertebrates,
invertebrates or animals having lower level of sentience and tissues, cells, sera and
embryos etc. of animal origin. These relative replacement models of course reduce or
prevent the use of conscious living vertebrates [1].
Scientific Importance of Zebrafish (Danio Rerio)
Among the accepted relative replacement models, the zebrafish (ZF) and its embryo
model have been of interest to the researchers due to its wide spectrum of scientific
applicability. ZF and its embryo have been used in diverse fields of science including
© The Author(s) 2019
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developmental biology, oncology, pharmacology, toxicology, teratology, genetics,
neurobiology, environmental sciences, stem cell research etc. [2–6]. Identification of
substances/key molecules responsible for regenerative capacity of damaged heart
muscle, retinal tissues of eyes, nerve fibers shed light for the scientists one day to focus
on new therapies for people with ischaemic heart disease, spinal cord injuries and to
combat degenerative eye disease damage in humans [7–9].
Scientific Attributes of Zebrafish
ZF, specially its embryo model has its wide acceptance and popularity as a replacement
model due to many scientific attributes such as small size of ZF, ease of maintenance,
low cost, rapid growth rate, high fecundity rate, external fertilization, optical trans-
parency of the embryo (Figs. 1 and 2), ease of genetic manipulations, high genetic
similarity to humans and regenerative capacity [2, 5].







Fig. 2. Normal Zebrafish embryo at 72 hpf. (Inverted microscope-Leica 10447137 model
10X/23, X2.0). A: Eyes, B: Otoloths, C: Heart, D: Yolk sac and its extension, E: Vertebral
coloumn
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Introduction of Zebrafish Model to Sri Lanka
Scientific benefits of ZF and its embryo was unknown to most of Sri Lankan
researchers until its introduction to Sri Lankans at the Inaugural Scientific Conference
of the Sri Lanka Association for Laboratory Animal Science (SLALAS) in January
2014 by Dr. Francois Busquet, CAAT-Europe Policy Coordinator, University of
Konstanz, Germany. ZF, which is a native species in Sri Lanka, is used as an orna-
mental fish [10]. The wild type and ZF in different colours, produced through genetic
manipulations by the breeders, are available in Sri Lankan aquaria for this purpose.
Materials and Methods
Comprehensive Training on Zebrafish Model
Transparency of the developing ZF embryo during demonstrations at the Inaugural
Conference of SLALAS was very impressive and an eye opener for most of Sri Lankan
researchers to concentrate on replacement alternatives. This created an interest for
acquisition of more knowledge and skills on ZF embryo model. Thus a 2-week
comprehensive training at the ZF lab in University of Antwerp, Belgium was possible
because of the Overseas Special Training Fellowship granted by the National Science
Foundation of Sri Lanka. The material such as ZF embryos, testing chemicals, inverted
microscopic facilities with recording of images etc. needed during training was kindly
provided by Prof. Dries Knapen, Head of the ZF lab of University of Antwerp through
the research grants secured by him.
During this 2-week training, the principal focus was on three areas.
1. Operation and daily maintenance of the ZF housing facility provided an insight in to
different housing systems; fully automated standalone, semi-automated tanking and
aquarium type housing systems that could be established in a ZF lab depending on
the financial capacities. Hands-on was possible on the frequency and method of
water quality testing for pH, temperature, salinity/conductivity and hardness of
water, which are prerequisites for reproduction, and maintenance of fish in the
tanks. It was also emphasized the need for different types of filters; chemical,
biological and UV. Maintenance of good standards improves quality of research
procedures and reproducibility of research data.
2. Daily maintenance and reproduction of ZF in practice covered nutritional require-
ments of ZF at different stages of growth, feeding patterns and need for variation in
food types. In order to use ZF embryo as a research model, knowledge on how to
facilitate spawning, collection of eggs, selection of good quality eggs are essential,
and thus practiced.
3. Standardized morphological scoring of ZF embryos and larvae as an important item
during training gave an insight in to how ZF embryo could be used for water quality
testing and acute toxicity testing of substances according to ISO 15088:2007 and
OECD guideline 236 [11–13]. Two concentrations; 600 mM and 1200 mM of
caffeine (Kofeina, 1, 3, 7-Trimethylxanthine, Sigma Aldrich) were used during
practice. When performing this test, newly fertilized ZF eggs (n = 60 per sample
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solution) in water samples different concentrations of toxic substances for a period
of 96 h (96 h post fertilization—96 hpf), with positive (3, 4-Dichlore aniline) and
negative control solutions should be incubated. Observations with an inverted
microscope at every 24 h are needed to identify the four endpoints; coagulation of
fertilized eggs, lack of somite formation, lack of detachment of the tail-bud from the
yolk sac (Figs. 3, 4 and 5), lack of heartbeat. At the end of the exposure period,
determination of acute toxicity could be done based on a positive outcome in any of
the above mentioned recorded observations leading to calculation of LC50 value.
Results
In addition to four end-points of acute toxicity test, abnormalities such as malformation of
tail, pectoral fin, yolk sac, head, eyes, otoliths, mouth and heart; pericardial and yolk sac
edema, accumulation of blood, disturbed or no blood flow in the tail; abnormal pigmen-





Fig. 3. At 72 hpf of exposure to 1200 mM of caffeine Solution. (Inverted microscope-Leica
10447137 model 10X/23, X3.0). A: Embryo is not hatched, B: Non detachment of the tail, C:
Presence of severe edema in the developing embryo and D: Lack of somite formation
Fig. 4. Coagulated embryo (Inverted microscope-Leica 10447137 model 10X/23, X1.0)
4 M. Gunatilake
movements of larvae, were also observed during this training. Necessity for adoption of a
scoring system to quantify observations for scientific presentation of data was emphasized.
When using ZF model in experimental procedures the need for ethics and welfare
aspects too need to be considered. It is accepted that ZF larvae develops the capability
in independent feeding without depending on the food supply from the yolk sac and
feeling of pain sensation around 120 hpf (Drs. An Hagenaars and Lucia Vergauwen of
Zebrafish lab, University of Antwerp- Personnel communication during training, [14]).
Therefore, the need for ethics approval for the use of ZF embryo in acute toxicity
testing does not arise.
Discussion and Conclusion
Acute toxicity test with ZF embryo as a replacement alternative has become the easiest
and most convenient test because the test could be performed within 4 days of post
fertilization (96 hpf) without breaching ethics and welfare. However, there are several
tests where ZF can be used subjected to ethics approval. ZF model has a wide spectrum
of applicability in the Sri Lankan context instead of rodents and rabbits thus the
application of 3Rs concept in the experimental procedures.
Scientific Applicability of Zebrafish Model in the Sri Lankan Context
Being a fresh water fish, ZF and its developing stages are sensitive to changes in their
immediate environment [15]. These changes could cause mortality, and also affects all
their activities and growth in developing stages. Therefore, ZF model could be used as
a replacement alternative for water quality testing in order to address one of the long-
standing problems of public health concern, ‘Chronic Kidney Disease of unknown
origin’ (CKDu) in Sri Lanka.
CKDu is said to be multifactorial in origin leading to hospitalization of over 1,100
CKDu patients per month in Sri Lanka and 300 deaths per year while the first patient
A
B
Fig. 5. At 72 hpf- Abnormal larvae. (Inverted microscope-Leica 10447137 model 10X/23,
X1.0) A: Percardial edema, B: Curved tail.
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was identified in 1994. Total number of patients in Sri Lanka exceeds 70,000. This
CKDu problem is prevailing among farming communities and it’s a condition, which is
slowly progressing and becomes irreversible. Moreover it is asymptomatic until last
stages producing mainly tubule-interstitial fibrosis and tubular atrophy as evident in
renal biopsies of affected patients [16, 17].
In this context the whole fish as well as its embryo and larvae as per OECD
guidelines 236, 203, 210 and 215 could be used to check the effect of suspected heavy
metals leading to CKDu and water samples obtained from all sources of water in the
endemic areas compared with that of non-endemic areas, as well as with laboratory
reconstituted water controls according to the following plan.
1. Collection of water samples from CKDu endemic and non-endemic areas
2. Performance of tests with
• collected water samples
• filtered water samples using specially developed filters
• suspected heavy metals in different concentrations
3. Histopathology with H&E for renal effects using the whole embryo and harvested
kidneys of adult fish.
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Testing Method Development and Validation
for in Vitro Skin Irritation Testing
(SIT) by Using Reconstructed Human
Epidermis (RhE) Skin Equivalent - EPiTRI®
Yu-Chun Lin1, Hui-Chun Hsu1, Chiu-Hsing Lin1, Cheng-Yi Wu1,
Wannhsin Chen1, and Huey-Min Lai2(&)
1 Biomedical Technology and Device Research Laboratories, Industrial
Technology Research Institute (ITRI), Hsinchu TW 300, Taiwan
2 Biomedical Technology and Device Research Laboratories, Industrial
Technology Research Institute (ITRI), Rm 207A Bldg. 13, No. 321, Sect. 2,
Kwan-Fu Road, Hsinchu TW 300, Taiwan
HMLai@itri.org.tw
Abstract. Current regulatory requirements focus on assessment of acute irri-
tation potential of chemicals and cosmetics in order to support risk management.
A trend has been changed from in vivo to in vitro testing due to 3R (replacement,
reduction, refinement) requirements has resulted from a recent animal testing
ban in Taiwan. RhE (Reconstructed human Epidermis) models use normal
human keratinocytes to form a multi-layered epidermis including a stratum
corneum at the top, which function as a barrier. Some commercialized RhEs
passed validation of skin irritation test (SIT) examined by ECVAM, but none of
them are originated from Chinese heredity. Therefore, ITRI started a RhE
project some years ago based on our long-term developed cell culture experi-
ences, such as isolation of cells from human donors, cell expansion technology,
and our own GTP/GMP qualified facilities. So far, a well differentiated and with
reproducible barrier function epidermis named EPiTRI® has been reconstructed.
We developed a protocol for EPiTRI® SIT in accordance to OECD TG 439. The
protocol displays a result of sensitivity of 100%, specificity of 70%, and
accuracy of 85% in international validation study. Thus, the human epidermal
skin equivalent EPiTRI® can be provided as an in vitro model for evaluation of
skin irritation and a reliable method has been developed accordingly.
Keywords: Reconstructed human epidermis  Skin irritation test
Validation of protocol
Introduction
Topical exposure to chemicals and cosmetic products can lead to various adverse skin
effects. Corrosion and irritation are commonly regarded as two major categories among
these adverse effects. Corrosive substances irreversibly damage the skin beyond repair,
while irritant substances lead to a reversible local inflammatory reaction caused by innate
immune system of the affected tissue. Some chemicals trigger an irritant response after
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repeated exposure to the same skin area, while other chemicals may cause irritation after a
single exposure. Current regulatory requirements focus on assessment of acute irritation
potential of chemicals and cosmetics in order to support the risk management. Data on
skin irritation effects are required by regulatory regimes for chemicals, pesticides,
pharmaceuticals and medical devices as a condition of marketing in many countries.
Internationally accepted test methods for skin irritation testing (SIT) include the
traditional in vivo animal test as well as in vitro test methods. However, there is a trend
away from in vivo to in vitro testing due to the 3R (replacement, reduction, refinement)
requirement resulted from recent cosmetic animal testing bans in Taiwan and else-
where. All accepted in vitro test methods are based on the RhE technology (Recon-
structed human Epidermis) validated by ECVAM. RhE models use normal human
keratinocytes which, during culturing, form a multi-layered epidermis including a
stratum corneum at the top and can function as a barrier. There are only few RhEs that
have been validated for SIT and approved by ECVAM. For the growing Chinese and
Asian cosmetic markets, we aimed to develop a human epidermis skin equivalent that
contains normal human epidermal structure and function derived from a Chinese
population. ITRI has started some years ago in-house based on our culture experience
of cells isolated from human donors, the cell expansion (scale up) technology, and our
own GTP/GMP facilities. So far, a multi-layered epidermis composed of well differ-
entiated stratified stratum corneum, granulosum, stratum spinosum and basal layer, and
with reproducible barrier function, was developed and used for skin irritation testing in
accordance to OECD TG 439 guideline.
In this study, we reported the progress about development of reconstructed human
epidermis (EPiTRI®) and the aim to develop the skin irritation testing protocol by using
EPiTRI® for validation. Quality control parameters for EPiTRI®, such as structure
morphology of tissue, thickness, TEER (trans-epithelium electrical resistant), and lipid
profile were investigated to study the correlation with barrier function. After obtaining
satisfactory quality control data, we conducted the validation process. During protocol
development, several important parameters were evaluated for obtaining better statistical
accuracy of data when compared with data from in vivo testing. These important
parameters include pre-incubation time, post-incubation volume, chemical exposure
time, washing method, etc. Resulting sensitivity of 100%, specificity of 70% and accu-
racy of 85% were obtained in current Phase I validation status. The study shows that the
human epidermal skin equivalent EPiTRI® could possibly provide as an in vitromodel to
evaluate the skin irritation, and a reliable SIT method has been developed accordingly.
Materials and Methods
EPiTRI® Reconstructed Human Epidermis
EPiTRI® RhE tissue was developed by Biomedical Technology and Device Research
Laboratories, ITRI (www.itri.org.tw). The tissue was a three-dimensional and fully
differentiated human epidermal skin equivalent, grown from normal human ker-
atinocytes in defined growth medium on the air liquid interface. On day 14, tissues
were transferred on nutritive agarose plates and enclosed in a temperature-controlled
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container for shipment to customers. Each experiment was performed in triplicate on
one single tissue production batch, but different batches were used for each repeated
experiment. On day 15, EPiTRI® RhE tissues were transferred in 2 mL ITRI culture
medium in 6-well plates for an 18–30 h pre-incubation step at 37 ± 1°C, 5 ± 1%
CO2.
Selection of Test Substances
Twenty test substances with diversity of functional chemical groups and physico-
chemical properties were selected according to OECD TG 439 (2015) and evaluated by
using of EPiTRI®. Details of the 20 test substances are described in Table 2. Phosphate
Buffer Saline solution (PBS) treated RhE tissues were used as negative control, Sodium
Dodecyl Sulphate (SDS 5% W/V aqueous solution) treated RhE tissues as positive
control.
Cell Viability Measurement by MTT Reduction
The MTT (3-[4,5-di-methyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was
performed to measure cell viability via converting yellow-colored MTT to blue/purple
formazan crystals by dehydrogenases of living cells [3]. Per test conditions, the three
EPiTRI® RhE tissues were incubated in 300 µL of MTT solution (1 mg MTT per
1 mL medium) for a 3-h incubation time at 37 ± 1 °C, 5 ± 1% CO2. Formazan crystal
inserts were dissolved in 2 mL isopropanol in 24-well plates for a 3-h extraction time at
room temperature.
After extraction, cell viability was analyzed by comparing the optical density of the
extracts measured at 570 nm in percentage to the negative PBS treated controls.
In Vitro Skin Irritation Test (SIT)
Step-wised protocol of SIT was shown in Fig. 1. Each test substance was applied
topically in triplicate of EPiTRI® RhE tissues. After treatment, tissues were rinsed with
PBS and incubated with fresh medium for 42 h at 37 ± 1 °C, 5 ± 1% CO2. At the end
of the incubation, cytotoxicity was determined by MTT conversion test. For each run,
the cell viability was calculated and expressed as a percentage relative of the NC.
Acceptance criteria for qualified experiment are: (1) 1.0  OD570 of NC  2.8;
(2) PC  20%; (3) SD of test substance <18%.
Fig. 1. Protocol of skin irritation test (SIT) developed by ITRI for EPiTRI®
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Prediction Model
The SIT protocol allows for prediction of skin irritation potential of test substances
according to the United Nations Globally Harmonized System of Classification and
Labeling (UN-GHS). Tissue viability that was equal or below 50% of the negative
control was used to classify the substance as “Category 2” (Irritant). Tissue viability
that was above 50% resulted in classifying the substance as “No category” (Non-
irritant).
Statistical Analysis
Mean optical density (OD) and standard deviation (SD) were determined. SD values
should be dealt carefully since ECVAM performance standards considers a test as valid
only if SD obtained from the three concurrently tested tissues is  18%. The test was
evaluated using contingency tables. Sensitivity (percent of Irritant (Category 2) sub-
stances correctly predicted in vitro), specificity (percent of No category substances
correctly predicted in vitro) and the concordance (percent of substances correctly
classified in vitro) were calculated.
Results and Discussions
Change of TER and Structural Morphology during the Reconstruction
of EPiTRI®
We have established an efficient protocol in our laboratory for the expansion, differ-
entiation and reconstruction of human skin epidermis equivalent EPiTRI® from pri-
mary human keratinocyte. Using our proprietary induction protocol, a multi-layered
epidermis composed of stratified stratum corneum, granulosum, stratum spinosum and
basal layer were formed after air-lift culture and resembled in vivo skin epidermis
structure. Moreover, immunohistochemically staining showed that loricrin, cytokeratin
10 and cytokeratin 14 were expressed in the granulosum, spinosum and basal layer
respectively, indicating that the reconstructed human epidermis skin equivalent was
Fig. 2. Structure morphology of EPiTRI® by H&E and immunohistochemical stain
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closely mimic the histology and morphology of human epidermis (Fig. 2). During
formation of EPiTRI®, transcutaneous electrical resistance (TER) measurements were
performed on EPiTRI® from Day 1 to Day 15. As shown in Fig. 3(A), the TER value
was very low at the first three days of differentiation. However, as the epidermis
gradually developed, the TER value increased dramatically from Day 3 to Day 9.
Process of EPiTRI® differentiation was shown in Fig. 3(B), which displayed a time-
coursed maturation of EPiTRI®. As time went by, a multi-layered epidermis was
formed. We found that Transcutaneous Electrical Resistance (TER) correlated to the
differentiation process from Day 1 to Day 9 or 10. After epidermis matured, the TER
maintained at a higher value.
(A) Transcutaneous electrical resistance (TER) measurements were performed on
EPiTRI® from Day1 to Day15. Data represented the average TER of three different
tissues at each day point. (B) EPiTRI® skin equivalent shows a time-dependent cell
maturation, generating a multi-layer epidermis composed of stratified stratum corneum,
granulosum, stratum spinosum and basal layer.
(A)
(B)
Fig. 3. TER and structural morphology during the reconstruction of EPiTRI®
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Quality Control of EPiTRI®
In order to meet the requirement of OECD TG 439, the quality control of EPiTRI® is
important. Quality factors that we measured include: the thickness of EPiTRI®, the
barrier property, the cell viability of negative control and positive control, and tran-
scutaneous electrical resistance. As shown in Fig. 4, the variation on these parameters
was small for EPiTRI®. Histology was used to measure the thickness of EPiTRI®. The
thickness of EPiTRI® was in the range from 67.06 lm to 85.20 lm (76.32 ± 4.85 lm,
CV = 6.36%) (Fig. 4(A)). Negative control OD values of EPITRI® was in the range of
1.33−1.58 (1.44 ± 0.07, CV = 5.2%) (Fig. 4(B)). Measured barrier function of EPi-
TRI® was in the range of 62.48%−75.01% (70.92 ± 2.53, CV = 4.97%) (Fig. 4(C)).
Measurements of TER: 11.3 kX−11.9 kX (11.6 ± 0.2 kX, CV = 1.4%) (Fig. 4(D)).
(A) Thickness of EPiTRI®: 67.06 lm−85.20 lm (76.32 ± 4.85 lm, CV =
6.36%); (B) OD values of Negative control: 1.33−1.58 (1.44 ± 0.07, CV = 5.2%);
(C) Barrier function: of 62.48%−75.01% (70.92 ± 2.53, CV = 4.97%); (D) Mea-
surements of TER: 11.3 kX−11.9 kX (11.6 ± 0.2 kX, CV = 1.4%).
Protocol Refinements for the Skin Irritation Test of EPiTRI®
Modification of Washing Method for SIT
Washing method is important in terms of being able to effectively wash away chem-
icals without damaging the epidermis tissue when considering the development of SIT
protocol. We have tried many washing method. Finally, we found an efficient proce-
dure (the last group as shown in Fig. 5(A)) which resulted in the least standard
deviation of testing chemicals. Thus we finalized the washing method for SIT in our
protocol: Washing off the chemical with continuous stream of PBS at a distance of
3 cm. Squeeze the bottle to maintain a continuous stream of PBS. Then flush the stream
against the wall of the insert near the six-o’clock direction for 3 s (4 ± 1 mL). Make
sure tissue surface will be fully covered by PBS stream during washing. After washing,
discard the PBS into a beaker by taping the insert for three times. Then, gently place the
insert on a sterile gauze sponge, tilt the insert on the gauze and tap for three times.
Repeat the flushing for another 2 times. Wash off the residual chemical from the insert
with PBS for 35 times. To avoid damaging tissues, it is strongly recommended to
maintain stable stream of PBS against the wall of the insert.
Chemical Exposure Time
Some parameters in the protocol are critical to develop a successful protocol, for
example, chemical exposure time. We found in our experiment for some specific
chemicals such as no. 26 and 29, change of exposure time may result in a totally different
classification as an irritant or a non-irritant. With 10 min of exposure, they could exhibit
non-irritant. However, with 30 min of exposure they apparently are irritant (Fig. 5B).
Pre-incubation Time and Post-incubation Volume
The incubation volume and time are also important to develop a good protocol.
Because skin irritation is a reversible reaction, for some chemicals such as No. 19,





Fig. 4. Quality control of EPiTRI® on (A) thickness, (B) OD of NC, (C) barrier function, and
(D) TER.




Fig. 5. Protocol refinements for the skin irritation test of EPiTRI®
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the increase of pre-incubation time resulted in its classification from irritant to non-irritant.
For some chemicals such as No. 16 in our experiment, a post-incubation volume could
improve the variation of results (Fig. 5C, D). The important parameters of SIT using
EPiTRI® when compared with other ECVAM proved products are listed in Table 1.
(A) Wash cycle refining test: the last group was selected due to the success of
SD < 18 for #12, #14, and #16 chemicals; (B) Optimal chemical exposure time was
30 min by using 7 non-coded chemicals. Δ represented SD  18; (C) Because the test
result of #16 chemical was different from UN GHS Cat. Data exhibited SD  18%,
thus 2 mL of medium volume in post-incubation was selected rather than 1 mL; (D)
Because the test result of #19 chemical was different from UN GHS Cat., thus 18−30 h
pre-incubation time was better than 4 h.
In the Phase 1 study of EPiTRI® for SIT, the lead lab ITRI tested the protocol by 20
chemicals (Table 2). Distribution of the testing results of 20 chemicals, with triplicates
on each, was shown in Fig. 6 expressed as % cell viability of negative control. 50%
viability cut-off was used for the prediction of irritants and non-irritants. The predictive
capacity in terms of sensitivity, specificity and accuracy, we obtained scores of 100%,
70%, and 85%, respectively (Table 3). Meet the requirement of OECD TG 439.
Three independent experiments performed for each reference chemical. Distribu-
tion of the 20 chemical test results, the average of the three experiments for each data
point, shown as % of tissue viability of negative control. 50% viability cut-off was used
for the prediction of irritants from non-irritants.
Table 1. Comparison of EPiTRI®-SIT with validated test tissues in OECD TG 439
Model
Procedure EpiSkin™ EpiDerm™ SIT (EPI-
200)
SkinEthic™ RHE LabCyte EPI-
MODEL24 SIT
EPiTRI Ver 3.2
Model surface 0.38 cm2 0.63 cm2 0.5 cm2 0.3 cm2 0.47 cm2
a) Pre-incubation
Incubation time 18−24 h 18−24 h <2 h 15−30 h 18−30 h
Medium volume 2 mL 0.9 mL 0.3 or 1 mL 0.5 mL 2 mL
b) Test chemical application
For liquids 10 lL (26 lL/cm2) 30 lL (47 lL/cm2) 16 lL (32 lL/cm2) 25 lL (83 lL/cm2) 35 lL
(75 lL/cm2)
For solids 10 mg
(26 mg/cm2) +DW
(5 lL)
25 mg (39 mg/cm2)
+DPBS (25 lL)
16 mg (32 mg/cm2)
+DW (10 lL)
25 mg (83 mg/cm2)
+DW (25 lL)
25 mg (53mg/cm2)
+ 20 lL DW
Use of Nylon
mesh




15 min 60 min 42 min 15 min 30 min
Application
temperature




Medium volume 2 mL 0.9 mL2 2 mL 1 mL 2 mL
d) Maximum acceptable variability
SD between
tissue replicates
SD ≦ 18 SD ≦ 18 SD ≦ 18 SD ≦ 18 SD ≦ 18
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Table 2. Twenty selected test substances and predictive capacity of EPiTRI® in comparison
with GHS Category or OECD VRM





UN GHS Cat. based
on in vivo results
In vivo
score
l-bromo-4-chlorobutane 6940-78-9 RT Liquid Cat. 2 No Cat. 0
Diethyl phthalate 84-66-2 RT Liquid No Cat. No Cat. 0
Naphthalene acetic acid 86-87-3 RT Solid No Cat. No Cat. 0
Allyl phenoxy-acetate 7493-74-5 RT Liquid No Cat. No Cat. 0.3
Isopropanol 67-63-0 RT Liquid No Cat. No Cat. 0.3
4-{methylthio)-benzaldehyde 3446-89-7 RT Liquid Cat. 2 No Cat. 1
Methyl stearate 112-61-8 -20 °C Solid No Cat. No Cat. 1
Heptyl butyrate 5870-93-9 RT Liquid No Cat. NoCat.(Optional
Cat. 3)
1.7
Hexyl salicylate 6259-76-3 RT Liquid No Cat. NoCat.(Optional
Cat. 3)
2
Cinnamaldehyde 104-55-2 4 °C Liquid Cat. 2 No Cat.(Optional
Cat. 3)
2
1-decanol 112-30-1 RT Liquid Cat. 2 Cat. 2 2.3
Cyclamen aldehyde 103-95-7 RT Liquid Cat. 2 Cat. 2 2.3
1-bromohexane 111-25-1 RT Liquid Cat. 2 Cat. 2 2.7
2-chloromethyl-3,S-dimethyl-
4- methoxypyridine HCI
86604-75-3 RT Solid Cat. 2 Cat. 2 2.7
Di-n-propyl disulphide 629-19-6 RT Liquid No Cat. Cat. 2 3
Potassium hydroxide (5% aq.) 1310-58-3 RT Liquid Cat. 2 Cat. 2 3
Benzenethiol, 5 (1,1-
dimethylethyl)-2-methyl
7340-90-1 RT Liquid Cat. 2 Cat. 2 3.3
l-methyl-3-phenyl-l-
piperazine
5271-27-2 RT Solid Cat. 2 Cat. 2 3.3
Heptanal 111-71-7 RT Liquid Cat. 2 Cat. 2 3.4
Tetrachloroethylene 127-18-4 RT Liquid Cat. 2 Cat. 2 4
Fig. 6. Distribution of the relative tissue viability obtained with the treatment of 20 selected
chemical substances on EPiTRI®.
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Conclusion
In this study, the good quality of RhE (EPiTRI®) model was presented in terms of its
stable thickness, TER, structural morphology and barrier function. Furthermore, we
demonstrated the development of a reliable SIT protocol using of EPiTRI®, producing
an overall sensitivity of 100%, specificity of 70% and accuracy of 85%. These results
meet the OECD guidelines. Based on its high predictive capacity, our in vitro SIT with
EPiTRI® could be a promising alternative to in vivo SIT.
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Abstract. Reconstructed Human Epidermis (RHE) is an artificial epidermis
made in such a way that it resembles human skin, and can be used for the
identification of irritant chemicals, especially for cosmetic and topical medicinal
products. Currently the new RHE is produced by European and American
countries, whose skin physiology is very different from Indonesia. Based on
this, the Center for Research on Drugs and Food, NADFC of Republic of
Indonesia took the initiative to develop the reconstruction of keratinocyte,
melanocytes and fibroblasts cells into RHE adapted to the anatomical and
physiological functions of the skin of Indonesians. RHE is made from an epi-
dermal layer composed of keratinocyte and melanocytes cells that are recon-
structed with a dermis layer composed of fibroblast and collagen cells.
Keratinocyte, melanocytes and fibroblasts cells are cultured on suitable medi-
ums by adding a suitable growth medium. To find out that RHE has been
successfully reconstructed, measured percentage of cell life, made histology
preparation to see the existence of cell nucleus, and conducted Immunohisto-
chemical examination to see existence of integration (bond) between antigen.
From the research results can be seen that keratinocyte cells grown on culture
medium Keratinocyte SFM (IX) with rEGF supplements; melanocyte cells
grown on Melanocyte 254 culture medium with HMGS supplementation; and
fibroblast cells grown on Fibroblast M 106 culture medium with LSGS sup-
plementation. The percentage of epidermal cell life grew well in the planting of
10  104 cells /mL keratinocytes and 0.25  104 cells /mL of melanocyte cells
and survived until the 11th day with live cell percentage of 93.45%. In making
preparation for histology with HE staining, there is a cell life in RHE tissue.
Used Immunohistochemical (IHC) examination using cytokeratin 10 antibody
marker to view physiological function of epidermal tissue.
Keywords: RHE  Keratinocytes cell  Melanocyte cell
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Back Ground
The wide use of cosmetics and the many types of cosmetics circulating in Indonesia
need strict supervision by the National Agency of Drug and Food Control (NADFC) to
ensure its safety and do not cause irritation and allergies.
Testing irritation and allergies on the skin previously carried out by using rabbits
and albino guinea pig, but with the widespread animal welfare issues causing restric-
tions on the use of experimental animals. So it is necessary to develop the method of
skin irritation test in vitro, one of them by using Reconstructed Human Epidermis or
RHE (Nelson et al. 1980).
RHE is an artificial epidermis made in such a way that its anatomy and physiology
resemble human skin, and can be used for the identification of irritant chemicals,
especially for cosmetic products and medical devices (Rehder 2004). Currently RHE is
newly produced by European and American countries, whose skin physiology is very
different from Indonesian skin physiology, so that RHE production in Indonesia is
considered very important, economical in terms of production, and reduce dependence
on other countries. Other advantages of in vitro toxicity testing are easy to do, efficient
and economical.
Structure of Skin Networks
The skin is the largest organ of the body and has two major layers, the epidermis and
the dermis. Each of these layers has specific functions and structures. The skin tissue
structure can be described as Fig. 1.
Fig. 1. Diagram of the structure of human skin tissue
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The epidermis occupies the outermost layer, followed by the dermis layer and the
hypodermic. The epidermis is an elastic layer and continues to be regenerated, whereas
the dermis is the inner layer that includes the sweat glands and produces sweat that
travels through the sweat channel to the pores that play a role in temperature regulation.
In the layers below the dermis there is a hypodermis composed of fatty tissue or
adipose tissue where there are many veins and arteries located between the dermis and
hypodermic layers (Montagna 1974).
Epidermis
The skin epidermis layer consists of the horn layer or corneum layer and the Malpighi
layer. The horn or corneum layer is a layer of dead skin, which can be peeled off and
replaced by new cells, while the Malpighi layer consists of layers of spinosum and
germinativum, each of which has its own function. In addition, the epidermal skin layer
contains a melanin pigment that gives color to the skin, therefore it is important to keep
the skin from UV radiation that can burn the skin and change the color of the skin
becomes darker.
The epidermis is the outermost layer of the human skin and consists of layers such
as: melanocytes that produce melanin, langerhans cells which has an important role in
skin immunology, and Merkel cells that act as sensory mechanoreceptor. Keratinocytes
layer composed of several stratums are the Stratum korneum, Stratum lucidum, Stratum
granulosum, Stratum spinosum, Stratum Basal, which is the lowest layer of the epi-
dermis (Schallreuter and dan Wood 1995).
Dermis
The dermis skin layer consists of blood vessels, hair roots, nerves, sweat glands and oil
glands. The function of this dermis skin layer is as a stimulating receptor organ,
protective against physical damage, illumination and disease protection, as well as for
regulation of body temperature.
The dermis skin layer is at the bottom of the epidermis skin which has two stratum
structures, namely the Stratum papilare which contain fibroblasts and stratum reticular
which composed of connective tissue (especially type 1 collagen). In addition to these
two stratum the dermis also contains some epidermal derivatives namely hair follicles,
sweat glands, and sebaceous glands. Below the dermis there is a layer of loose con-
nective tissue called the subcutaneous tissue and contains fat cells. This network is also
called superficial fascia or paniculus adiposus. This tissue contains rich bundles of
blood vessels and lymph vessels (Montagna 1974).
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Keratinocytes Cells
Keratinocytes are a type of cell that dominates 90%more cells that exist in the outermost
layer of the skin (epidermis). Keratinocytes are found in the basal layer (Stratum ger-
minativum) of the skin to be referred to as “basal cells” or “basal keratinocytes”.
Squamous keratinocytes are found in the oral and esophageal mucosa, as well as the
cornea, conjunctiva, and genital epithelium (Morgan 2003) (Figs. 2 and 3).
The main function of keratinocytes is as a barrier to environmental damage such as
pathogen bacteria or fungi or viruses, heat, UV radiation and water loss. When
pathogen invade the epidermal top layer, keratinocytes may react by producing certain
proinflammatory and chemokine mediators such as interleukin 1, interleukin 2, inter-
leukin 6, and TNF-a that attract leukocytes to site of pathogen invasion (Morgan 2003).
A number of structural proteins (filaggrin, keratin), enzymes (proteases), lipids and
antimicrobial peptides (defensin) contribute to maintaining important skin barrier
functions. Keratinization is part of the formation of a physical barrier (cornification), in
Fig. 2. Skin epidermis with keratinocyte and melanocytes cells
Fig. 3. Keratinocyte cells on day 5 in the media culture
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which keratinocytes produce keratin as an overriding primary protein and eventually
undergo programmed cell death. Keratin is what makes up the hair and nails (Morgan
2003).
Melanocytes Cell
Melanocytes are somatic cells that produce melanin, providing important physiological
functions in the epidermal basal layer (stratum basal) of the skin, the middle layer of the
eye (uvea), the inner ear, the bone, and the liver. Functions related to human melanin
production include photo protection, capture of reactive oxygen, execution of metal
ions, and bind to certain drugs and organic chemicals (Tolleson 2005). Melanin is the
main pigment responsible for skin color. Melanin is dark and absorbs all UV-B light.
This melanin is produced through a process called melanogenesis. This melanogenesis
causes pigmentation, which is different from the pigmentation derived from the existing
melanin oxidation. In general, lighter-skinned people have low-grade basal melano-
genesis. Exposure to UV-B radiation causes melanogenesis to increase. The goal of
Fig. 4. Melanocyte cell on day 3 in culture medium M 254
Fig. 5. Melanocyte cells in the epidermal tissue of human skin
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melanogenesis is to protect the hypodermis, the lower layers of the skin, from UV-B
rays that can damage DNA (Tolleson 2005) (Figs. 4 and 5).
In general, for per square millimeter of skin containing between 1000 and 2000
melanocytes. The difference in skin color between light and dark of a pigmented
individual is due to the amount of melanocytes in their skin, but to the extent of
melanocyte activity depends greatly on the quantity and relative amount of eumelanin
and pheomelanin). This process is under hormonal control, including peptides from
Melanocyte-Stimulating Hormones (MSH) and Adrenocorticotropic Hormone (ACTH)
resulting from propiomelanocortin precursor.
Fibroblasts Cell
Fibroblasts are cells that produce collagen and elastin that provide a middle layer of
skin structure called the dermis. The dermis is the middle layer of the skin (below the
epidermis) containing collagen fibers, elastic fibers, hyaluronic acid, blood vessels and
lymphatic vessels, hair follicles, nerves, glands, and many others. This dermis is the
“brain” of the skin, also called kutis (Doyle and dan Griffiths 2000).
Fibroblast cells include connective tissue because fibroblast cells have an important
role in the formation of connective tissue that is forming fibers (collagen, reticular, and
elastin) and producing macromolecules (glycosaminoglycans and proteoglycans)
which are the basic components of connective tissue, because the cells are relatively
stable and very little of movement.
Elastin is a structural protein that forms thin elastic fibers, similar to collagen. This
material is produced by fibroblasts and serves to restore the skin to its position while
resting. Collagen is a protein that is a major element of connective tissue and bone, and
provides strength and endurance to the skin. Aging causes a decrease in collagen
production that causes thinning, wrinkled, and sagging skin. Collagen in skin cream is
almost useless, but collagen can be stimulated with retinoids, vitamin C and some other
antioxidants, lasers and certain injections (Harlystiarini 2010) (Fig. 6).
Fig. 6. Fibroblast cells in culture medium containing FBS with 10x magnification
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Reconstruct Ed Human Epiderm is (Rhe)
Reconstructed Human Epidermis (RHE) is defined as human skin tissue obtained from
the in vitro process in which human keratinocyte cells are cultured on an inert poly-
carbonate medium. RHE has a major advantage for growing donor epidermal cells in a
serum-free culture environment. After the preparation of the acquired keratinocyte
culture has rapidly multiplied, the epidermal cells produced on the inert filter substrate
are lifted to the air-fluid interface in the CO2 incubator. A nutrient medium as a food of
the basal cells through sub-stratum filters. After 14 days, a stratified epidermis has
formed that resembles the human epidermis in vivo. Morphologically, this culture
shows stratified epithelial and cornified epidermis by significantly improving barrier
function and metabolic activity. Marker differentiation such as keratin suprabasal,
integrin b4, integrin a6, fibronectin, involucrin, filaggrin, trichohyalin, type I, III, IV, V
and VII collagen, laminin, heparin sulfate and membrane-bound transglutaminase have
been found, presented similarly to human epidermis (Rehder 2004).
RHE is formed from a layer of an inert filter substrate containing collagen with
fibroblast cells and cultured in an appropriate medium. This layer is a feeder layer that
will become the growth medium of keratinocyte cells and melanocytes as the composer
of the artificial skin epidermis. RHE can also be composed of keratinocyte cells and
melanocytes cultured on biological matrix and the system stored at the air-liquid
interface, in a suitable culture medium, to form a human epidermal layer with histo-
logic characteristics of the epidermis in vivo. RHE is considered good when histologic
observations indicate reconstructed in vitro epidermis has a similar arrangement of
human epidermis in the correct position, with functional keratinocytes and melanocytes
similar to in vivo epidermis (Rehder 2004).
The function of RHE is very important as an alternate model of animal experiments
for testing the toxicity and effects of topical products since current testing of cosmetic
products with experimental animals has been prohibited. In vitro testing using the
reconstructed human skin epidermal tissue model (RHE) has been widely used in the
cosmetics, pharmaceutical and chemical industries as an alternative to animal testing
for various applications including toxicity, efficacy, pharmacology and skin absorption
studies. The pharmaceutical and dermocosmetic industries have switched to using the
human skin epidermis that was reconstructed into RHE as a model for testing such as:
skin penetration rates of various substances, inflammatory reactions, effects of ultra-
violet radiation, hormone metabolism and so on. The continuous improvement of this
model makes an efficient predictor for research and development of topical toxicity
tests (Nelson et al. 1980).
Various Models for epidermal testing have passed scientific validation in ECVAM
(European Committee Validation of Alternative Method, a Validation Center for
Alternative Methods for European Veterinary Testing) to predict skin irritation and be
accepted for regulatory purposes in predicting skin corrosion (OECD 2013) and skin
permeation (OECD 2004). But now all models have been properly validated, protected
by patents and/or are traded using proprietary tissue culture procedures by some private
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companies, so its availability depends entirely on the strategy of each company
(Berking and dan Herlyn 2001).
The epidermis of the skin is an important tissue that produces a strong internal
organ body protector, flexible and able to repair itself against environmental influences.
Its main function is to protect the body from dehydration, loss of nutrients and
unwanted effects due to substances that contact with the skin in various forms
depending on its physicochemical properties. The epidermis can contribute to the
protection of living organisms that we encounter around us, such as animals, plants and
fungi, as well as invisible micro-organisms by the human eye such as bacteria and
viruses.
In order to be and remain effective, the epidermal layer should be able to protect the
body from the substance most often potentially harmful to physical, chemical or bio-
logical. Therefore, most epidermal studies are related to the production, maintenance
and repair of the epidermal layer (Poumay and dan Coquette 2007). Since the skin is
often exposed to cosmetic products or other ingredients whether intentionally or not,
the potential for irritation or corrosion of the skin is large enough that as part of the
overall safety assessment process, a product must be carefully evaluated.
Skin Irritation Test
Skin irritation test can be done both in vivo and in vitro. In vivo testing typically used
experimental animals as albino rabbits, while in vitro testing was used as an experi-
mental model of RHE. In vitro testing is a strategy for assessing potential corrosion and
irritation. Testing of chemicals for skin irritation after acute exposure is considered to
be one way to evaluate the toxicology of simple endpoints. Historically, this process
involves only exposure to chemicals in rabbit skin and observing the results (OECD
2010). Over the past decade, various non-animal test methods (in vitro tests) have been
developed and validated to predict the potential for skin corrosion and chemical skin
irritation (Doucet et al. 2010).
Examination of Histology Network with Hematoxyline - Eosin
Determination
Histology is a branch of biological science that studies the structure of tissues in detail
using a microscope on a thinly cut tissue preparation. Histology can also be referred to
as a microscopic anatomical science.
Histology is divided into two parts: general histology that includes studies of
tissues contained in the body and special histology or organ histology that includes the
histological structure of the organs of the body. The tissues of the body are formed by
two interacting components of the cell and the extracellular matrix. The extracellular
matrix consists of many types of molecules, and most of them are very complex and
form complex structures, such as fibers and basement membranes. To analyze the tissue
structure that has been cut thinly used the method of haematoxylin-eosin staining (HE),
because this coloration can show most of the histology structure. The hematoxillin will
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form the nucleus of the cell (nucleus) and other acidic structures of the cell (such as the
RNA-rich portion of the cytoplasm and the cartilage matrix) into blue, while the Eosin
is acidic, which will color the cytoplasm and collagen into pink (Dharma 1985).
Immunohistochemical (IHC)
Immunohistochemistry is a method to detect proteins in cells of a tissue by using the
principle of binding between antibodies and antigens in living tissues. Immunohisto-
chemical painting are widely used in the examination of abnormal cells such as cancer
cells. Specific molecules will color certain cells such as dividing cells or dead cells that
can be distinguished from normal cells. This check requires a network.
of varying amounts and thicknesses depending on the purpose of the inspection.
Generally the tissues that come from the body will be cut into very thin pieces by using
a tool called vibrating microtome.
Some commonly used immunohistochemical examples include Keratin 10, Carcino
Embryonic Antigen (CEA), CD 15, CD 30, Prostate Spesific Antigen (PSA), CD 117,
Estrogen and Progesteron, CD 20 and CD 3.
Result and Discussion
Cell Culture of Keratinocytes, Melanocytes and Fibroblasts
Keratinocyte cells in culture using Keratinocyte SFM (IX) medium, with addition of
human recombinant Epidermal Growth Factor (rEGF) and Bovine Pituitary Extract
(BPE). The 7th day keratinocytes and confluent 11th day keratinocytes can be observed
with an inverted microscope of 100  magnification.
Melanocyte cells in culture using 254 Medium plus Human Melanocyte Growth
Supplement (HMGS). The 3rd day melanocytes and confluent 6th day of melanocyte
can be observed with an inverted microscope of 100  magnification.
Fibroblast cells in culture using M 106 Medium plus LSGS supplement. The 4th
day fibroblast cells and confluent 7th day of fibroblast can be observed with an inverted
microscope of 100  magnification.
Making of Feeder Layer (Dermis Eqivalen)
The feeder layer (dermis eqivalen) is made of a mixture of fibroblasts and collagen cells
that function as a scaffold in the preparation of RHE. The results show that the eqi-
valent dermis forms a layer that does not stick to the bottom of the plate, can be
observed after incubation for 3 days at 37 °C using 5% CO2 incubator.
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Making of RHE Tissue (Reconstructed Human Epidermis)
The RHE is made of from the eqivalent dermis layer coated with the epidermis layer,
where the epidermis layer is on the seedling above the sterile insert comprising a
mixture of keratinocyte cells and melanocyte cells in ratio (40: 1), then cultured on an
epidermal medium (IMDM) containing vitamin C 37.5 lg/mL. The purpose of adding
vitamin C to the culture medium is as an antioxidant to strengthen the epidermal
membrane layer so that the layer is not easily separated. The results of making RHE
network can be seen in Fig. 7.
Measuring of Cell Life Using MTT Method
Measurements of cell life from RHE tissue were used MTT method, wherein ker-
atinocyte and melanocyte cell life was obtained by calculation using formula:
%celllife¼ treatmentabsorption blankoabsorption 100%Blankoabsorption
Blankoabsorption
Measurements of cell life from the epidermal layer were performed on day 1
(considered as base line), day 3, day 7, day 11 and day 14. The increase in the number
of living cells occurred only until the 7th day, then there was a decrease on the 11th
day. This may be due to the fact that the number of keratinocyte and melanocyte cells
grown too much, so that the availability of culture media on the propylene ring is
insufficient, eventually the growth of cells in the tissue becomes blocked and some die.
Epidermis layer production is repeated by decreasing the number of planting cells
to one fifth of the number of cells grown in the first experiment. So the number of cells
changed from 50  104 cell/mL to 10  104 cell/mL for keratinocyte cells and 1,25 
104 cell/mL to 0,25  104 cell/mL for melanocyte cells.
Fig. 7. RHE tissue consisting of an equivalent dermis and epidermal layer
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Making Histology Preparations of Reconstructed Human
Epiderm Using Staining of Hematoxylin-Eosin (HE)
Hematoxylin and Eosin are coloring methods that are widely used in the staining of
histological tissues. Hematoxylin memulas the nucleus and other acidic structures of
the cell (such as the RNA-rich cytoplasm section and cartilage matrix) to blue/purple.
Haematoxylin will color the nucleus while eosin will color the cytoplasm. Eosin is
acidic, which will color the cytoplasm and collagen into pink.
The result of preparation of histology and staining using HE can be seen in Fig. 8
here is the presence of cell nucleus (purple blue color) but not yet showing the for-
mation of tissue component (not yet showing any protein expressed in skin tissue), so
immunohistochemistry is needed antibody (marker) that is specific to skin tissue.
Fig. 8. The results of skin tissue reconstruction on the 11th day
Fig. 9. IHC examination of normal skin tissue
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Immunohistochemical (IHC) Examination of RHE Skin Tissue
Using Cytokeratin 10 Antibody Marker
Immunohistochemical (IHC) is a technique for detecting a specific protein (antigen) in
tissues or cells using specific antibodies (markers). The purpose of this IHC exami-
nation is to validate the reconstructed skin tissue, using antibodies specific to the
epidermis. The results of immunohistochemical examination of RHE skin tissue can be
seen in Fig. 9.
The results of IHC examination of reconstructed skin tissue using cytokeratin 10
antibody marker have not shown any integration (bonding) between the epidermal layer
with the marker, this is probably because the proteins formed are incompatible with
antibody cytokeratin 10. Other possibilities is not yet formed protein so physiological
function of the epidermis has not existed, therefore RHE skin tissue cannot be used as
skin irritation test model in vitro.
Conclusion
Keratinocyte, melanocytes and fibroblasts cells can grow well on suitable medium with
the addition of suitable growth medium that is keratinocyte cells grown on Ker-
atinocyte SFM (IX) culture medium with Human recombinant supplement (rEGF);
melanocyte cells grown on Melanocyte 254 culture medium with HMGS.
supplementation; and fibroblast cells grown on Fibroblast M 106 culture medium
with LSGS supplementation. The percentage of epidermal cell life grew well in the
planting of 10  104 cells /mL keratinocytes and 0.25  104 cells /mL of melanocyte
cells and survived until the 11th day with live cell percentage of 93.45%. The
preparation of histology preparations with HE staining shows the presence of cell life in
RHE tissue. IHC examination using cytokeratin 10 antibody marker not shows any
physiological function of the epidermis tissue.
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Alternative research is currently conducted all over the world and its recent progress is
remarkable as 3Rs research. This article describes a review of alternative research and
3Rs in the world, Asia and Japan.
The World
“Principles of Humane Experimental Technique” were first articulated in the 1950s by
Russell and Burch (1959), giving birth to a new field of laboratory animal welfare and
the “3Rs” concept of replacement, reduction and refinement in life sciences research.
A decade later, the Fund for the Replacement of Animals in Medical Experiments
(FRAME 2018) was founded, with a mission to support alternative research, together
with the journal Alternatives to Laboratory Animals (ATLA), which has become a
leading academic journal of this field.
In 1981, the Center for Alternatives to Animal Testing (CAAT) was founded at
Johns Hopkins University. The center co-organized the 1st World Congress on
Alternatives and Animal Use in the Life Sciences in 1993 (CAAT 2018). The first
president of World Congress of Alternatives was Dr. Alan Goldberg and then he is one
of the prominent leaders of this field. His remarkable effort of alternatives to animal
testing in toxicology is realistic strategy for alternative research. Because the most of
chemicals should be tested their safety before marketing, the toxicological study using
animals was a common sense in this field. However, Dr. Goldberg proposes many non-
animal testing methods for their safety.
The European Reference Laboratory for Alternatives to Animal Testing (EURL-
ECVAM) (ECVAM 2018), founded in 1991 as the European Centre for the Validation
of Alternative Methods, was given a new name and broader mandate in 2010 for
promoting the not only scientific but also regulatory acceptance of non-animal tests
which are of importance to biomedical sciences. EURL-ECVAM does so by supporting
research, test development and validation, the establishment of a specialised database
service, and engagement with international academic organizations in this field. Their
targets include chemicals and products of various kinds, including medicines, vaccines,
medical devices, cosmetics, household products and agricultural products.
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The US Interagency Coordinating Committee on the Validation of Alternative
Methods (ICCVAM) was established by law in 2000 (ICCVAM 2018) as a permanent
committee of the NIEHS under the National Toxicology Program Interagency Center
for the Evaluation of Alternative Toxicological Methods (NICEATM). ICCVAM is
composed of representatives from 16 federal regulatory and research agencies that
require, use, generate, or disseminate toxicological and safety testing information. The
importance of alternative research is beginning to shift from scientific to regulatory
needs.
For animal welfare, the Council for International Organaization of Medical Science
(CIOMS) published International Guiding Principles for Biomedical Research
Involving Animals in 1985. This principle is proposed by scientific group and the
regulatory bodies of animal welfare of many governments was accepted its concepts.
These principles were revised in 2012 in conjunction with the International Council for
Laboratory Animal Science (CIMOS and ICLAS 2018).
The International Standardisation Organization (ISO) also created an international
document “Animal Welfare Requirement” as ISO 10993-2 in 1996 (ISO 2018). This
standard is for biological and clinical evaluation of medical devices and then it is
revised regularly to expand their target.
The World Animal Health Organization (OIE) is also keen to protect animal health
and has introduced animal welfare as a part of animal health. The international standard
of animal health (OIE Terrestrial Animal Health Code) includes not only domestic
animal welfare but also research animal welfare (OIE 2018).
Asia
In Asia, the Japanese Society for Alternatives to Animal Experiments (JSAAE) was
founded in 1984 as a world-first academic society consisting of scientists for alternative
research (Sugawara 1990), and today JSAAE collaborates with many international
organizations in this field. JSAAE is a scientific organization that undertakes research,
development, education, and surveillance activities for promoting international
acceptance of the 3Rs as guiding principles for the proper use of animals in scientific
testing. JSAAE has published its academic journal Alternatives to Animal Testing
and Experimentation (AATEX) since 1990, making it one of the oldest academic
journals in this field (AATEX 2018). The society celebrated its 30th annual meeting in
2017 (JSAAE 2018).
The 6th World Congress on Alternatives was invited to Tokyo in 2006. The con-
gress included three satellite meetings in other Asian parts, namely Beijing, Seoul and
Kyoto, making it a milestone of expansion of alternative research into Asian region.
Indeed, the Korean Society for Alternatives to Animal Experiments (KSAAE) was
founded that same year.
The Asian Federation of Laboratory Animal Science Associations (AFLAS) is one
of other remarkable activities of alternatives research. The first congress was held in
Nagasaki in 2004, with subsequent meetings every two years. In 2016 the congress was
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hosted in Singapore (AFLAS 2018), where subjects discussed included laboratory
animal welfare and 3Rs with other subjects in laboratory animal science. The AFLAS
membership is now expanded to 11.
Japan
In Japan, JSAAE has a central position to propagate 3Rs activities. The initial activities
of JASSE were focused on cosmetics. However, since Japan’s Animal Welfare Act
took 3Rs as key words, the concept has become well recognized by biomedical
research organizations. The practical activities of 3Rs are held by the Japanese
Association of Laboratory Animal Science (JALAS), the Japanese Society of Labo-
ratory Animal and Environment (JSLAE), and the Japanese Association for Experi-
mental Animal Technologists (JAEAT) as education and training sessions. Through
these efforts, the 3Rs are now expanding to be recognized by industries.
Today, the 3Rs are now accepted in Asian countries widely, culminating in the first
biennial Asian Congress on Alternatives being organized in 2016 in Karatsu, Japan
(Asian Congress 2018). In the future, the World Congress on Alternatives is expected
to be held in Asia again as well.
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Abstract. In this study, we considered whether acute oral toxicity hazard
classifications for pesticide formulations and active ingredients (AIs) could be
used to assign acute dermal toxicity hazard classifications using U.S. Environ-
mental Protection Agency (EPA) and the United Nations Globally Harmonized
System of Classification and Labelling of Chemicals (GHS) hazard categories.
This retrospective analysis used highly curated acute toxicity data for 503 for-
mulations and 297 AIs. Hazard classifications based on rat oral LD50 values were
compared to hazard classifications based on rat dermal LD50 values for the same
substance. The concordance of oral and dermal hazard classification was 62% for
formulations and 64% for AIs using the EPA system and 71% for formulations
and 55% for AIs using the GHS. Overprediction of dermal hazard was 38% for
formulations and 32% for AIs using the EPA system and 28% for formulations
and 41% for AIs using the GHS. Underprediction of dermal hazard was 1% for
formulations and 3% for AIs using the EPA system and 1% for formulations and
3% for AIs using the GHS. While concordance overall was modest, the very low
underprediction rates show that acute oral hazard categories are sufficiently
protective for acute dermal hazard classification. Use of oral hazard data to also
classify dermal hazard would obviate the need to perform acute dermal toxicity
tests for classification and labeling and thereby reduce the number of animals
used for acute systemic toxicity testing of pesticides.
Keywords: Acute toxicity  Dermal toxicity  Oral toxicity
Hazard classification
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Introduction
Dermal exposure to chemicals can occur during routine handling of chemicals or
during accidental spills. Dermal exposure can contribute considerably to the internal
dose of users exposed to hazardous substances [4], and in particular is an important
source of internal dose for occupational chemical exposures [1, 15, 26]. For some types
of chemicals, such as pesticides, the dermal route can be the most important route of
exposure [12]. Because of this, the industrial hygiene community develops specific
notations for substances expected to present a toxic hazard via dermal absorption [5].
Regulatory agencies use data from acute oral and dermal toxicity tests to determine the
potential systemic toxicity of chemicals and chemical products following oral ingestion
and topical exposure to the skin, respectively. LD50 values from such tests, representing
the dose expected to produce lethality in 50% of the animals tested, are used to assign
substances to oral and dermal hazard categories. The hazard categories are then used to
assign product packaging labels to caution workers and consumers about poisoning
potential.
Figures 1 and 2 show two systems for classifying substances for acute toxicity
hazard. Figure 1 summarizes the hazard classification system used by the U.S. Envi-
ronmental Protection Agency (EPA). EPA requires hazard labeling to be applied to
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Fig. 1. EPA classification system for acute oral and dermal hazard according to the EPA Label
Review Manual [8]. NR not required. LD50 dose range is not to scale Chart is adapted from
Seidle et al. [27]
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The EPA hazard classification system assigns a chemical to one of four oral and dermal
hazard categories according to its relevant LD50 value, with each category associated
with specific signal words and hazard statements that must be used in labeling that
chemical. Dermal hazard categories are associated with specific recommendations for
personal protective equipment to mitigate skin exposures.
Figure 2 provides the requirements for labeling according to the United Nations
Globally Harmonized System of Classification and Labelling of Chemicals (GHS) [30].
The GHS was established with the goal of harmonizing rules and regulations for
chemical handling and labeling at the national and international levels. The GHS has
five hazard categories that are associated with specific signal words and hazard state-
ments to be used on product labels for chemicals with LD50 values less than or equal to
5000 mg/kg. However, Category 5, which provides for classification of chemicals
having LD50 values greater than 2000 mg/kg but less than or equal to 5000 mg/kg, is
optional. When Category 5 is not used, the GHS hazard categories provide hazard
notations for chemicals with LD50 values less than or equal to 2000 mg/kg.
The GHS has been implemented in the European Union by Regulation
No. 1272/2008 on classification, labelling and packaging of substances and mixtures,
although the European Union does not use the optional Category 5 [11]. Some U.S.
regulatory agencies have harmonized their classification systems with GHS. The U.S.
Occupational Safety and Health Administration uses the same GHS categories as the
European Union, omitting use of the optional Category 5 [25]. The U.S. Department of
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Fig. 2. GHS classifications for acute oral and dermal hazard [30]. NR not required, NC not
classified. LD50 dose range is not to scale. The shaded category is optional and was not used for
the analyses herein. Chart is adapted from Seidle et al. [27]
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Transportation uses a packing group system that is consistent with GHS Categories 1
through 3 to determine appropriate packaging and labeling of poisonous materials
during transport [3].
Acute toxicity tests are the most commonly conducted product safety tests
worldwide [13]. These tests can require large numbers of animals, and the animals used
may experience significant pain and distress. Test methods for acute dermal systemic
toxicity are described in test guidelines issued by EPA and the Organisation for
Economic Co-operation and Development (OECD). The current EPA test guideline [6]
and the previous OECD test guideline [17] recommend using a minimum of 20 animals
for the main test. A recently revised OECD test guideline adopted in late 2017 uses a
stepwise procedure that requires less than 10 animals per test [24]. Acute oral systemic
toxicity test guidelines were updated years ago to minimize the number of animals used
[7, 19, 20, 22] and provide refinement by minimizing pain and distress [19]. Addi-
tionally, an OECD guidance document [23] provides information on using an in vitro
test method to predict a starting dose, thereby further reducing animal use. Currently,
acute oral tests can typically use five to nine animals for main tests and five to six
animals for limit tests [18].
While significant reductions in animal use for acute systemic toxicity testing have
been achieved, there is a great deal of interest, for both efficiency and ethical con-
siderations, in further reducing the number of animals used for this purpose. If acute
oral toxicity data were found to be sufficient to classify pesticides for both oral and
dermal hazards, the acute dermal toxicity test would then be unnecessary, thereby
reducing the number of animals used for acute systemic toxicity testing. This paper
describes an evaluation to determine whether acute oral toxicity classifications for
pesticide formulations and active ingredients (AIs) can be used in lieu of acute dermal
toxicity data for dermal hazard classification and labeling.
Materials and Methods
We collected acute oral and dermal LD50 data for 503 pesticide formulations and 297
AIs. To eliminate the uncertainty associated with comparing results across species, we
only used LD50 data from acute oral and dermal tests that used rats. We obtained these
data from the following sources:
• EPA Data Evaluation Reports
• EPA Reregistration Eligibility Decision documents
• Study reports submitted to fulfill EPA regulatory requirements (provided by EPA)
• Two peer-reviewed publications on acute toxicity testing of chemicals [2, 16]
• Two publicly available online toxicity databases:
a. Hazardous Substances Data Bank [31]
b. European Chemicals Agency database [10]
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Data Quality Evaluation
Data were evaluated for reliability using Klimisch categories [14]. Only LD50 data with
a reliability score of 1 (reliable without restriction) or 2 (reliable with restrictions) were
used for our analyses. The exception was data from Creton et al. [2]; this reference
indicated that the data included were reliable, but did not specify the methods used to
determine reliability.
Categorization of Data
We assigned oral and dermal hazard classifications to the 503 pesticide formulations
and 297 AIs according to the EPA and GHS classification systems using the respective
oral and dermal LD50 values. We adopted the implementation of GHS that does not use
the optional Category 5. Thus, substances with LD50 values greater than 2000 mg/kg
were unclassified. If more than one LD50 value was available for a substance (for
example, if LD50 values were reported for male rats, female rats, and both sexes
combined), we used the lowest (i.e., most toxic) LD50 value to categorize the sub-
stance. When an LD50 was listed as greater than a specific value (e.g., greater than 2000
mg/kg), it was assigned a value just above the specific value (i.e., 2001 mg/kg for the
preceding example) to assign the hazard category.
Analyses
We calculated concordance, underprediction, and overprediction rates for the classifi-
cation of dermal hazard on the basis of the oral hazard classification. In these calcu-
lations, we excluded 27 formulations and 64 AIs from EPA classification because of
the uncertainty of their dermal hazard classifications. These substances were charac-
terized on the basis of limit tests as having oral LD50 values greater than 5000 mg/kg
and dermal LD50 values either greater than 2000 mg/kg or greater than 4000 mg/kg.
Although the oral hazard classifications for these substances were unequivocal, their
dermal classifications could be either EPA dermal hazard Category III (LD50 greater
than 2000 mg/kg but less than or equal to 5000 mg/kg) or Category IV (LD50 greater
than 5000 mg/kg). Thus, an accurate comparison of oral and dermal hazard was not
possible because the highest doses tested for the two routes were not the same. The
resulting subsets of 476 formulations and 233 AIs were used for the EPA classification
analyses. As noted previously, the GHS hazard classifications were determined with
four hazard categories and a “not classified” category (i.e., LD50 greater than
2000 mg/kg). No substances were excluded from the GHS classification analyses
because a substance with a dermal LD50 greater than 2000 mg/kg is not classified, even
if the LD50 is actually greater than 5000 mg/kg. Thus, the full data sets of 503
formulations and 297 AIs were used for the GHS analyses.
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Results
Distribution of Substances Among Hazard Categories
Figure 3 shows that, according to both the EPA and GHS hazard classifications, for-
mulations and AIs in this data set were much more likely to be toxic via the oral route
than via the dermal route, and formulations were less toxic than AIs.
EPA Hazard Categories
The majority of the formulations in our data set (70% [331/476]) were classified by the
EPA system as Category IV for dermal hazard (dermal LD50 greater than 5000 mg/kg).
However, only 36% (173/476) of these substances were classified by the EPA system
as Category IV for oral hazard (Fig. 3a). Similarly, 23% (54/233) of the AIs were
classified by the EPA system as Category IV for dermal hazard, but only 12% (29/233)
of these substances were classified as Category IV for oral hazard (Fig. 3b).
The higher toxicity of the AIs is indicated by the lower proportion of AIs in the
lowest toxicity categories, compared to the formulations. A higher proportion of for-
mulations were classified by the EPA system as Category IV for oral hazard compared
to the AIs (36% [173/476] vs. 12% [29/233]), and similarly, more formulations than
AIs were classified as EPA Category IV for dermal hazard (70% [331/476] vs. 23%
[54/233]) (compare Figs. 3a and b).
GHS Hazard Categories
Nearly all of the formulations in our data set (98% [494/503]) were not classified by the
GHS for dermal hazard (dermal LD50 greater than 2000 mg/kg) (Fig. 3c). As for the
EPA system, a lower proportion of these substances (71% [355/503]) was not classified
by GHS for oral hazard. Similarly, 86% (255/297) of the AIs were not classified by
GHS for dermal hazard, but only 51% (151/297) of these substances were not classified
for oral hazard (Fig. 3d).
As with the EPA system, the AIs as a group were classified by GHS as more toxic
than the formulations. A higher proportion of formulations were not classified for oral
hazard by GHS compared to the AIs (71% vs. 51%), and similarly, more formulations
than AIs were not classified by GHS for dermal hazard (98% vs. 86%) (compare
Figs. 3c and d).
Concordance of Oral and Dermal Hazard Classifications
Figure 4 compares the concordance of EPA and GHS oral and dermal hazard classi-
fications for formulations and AIs. The EPA classifications for dermal and oral hazard
were concordant for 62% (293/476) of the formulations (Fig. 4a) and 64% (150/233) of
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the AIs (Fig. 4b). The EPA oral hazard classifications overpredicted dermal hazard for
38% (179/476) of the formulations and 32% (75/233) of the AIs. The EPA oral hazard
classifications underpredicted dermal hazard for 1% (4/476) of the formulations and 3%
(8/233) of the AIs.
The GHS classifications for dermal and oral hazard were concordant for 71%
(358/503) of the formulations (Fig. 4c) and 55% (164/297) of the AIs (Fig. 4d).
The GHS oral hazard classifications overpredicted dermal hazard for 28% (142/503) of
the formulations and 41% (123/297) of the AIs. The GHS oral hazard classifications
underpredicted dermal hazard for 1% (3/503) of the formulations and 3% (10/297) of
the AIs.
Fig. 3. Distribution of substances across EPA and GHS acute oral and dermal hazard categories.
a) 476 formulations across EPA classifications b) 233 active ingredients across EPA
classifications, c) 503 formulations across GHS classifications, d) 297 active ingredients across
GHS classifications. UNC unclassified
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Fig. 4. Performance of oral hazard classification for predicting dermal hazard classification.
Performance using the EPA classification system is shown with: a) 476 formulations and b) 233
active ingredients. Performance using the GHS classification system is shown with: c) 503
formulations and d) 297 active ingredients. F formulations
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Discussion
Regulatory acceptance of any new alternative test method or approach requires that the
new method or approach provide equivalent or better protection of human health [21,
28]. We conducted the current analysis of the use of acute oral hazard classification to
classify substances for dermal hazard primarily to determine if there are instances
where the acute dermal hazard is greater than the acute oral hazard. When the acute
dermal toxicity hazard is greater than the acute oral toxicity hazard, the dermal hazard
would be underpredicted by the oral hazard classification if that were used for dermal
hazard classification. However, if such cases are rare or nonexistent, the use of oral
hazard classification to predict dermal hazard would be at least as protective as using
dermal LD50 data for this purpose because all of the predictions would either be
concordant or would overpredict dermal hazard. Therefore, oral hazard categories
could be used to determine dermal hazard classification without compromising public
health, and product labeling could be based on the oral hazard without the need for an
acute dermal systemic toxicity test.
Our analysis, which focused on the EPA hazard classification system and primarily
included substances of interest to the EPA, found that using oral hazard classifications
to predict dermal hazard classifications resulted in very few substances being under-
predicted for dermal hazard. This is consistent with similar analyses conducted by other
investigators [2, 16, 27]. Our reanalyses of these investigators’ data, to the extent such
data were available, provide further support for this conclusion.
Using a data set of 240 pesticide AIs, Creton et al. [2] showed that oral hazard
underpredicted dermal hazard for only 0.8% (2/240) of the substances using the
obsolete United Kingdom (UK) Chemicals (Hazard Information and Packaging for
Supply) Regulations system [29]. The UK system was a four-category hazard classi-
fication system. Like GHS without the optional Category 5, the UK system did not
classify substances with LD50 values greater than 2000 mg/kg as hazards, but the UK
LD50 ranges for the other hazard categories were different from those used by the GHS.
Because Creton et al. provided the dermal and oral LD50 data for the AIs, we were able
to analyze them using the GHS and the EPA system. For our analysis of these data
using the EPA system, we excluded substances with oral LD50 values greater than 5000
mg/kg and dermal LD50 values greater than 2000 mg/kg, as we did for our analysis.
The underprediction rates for both EPA and GHS categories were very similar to those
of our data set, which includes the Creton et al. data (Table 1).
In an analysis of a different set of 337 pesticide AIs using the same four GHS
hazard categories we used, Seidle et al. [27] obtained concordance and underprediction
rates similar to our AI analysis. Because this paper did not include LD50 data, we were
not able to reanalyze their data to determine the concordance, underprediction, and
overprediction rates for the classification of dermal hazard on the basis of the oral
hazard classification using the EPA system.
Moore et al. [16] analyzed a broader data set of 335 substances, which included 110
pesticide AIs from Creton et al. [2] and 225 uncharacterized substances from the
European Chemicals Agency database. Table 1 shows that concordance achieved by
Moore et al. using GHS was much lower than ours and those of the other studies, and
Approaches to Reducing Animal Use 45
that their underprediction rates were higher. Our dataset consisted of only pesticide
formulations and AIs. The higher underprediction and overprediction rates and lower
concordance for the Moore et al. analysis could be due to inclusion of the uncharac-
terized substances, which comprised approximately 67% of their database. Again,
because this paper did not include LD50 data, we were not able to reanalyze this data set
to determine concordance using the EPA classification system.
While underprediction of dermal hazard would pose a clear danger to users,
overprediction of dermal hazard is also undesirable, as overuse of stringent hazard
warnings has a desensitizing effect, ultimately causing users to disregard them. The
categorization approaches for our data sets showed that dermal hazard might be
overpredicted by the oral hazard classification for 38% (179/476) of formulations using
the EPA system and 28% (142/503) of formulations using the GHS (Fig. 4a, c).
Similarly, rates for overprediction of dermal hazard for AIs were 32% (75/233) with the
EPA system and 41% (123/297) with GHS (Fig. 4b, d).
The consequences of underprediction are more severe. Underprediction of dermal
hazard could lead to warning labels and protective equipment recommendations
inadequate to protect exposed persons, resulting in increased public health risk.
Underprediction of dermal hazard would also affect the caution and care with which
users handle consumer products. However, because dermal hazard classifications for
only a small proportion of formulations (1%) and AIs (3%) in our dataset were
underpredicted by using oral hazard data, our analyses suggest that acute oral hazard
would provide appropriate recommendations for personal protective equipment for all
but a small number of substances. If acute oral hazard were used to predict acute
dermal hazard, animal testing for acute dermal toxicity would be necessary for few
substances.
Our analyses, along with the others discussed here, indicate that it may be feasible
to greatly reduce the use of animals for acute dermal toxicity testing of pesticide
formulations and AIs. Based on the EPA acute dermal toxicity test guideline [6],
waiving the dermal acute toxicity test and using oral hazard classification to assign
dermal hazard classification would reduce the number of animals by 10 animals per
pesticide for a limit test and 20 animals per pesticide for a main test.
EPA has used an analysis similar to ours to support guidance for waiving all acute
dermal LD50 studies for pesticide formulations when acute oral LD50 studies are
available [9]. Because EPA receives hundreds of acute dermal submissions for for-
mulations each year, this development has the potential to reduce animal use signifi-
cantly for acute toxicity testing. Although EPA has not waived the dermal test
requirement for AIs, the waiver for formulations has a much larger impact on animal
savings because the vast majority of new data submissions support registrations for
formulations rather than AIs.
Future efforts to further reduce animal use for acute toxicity testing of pesticide
formulations and AIs should be directed towards developing approaches to identify the
small number of substances that might be underpredicted by acute oral toxicity testing
before dermal tests are performed. In silico investigations of route-specific bioavail-
ability could assist in identifying those substances. For substances that are likely to be
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more toxic dermally than orally and must be tested using the acute dermal toxicity test,
the OECD test guideline has recently been revised to use a stepwise procedure that
requires fewer than 10 animals [24].
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Abstract. We reviewed six key peer-reviewed publications that assessed the
need for one-year studies of pesticide toxicity in dogs. Each of the six papers
took a different approach to comparing the value of one-year studies relative to
three-month studies, and despite the adoption of different databases and
approaches, each study reached the same conclusion: the recommended limit to
the testing of pesticide toxicity in dogs should be three months.
Therefore, the present review supports the conclusion that the routine inclu-
sion of a one-year dog study should not be a mandatory requirement for the
safety assessment of pesticides, since it is scientifically no longer justifiable. We
recommend that the OECD should adapt a harmonized approach that is in line
with the legislation in Europe and the USA.
Keywords: Safety testing of pesticides  Regulatory testing  Dog studies
Length of studies  NOAEL
Introduction and Objective
Assessment of user safety and consumer safety is a key element in the development of
crop protection products and their active ingredients. Conventionally, toxicity tests
using laboratory animals have been the standard means for assessing potentially haz-
ardous effects of the chemicals used in drugs, pesticides, and consumer products like
food and feed. Testing in animals has long been criticized, and the publication in 1959
of Russell and Burch’s Three Rs (Russell and Burch 1959) laid the groundwork that
eventually led to the banning of animal tests for the safety assessment of cosmetics in
the EU (EU Commission 2009a). Moreover, since safety testing using monkeys and
companion animals, such as cats and dogs, has always been the target of criticism,
scientists tend to avoid using these species in testing for regulatory purposes. Conse-
quently, although safety studies using dogs are still conducted for pesticides and drugs,
they are no longer mandatory for other consumer products. Therefore, my colleagues
and I at the German Federal Institute for Risk Assessment (BfR) have tried to assess
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whether or not dog studies are a truly necessary means for the safety assessment of
pesticides, and if they are, which types of dog studies should be used.
For the registration of pesticides repeat-dose studies with rodents and dogs have
been essential elements for more than 50 years. According to international (OECD,
EU) and national (US EPA and many others) test guidelines 90-day and one-year oral
studies in rodents and dogs are the established standards for evaluating toxicity of
pesticides. Testing typically consists of initial exploratory studies across a range of
different concentrations to establish a dose that is then used in the three-month and one-
year toxicity studies. Since at least 70 dogs are used to test each new chemical, and
dozens of new chemicals are tested each year, the total number of animals needed
quickly reaches the thousands. In recent years, changes to regulatory requirements have
eliminated the need for one-year dog studies in the EU (EU Commission 2009b), and
they are now required in the US, Canada, (Health Canada PMRA 2016; Linke et al.
2017) and Australia only when it can be demonstrated that dogs are more sensitive than
rodents in 90-day studies.
Nevertheless, South Korea, Japan, and other countries still require a one-year dog
study before a product can be approved, and this means that companies must conduct
the study to be able to market the product in those countries, irrespective of the fact
such testing is not required elsewhere.
The purpose of this review is to critically evaluate the need for three-months and
one-year dog studies of toxicity and in particular to determine the importance, which of
each of these dog studies has for the safety assessment of pesticides.
Review of Regulatory Data not in the Public Domain
For more than 50 years a three-months and a one-year dog study have been mandatory
for the global registration of pesticides. It is the purpose of the studies is to identify the
dose at which no adverse effects occur, this is the “no observed adverse effect level”
(NOAEL), which is then used for setting a safe reference dose for humans in order to
enable a risk assessment.
The toxicity data used in safety studies is obtained from testing performed by
private enterprise and submitted to regulatory agencies in confidential reports. In other
words, they are not in the public domain and cannot be readily obtained for other
scientific purposes, such as evaluating the extent to which dog studies are actually
necessary for determining a NOAEL. And in spite of the fact that such evaluations
important for scientific, animal welfare, and economic purposes, proprietary toxicity
data cannot be obtained or used for such purposes without the consent of the owners of
the reports, e.g., agrochemical companies.
As a regulatory scientist at the Federal Institute for Risk Assessment (BfR) in
Germany, which is also the national agency for the regulation of pesticides, I was able
to request permission from the owners of such data and from my colleagues in the
pesticides administration of the BfR to conduct an evaluation of the extent to which
dog studies are necessary to the safety assessment of pesticides. In order to protect the
confidentiality of the data, the chemicals had to be coded for use in the study. Although
the same data is held in the files of regulatory agencies in all EU member states, Japan,
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and the US EPA, proprietary data on pesticides had never before been used for this type
of study. In fact, the only agency that later followed our example and conducted a
similar study was the US EPA. Consequently, there are only the three studies from our
group at the BfR in Germany (Gerbracht and Spielmann 1998; Box and Spielmann
2005; Spielmann and Gerbracht 2001) and the three studies from the USA, in which the
EPA was engaged (Baetcke et al. 2005; Doe et al. 2006; US 2006). Together with the
232 pesticides we analyzed in the German studies, the US EPA studies included both
these same 232 chemicals and roughly 150 additional ones, which suggests that dog
studies have been conducted for approximately no more than 380 chemicals. Unfor-
tunately, not all the reports submitted for regulatory purposes included data from rodent
studies, which would be a prerequisite in order to determine the NOAEL for pesticides
using long-term rodent studies alone or by combining long-term rodent studies with
short-term dog studies, rather than just long-term dog studies.
Results of the Studies Conducted in Germany
The results of the safety reports submitted to the BfR in Germany for 232 pesticides
(Gerbracht and Spielmann 1998; Spielmann and Gerbracht 2001; Box and Spielmann
2005) provided two major conclusions:
1. The testing of pesticides in dogs is indeed necessary because the dog has proved to
be the most sensitive species for about 15% of the compounds examined.
2. Chronic studies are of limited value, since they provide essential information that
cannot be obtained in sub-chronic studies only in about 5% of all cases.
These conclusions are corroborated by several retrospective analyses of safety
studies on pharmaceutical drugs carried out in the context of the International Con-
ference on Harmonization (ICH) for the registration of pharmaceuticals for human use.
Over 90% of the drugs test elicited no toxic symptoms in one-year dog studies that
were conducted in addition to prior 90- or 180-day dog or rodent studies. Another
approach, in which the results from pre-clinical animal studies were compared with
those from clinical studies, demonstrated that animal studies predicted about 70% of
the effects observed in volunteers, and that in about 94% of the cases, these effects
occurred in animal studies lasting no more than one month.
Based on these results, the report recommended abandoning the regulatory
requirement for the routine carrying out of one-year dog studies. Also, while 90-day
studies should be conducted in both dogs and rodents, chronic studies should only take
place in rodents. In cases where dogs are more sensitive than rodents in the 90-day
study, rather than conducting a one-year dog study, an additional safety factor should
be applied to the NOAEL value obtained in the chronic rodent study in order to set an
appropriate threshold for safe human exposure. This safety factor may be calculated
from chronic NOAEL data available from several pesticide databases. Chronic tests
using dogs would then only be required if the test compound belongs to a new class of
chemicals that has never been tested before. Thus, the report concludes that, according
to current scientific knowledge, routine one-year dog studies are no longer required for
agricultural chemicals and pesticides, and international regulations should be changed
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accordingly. Active international support of such measures is welcomed from both an
economic and an animal-welfare perspective.
Results of the Studies Conducted by the US EPA
The review performed by Baetcke et al. (2005) was based on a comprehensive database
of registered compounds that is maintained by the US EPA. The authors showed for 77
compounds that data from dog studies had an impact on the derivation of reference
doses.
The authors of the study concluded: “Thus the present analysis indicates that a 13-
week dog study would be adequate for identification of a NOAEL or LOAEL that would
be similar to that established from a chronic dog study except 3 pesticides (3/77or 4%)
of the cases evaluated.” And “Thus, the results of this current retrospective analysis of
studies on pesticides, when considered with the results of the analysis by Spielmann
and Gerbracht (2001), show, with few exceptions, that a 13-week dog study is as
adequate as a 1-year dog study for identification of a NOAEL.”
In 2006 the US EPA conducted additional analyses of dog studies conducted with
pesticide chemicals (Length of Dog Toxicity Study(ies) that is Appropriate for Chronic
RfD Determinations of Pesticide Chemicals). In this analysis a total of 110 pesticides
representing more than 50 classes were scrutinized.
The authors of the study concluded: “This larger analysis supports the conclusion
that longer-duration studies (one year) in the dog do not result in appreciably lower
NOAELs or identify new effects for the majority of chemicals when compared to the
shorter-duration study 13-week study in this species. Thus, reliance on the required
chronic rodent studies, two-generation rat reproductive study, and the thirteen-week
dog toxicity study is generally expected to provide an adequate basis for chronic NOEL
derivation in pesticide risk assessment. EPA acknowledges that there may be situations
where a longer duration dog toxicity study may be warranted when a pesticide
chemical is highly bio-accumulating (e.g. builds up in body fat) and is eliminated so
slowly that it does not achieve steady state or sufficient tissue concentrations to elicit
an effect during a 90-day study. EPA anticipates that this situation will be infrequent
since current pesticides are not usually designed to be highly persistent and bio-
accumulating. If such a chemical is encountered, EPA would require the appropriate
tier 2 metabolism and pharmacokinetic studies to more precisely evaluate bioavail-
ability, half-life, and steady state and determine if a longer duration dog toxicity study
is needed.”
Based on this conclusion, the US EPA removed the one-year study in dogs from the
list of studies required for the regulation of pesticides.
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Relevance of the One-Year Dog Study in Assessing Human
Health Risks for Registration of Pesticides. An Update
to Include Pesticides Registered in Japan
A recent publication by Kobel et al. (2014) focused on Japan, which is considered a
key region, and demonstrated the redundancy of the one-year dog study for agro-
chemical testing based on an analysis of data on the 400+ pesticides registered in that
region. The setting of a so-called Acceptable Daily Intake (ADI), which defines limits
on the amount of any particular chemical that a human should be exposed to over a
lifetime, is a key means of protecting human health. ADIs derived from dog studies are
available for 45 of these 400 pesticides, and these 45 ADIs were analyzed in detail. The
study showed that excluding data from the one-year dog studies would have made no
real difference in the setting of exposure limits for over 90% of these 45 pesticides.
Additionally, there might have been a difference in 6.5% of the cases, and there would
have been a genuine difference in the ADI recommendation in only 2.2% of the cases,
which is to say, one chemical.
The retrospective data analysis showed that, in 99% of cases there would have been
no significant impact on the safe exposure levels derived in Japan had the one-year dog
studies not been conducted, and that in all cases consumer exposure would have
remained well below the ADI.
This key publication adds substantially to the weight of published literature now
indicating that one-year dog studies add no significant value to the safety assessment of
agrochemicals. European regulations no longer require one-year dog studies. We now
need to work towards a harmonized approach with countries in other parts of the world.
The time has come for one-year dog studies to be removed from test requirements
globally.
Discussion
The limitations of each of these reviews are well understood as is the need for greater
comprehensiveness, and Baetcke et al. (2005) have asked for a broader review of entire
databases, not just the chemicals for which dog studies drive the safety assessment. In
response to this, the US EPA performed an extensive review in 2006 and concluded
that for pesticide risk assessment dog studies should be conducted for more than three
months. There is no disputing the need for repeat-dose studies in dogs of three months’
duration. The weight of evidence, however, of all these reviews together—and in
particular the studies conducted in dogs (Gerbracht and Spielmann 1998; Spielmann
and Gerbracht 2001; Box and Spielmann 2005; Doe et al. 2006; Baetcke et al. 2005;
Kobel et al. 2010; US 2006)—shows conclusively that there is little value in con-
ducting a one-year dog study in addition to a three-month study, which strongly
suggests that such studies can be safely eliminated from the list of studies that are
mandatory for the safety assessment of pesticides. Of all the chemicals in the databases
analyzed in the four main publications critically reviewed here, only 3–4% had ref-
erence doses the setting of which was influenced by the results of a one-year dog study.
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We consider the combined weight of evidence from these four reviews clearly
demonstrates that dog studies for pesticides need be no more than three months long.
The fact that each review arrived at a similar conclusion despite having taken a different
approach to the subject matter provides additional support for our conclusion. In cases
where dogs are apparently more sensitive than rodents in three-month studies a com-
parative evaluation for kinetics, and differences in dynamics should be analyzed.
Evidence from all of these reviews as well as from their combined consideration
supports the conclusion that dog studies are necessary but can be limited to three
months’ duration without compromising human safety. Thus, as suggested in some of
the reviews, improvements in study design are called for. Therefore, a balanced con-
sideration from the scientific and animal welfare perspectives suggests that national
requirements which are insisting on one-year dog studies for the regulation of pesti-
cides should be updated in order to be in line with the regulations established in the EU
and the USA, which would eliminate the requirements for dog studies longer than 3
months’ duration.
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Abstract. United Kingdom was the first to ban animal testing of cosmetics, and
it happened in 1998. The European Union (EU) went through legislations and
endeavors implementing animal testing ban in a phased manner, and the final
step was done in 2013. Consequent to this, there was enormous canvassing for
ban of cosmetic testing on animals in India, to harmonize the marketing as well
as import ban of EU. The Indian Drug and Cosmetic Regulatory Authority
conceded the demand resulting in the final ban in 2014. This review traces the
evolution of thought sequence resulting in the ban, and approval of adopting
OECD Guidelines for in vitro testing of skin and eye irritation and corrosion.
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Introduction
The EU defines a cosmetic product as “any substance or preparation intended to be
placed in contact with the various external parts of the human body (epidermis, hair
system, nails, lips and external genital organs) or with the teeth and the mucous
membranes of the oral cavity with a view exclusively or mainly to cleaning them,
perfuming them, changing their appearance and/or correcting body odors and/or pro-
tecting them or keeping them in good condition”1.
Cosmetics and ingredients therein, however much applied only externally, are all
chemicals, some of which are known or speculated to produce adverse reactions locally
and occasionally systemically in view of dermal absorption or inhalation. Therefore,
the regulatory authorities of cosmetics in many countries have mandated testing of the
cosmetics/ingredients for risks/adverse effects. For much of the last century this testing
has been done in animals, and different animals are used in different tests; for e.g. skin
and eye irritation/corrosion are tested in rabbits (Draize tests); dermal penetration, 90
day repeated oral dose, carcinogenicity, reproductive toxicity, and acute oral toxicity in
1 www.cosmeticsinfo.org/Regulation-in-eu.
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rat; skin sensitization and phototoxicity in guinea pig; genotoxicity in mouse; and
phototoxicity and carcinogenicity in mouse also. In view of lack of relevance of data
generated in animal models to humans in many instances, and the harm done to
the animal subjects, this testing has been opposed. The awareness thus created resulted
in European Union (EU) ban of cosmetic animal testing and sales in a phased manner,
with the final stage falling through in 2013 [1–3]. Thereupon, towards harmonization of
EU Cosmetic Regulation, several other countries- Israel, Norway, India, New Zealand,
Taiwan, South Korea, Turkey, Switzerland, and Guatemala, and six states in Brazil,
have banned or restricted animal testing of cosmetics [3, 4]. Similar legal measures
have been proposed and are under political debate in several other countries, including
the United States, Canada, Australia, and South Africa [5]. This article reviews the
evolution of thought sequence in India.
History of Ban of Animal Testing of Cosmetics in EU
The EU, consisting of 28 member states, became the world’s first set of countries to
ban cosmetic animal testing and trade. In 1993 the 6th Amendment to EU Directive
76/768/EEC was passed and contained a ban on the sale of newly animal-tested cos-
metic products. To make sure that adequate time was given to find non-animal
methods, the deadline for the ban to come into effect was 1st January 1998. In 1997 the
ban was delayed until 30th June 2000, and then further delayed until 30th June 2002 due
to a lack of adequate validated alternative methods. In 2003 the 7th Amendment to EU
Directive 76/768/EEC was passed and contained a phased-in ban on animal testing for
cosmetics with a deadline of 2013: Ban on animal testing of finished products, ban on
animal testing of cosmetic ingredients, ban on marketing of finished products tested on
animals post-enactment, and ban on marketing of cosmetics containing ingredients
tested on animals post-ban. Thus, on 11th September 2004 the ban on animal testing of
finished cosmetic products came into force. The sale of cosmetic ingredients tested on
animals outside the EU using methods that have been replaced within the EU was also
banned. On 11th March 2009 the ban on animal testing of cosmetic ingredients within
the EU was implemented. The sale of cosmetic products containing newly animal-
tested ingredients was banned; however, animal testing was still allowed for complex
human health issues such as repeat dose toxicity, reproductive toxicity and toxico
kinetics. On 11th March 2013 the full ban came into effect and it is now illegal to
market or sell cosmetics in the EU where the finished product or ingredients have been
tested on animals after enactment of the relevant phase of the ban. As of 11th July 2013
EU Directive 76/768/EEC has been replaced by EU Regulation 1223/2009 (Cosmetics
Regulation), which contains all the same provisions (Fig. 1). Thus, the entire endeavor
took more than 20 years to reach the final phase, as of now, and of course great lot of
financial input from governmental agencies and cosmetic industry partners, and a great
lot of scientific deliberations [1, 3], this long time and money to ensure that adequate
58 M. A. Akbarsha and B. Mascarenhas
and appropriate non-animal testing methods have become available. Due to the
development of non-animal techniques it became apparent that these animal studies
were no longer required.2
Cosmetic Regulation in India
The Central Drugs Standard Control Organization (CDSCO) is the Central Authority
for discharging regulatory functions relating to drugs and cosmetics, assigned to the
Central Government under the Drugs and Cosmetics Act, 1940 (D&C Act), and Drugs
and Cosmetics Rules, 1945. It is headed by Drugs Controller General (India), head-
quartered in New Delhi. The vision of CDSCO is to protect and promote public health
in India. It has as mission “to safeguard and enhance public health by assuring the
safety, efficacy and quality of drugs, cosmetics and medical devices”. Each of the 29
States and 7 Union Territories of India has its own Drug Control Authority (SDCA)
headed by the Drug Controller/Commissioner/Director, who is responsible for dis-
charging regulatory functions assigned under the provisions of the Drugs and Cos-
metics Act, 1940, and Drugs and Cosmetics Rules, 1945.
The Bureau of Indian Standards (BIS) is a statutory organization under the Bureau
of Indian Standards Act, 1986. The BIS formulates national standards and carries out
conformity assessment by operating the Product and Management System Certification
Scheme. One of the activities of BIS is to lay down standards for cosmetics in India.
The Cosmetic Regulation is governed by Drugs and Cosmetics Act, 1940, and the
Drugs and Cosmetics Rules, 1945, made under the Act.
Fig. 1. Connecting the dots for animals: History of the EU ban on animal testing for cosmetics.
[Adopted from www.understandinganimalresearch.org.uk/policy/cosmetics/]
2 www.understandinganimalresearch.org.uk/policy/cosmetics/.
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Cosmetic is defined under the D&C Act as any article intended for cleansing,
beautifying, promoting attractiveness, altering the appearance and any article intended
for use as a component of cosmetic. Under the said rule and law, no cosmetic can be
manufactured for sale except in accordance with the conditions of manufacturing
license issued by the respective SDCA. No cosmetic can be imported for sale except in
accordance with the conditions of Import Registration Certificate issued by the DCGI.
D&C Act and Rules require that cosmetics marketed in the country are safe and of
standard quality; importort manufacture of sub-standard, misbranded, adulterated and
spurious cosmetics is prohibited, and the Central Government has power under the
D&C Act to prohibit manufacture or import of any cosmetic, use of which is likely to
involve any risk to human beings.
Schedule-S to D&C Rules contains a list of 30 different cosmetics which include
skin powders and creams, tooth powders and pastes, hair oils, powder hair dyes,
shampoo, nail polish, lipstick, after-shave lotion, shaving creams, soaps, etc. The
cosmetics in finished form included under Schedule-S of D&C Rules shall conform to
the Indian Standards specifications laid down from time to time by the BIS. No cos-
metic shall contain dyes, colours, and pigments other than those specified by the BIS
(IS4707 Part 1 as amended) and Schedule-Q. The IS 4707 (Part 1) lists dyes, pigments
and colors which are generally recognized as safe (GRAS) and which when used in
concentrations conventionally adopted or within the limits as stipulated is permissible,
and IS 4707 (Part 2) lists cosmetics raw materials and adjuncts, other than dyes, colors,
and pigments in the following four groups: (A) list of substances classified as ‘GRAS’
which must not form part of the composition of cosmetic products -Annexure A of the
standard; (B) list of substances which cosmetic products must not contain except
subject to the restrictions and conditions laid down (Annexure B of the standard);
(C) list of preservatives allowed (Annexure C of the standard); and (D) list of UV filters
allowed in sunscreen products (Annexure D of the standard). Cosmetic products for-
mulated as per the restrictions imposed by IS 4707 (Parts 1 and 2) and the list of
Cosmetics, Toiletry and Fragrance Association (CTFA), European Economic Com-
munity (EEC) and the guidelines of Cosmetics Europe Guidelines on Exchange of
Information (IFRA) are likely to be safe, and such products may not warrant any safety
testing, whereas products which contain novel ingredients which are not under the
purview of the above documents shall require safety testing as per the guidelines
provided in IS 4011. The IS 4011: 1997 laid down by BIS prescribes “Methods of test
for safety evaluation of cosmetics”. Requirement of labeling of products not tested for
safety on animals with the statement “The product has not been tested on animals for
safety” was deleted from the Standard in 2002. Skin irritation test and eye irritation test
(Draize tests in rabbits) were removed from the Standard in 2007. In February 2014,
the IS 4011 was amended specifying that when there is a need for safety evaluation of
cosmetic products to demonstrate absence of oral toxicity and/or oral mucosal irrita-
tion, the manufacturer shall submit the safety data based on alternative non-animal test
methods to the concerned State Licensing Authorities for their consideration and
approval.
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Ban on Use of Animals in Cosmetic Testing
In response to public campaigning led by Humane Society International-India, PETA
India, and PfA, the Drug Technical Advisory Board (DTAB), a statutory body under
the D&C Act deliberated the issue of testing of cosmetics on animals in its 65th meeting
held on 25.11.2013 and recommended prohibition of the same by amending the D&C
Rules. Based on the recommendation, Government of India published a draft Rule vide
G.S.R. 16(E) dated 13.01.2014 for prohibition of testing of cosmetics on animals. The
draft rule was made available for public comments. After examination of the public
comments, Government of India prohibited the testing of cosmetics on animals vide
G.S.R. 346(E) dated 21.05.2014 by inserting the following rule in the D&C Rules,
“148-C: Prohibition of testing of cosmetics on animals-No person shall use any animal
for testing cosmetics”. Further, it was specified that when there is a need for safety
evaluation of cosmetic products to demonstrate absence of oral toxicity and/or oral
mucosal irritation, the manufacturer shall submit the safety data based on alternative
non-animal test methods to the concerned State Licensing Authorities for their con-
sideration and approval [6].
Prohibition of Import of Cosmetics Tested on Animals
The Government of India published Draft Rules vide G.S.R. 311(E) dated 05.05.2014
for prohibition of import of cosmetics tested on animals. The draft rule was made
available for public comments. After examination of the public comments, the
Government of India amended the D&C Rules, which prohibited the import of cos-
metics tested on animals vide G.S.R. 718(E) dated 13.10.2014. Further clarifications
were issued on 15.02.2015 and 29.06.2015, according to which the importer should
submit original undertaking from the manufacturer (legal/actual brand owner) of the
registered products stating that cosmetic products have not been tested on animals on
and after 12.11.2014; and new applicants should submit this undertaking along with
registration dossier to CDSCO wherein copy of the undertaking may be produced at
ports for clearing the consignments.
Conclusion
It is of historical importance that India has earned reputation as the first south east
Asian country to implement ban of animal testing of cosmetics, finished products as
well as ingredients, domestic as well as import. Yet, it may be some more time before
internationally recognized non-animal testing methods are fully implemented in India,
and until full non-animal replacements are available for all endpoints. As of now, the
OECD non-animal guidelines for skin and eye irritation and corrosion, skin sensiti-
zation, and other endpoints are to be followed, using weight of evidence and Integrated
Approaches to Testing and Assessment (IATA), in order to assess the toxicity potential
of novel cosmetic ingredients or finished product.
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Abstract. In accordance with a notification issued by Japan’s Ministry of
Health, Labour and Welfare (MHLW) in 2011, the Japanese Center for the
Validation of Alternative Methods (JaCVAM) has accelerated applications for
new test methods developed as alternatives to animal testing for the safety
assessment of the manufacture and sales of cosmetic products and quasi-drug
products that contain new ingredients. Taking advantage of this opportunity to
strongly impact testing throughout Japan, researchers have been coordinating
guidance on the use of such alternative test methods since 2012. Based on test
guidelines issued by the Organisation for Economic Co-operation and Devel-
opment (OECD) and JaCVAM evaluation documents, dermatologists and rep-
resentatives of cosmetic companies as well as specialists from both the
Pharmaceuticals and Medical Devices Agency (PMDA) and the National
Institute of Health Sciences (NIHS) have drafted guidance documents for a
number of alternative test methods.
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A complete ban on the marketing of cosmetic products and cosmetic ingredients that
have been tested on animals has been in effect in the EU since March 2013 [1]. In the
light of this regulation, almost all Japanese cosmetic manufacturers have ceased the use
of animal testing in the development of cosmetic products and ingredients. Just as in
the EU, Japanese regulatory agencies as well as the MHLW have adopted positive and
negative lists and generally do not require permits for the manufacture and sale of new
cosmetic products that contain known ingredients. In cases where safety assessment of
the manufacture and sales of quasi-drug products that contain new ingredients and new
cosmetic ingredients is required, however, the MHLW still requires that applications
for safety assessment be supported with animal data.
MHLW Updates
As shown in Table 1, the use of new cosmetic ingredients requires the submission of
results from safety assessment performed with animal testing, In such cases, the test
methods must ordinarily conform to notifications regarding pharmaceutical safety,
OECD test guidelines, and other publicly-recognized standards. They must also appear
in the keshohin-iyakubu gaihin seizou hanbai gaidobukku 2011–2012 (the 2011–2012
Guidebook on the Manufacture and Sales of Cosmetics and Quasi-Drugs) [2]. Also, all
animal testing must conform to koseirodousho non shokan suru jisshikikan ni okeru
doubutsu jiken tou no jisshi ni kan suru kihonhoushin (Basic Policies Regarding
Implementation of Animal and Other Testing at Organizations under the Jurisdiction of
the MHLW), as well as all other laws and regulations relevant to animal and other
testing [3].
An administrative notice [4] issued in July 2006 by the MHLW Evaluation and
Licensing Division indicated that the inclusion of results from alternative test methods
as documentary evidence in an application was acceptable, provided that the alternative
test methods conformed to accepted OECD test methods or had been similarly vali-
dated in a suitable manner. The administrative notice further stipulated that, in cases
where animal testing was to be performed, if information about the physicochemical
properties of the test chemical itself or similar chemical substances as well as the results
of non-animal testing (in vitro, in chemico, in silico testing) led to the reasonable
expectation that the test chemicals could induce distress or suffering in test animals,
efforts to mitigate such distress or suffering by diluting test chemicals would be
required.
On 4 February 2011, the MHLW issued a notification that data obtained with
alternative test methods approved by JaCVAM could be used for the submission of
quasi-drug applications, or for petitions to include ingredients in the Standards for
Cosmetics [5]. Information is available on the JaCVAM website [6] to help ensure
proper preparation of the documentary evidence to be included with applications for
approval of manufacturing and sales of quasi-drug products as well as in requests for
revisions to the positive list for cosmetics. This information has been made available to
the appropriate businesses and other concerned parties industrywide. In addition,
administrative notices issued in April 2012 and May 2013 by the MHLW Evaluation
and Licensing Division publicized the availability of alternative test methods for
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phototoxicity testing and skin sensitization testing for use in safety assessment of
cosmetics and quasi-drugs [5]. Additional information on other alternatives to animal
testing will be issued as it becomes available. Dermatologists and representatives of
cosmetic companies as well as specialists from both the PMDA and the NIHS have
drafted guidance documents for a number of alternative test methods based on OECD
test guidelines and JaCVAM evaluation documents.
Alternative test methods developed for OECD test guidelines are useful in predicting
potential hazards of exposure to chemicals, even though they are not always suitable for
providing the wide range of information needed for comprehensive safety and risk
assessment. Thus, manufacturers often have difficulty gaining approval from Japanese
regulators for new cosmetic ingredients unless they perform animal testing [6].
JaCVAM Update
JaCVAM was established to promote the use of alternative methods to animal testing in
regulatory studies, thereby replacing, reducing, or refining the use of animals wherever
possible, while meeting the responsibility of the National Center for Biological Safety
and Research (BSRC) to ensure the protection of the public by assessing the safety of
chemicals and other materials, as stipulated in the regulations of the NIHS in November
2005. JaCVAM activities are also beneficial to the application and approval for the
manufacture and sale of pharmaceutical, chemical, pesticide and other products, as well
as to revisions to standards for cosmetic and quasi-drug products [7–9].
Over the past 12 years, JaCVAM has played an active role in gaining approval for
the adoption of OECD test guidelines for more than ten different test methods
Table 1. Test methods for regulatory use in safety assessment of ingredients in Japan
Quasi-drug safety evaluation guidance
For main ingredients For additives
Acute toxicity Acute oral toxicity
Repeat dose toxicity (Sub-chronic, Chronic) NR
Reproductive toxicity NR
Local irritation (Skin, Mucous membrane) Primary skin irritation
Cumulative skin irritation
Ocular irritation
Skin sensitization Skin sensitization
Photo safety Photo safety
Genotoxicity Genotoxicity
Carcinogenicity (case by case) NR
ADME ADME (case by case)
Human patch test Human patch test
Human use test NR
NR: Not Required
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developed by Japanese researchers [6] and has evaluated alternative methods to animal
testing based on OECD test guidelines as well as International Conference on Har-
monisation of Technical Requirements for Registration of Pharmaceuticals for Human
Use (ICH) guidelines. Moreover, JaCVAM has recommended twenty-one test methods
for adoption by Japanese regulatory agencies [7], as shown in Table 2. The notification
issued by MHLW in 2011 presented JaCVAM with the opportunity to impart a strong
impact on testing throughout Japan by accelerating the development of new non-animal
test methods.
Guidance for Alternative to Animal Testing
The following guidance documents have been approved by the MHLW [5]. Based on
OECD test guidelines and JaCVAM evaluation documents, dermatologists and rep-
resentatives of cosmetic companies as well as specialists from both the PMDA and the
NIHS have drafted guidance documents for a number of alternative test methods.
• Guidance on the use of alternative test methods for skin-sensitization and photo-
toxicity in safety assessment of cosmetics and quasi-drugs (Appendix 1: Guidance
on the use of LLNA1 for skin sensitisation test as an alternative test method in
safety assessments of cosmetics and quasi-drugs, Appendix 2: Guidance on the use
of the in vitro 3T3 NRU2 phototoxicity test as an alternative test method in safety
assessments of cosmetics and quasi-drugs), dated April 26, 2012
• Guidance on the use of alternative test methods for skin-sensitization (LLNA:DA,
LLNA:BrdU-ELISA) in safety assessments of cosmetics and quasi-drugs, dated
May 30, 2013,
• Guidance on the use of the BCOP3 test as an alternative method for testing ocular
irritation in the safety assessment of cosmetics and quasi-drugs, dated February 4,
2014
• Points of consideration for ocular irritation testing in the safety assessment of
cosmetics and quasi-drug, dated February 27, 2015
• Guidance on the use of the ICE4 test as an alternative method for testing ocular
irritation in the safety assessment of cosmetics and quasi-drugs, dated November
16, 2015
• Guidance on the use of in vitro skin penetration assay (in vitro skin absorption
assay) in the safety assessment of cosmetics and quasi-drugs, dated November 15,
2016
• Guidance on the use of combinations of in vitro skin sensitization assays in the
safety assessment of cosmetics and quasi-drugs, dated January 2018.
1 LLNA: Local lymph Node Assay.
2 NRU: Neutral Red Uptake.
3 BCOP: Bovine Corneal Opacity and Permeability.
4 ICE: Isolated Chicken Eye.
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Almost all Japanese cosmetic companies have stopped animal testing voluntarily
and now hope that the MHLW and PMDA will approve the use of new cosmetic
ingredients without animal testing. Many procedures for regulatory acceptance still
require animal testing, and it is difficult to gain approval even for additives to quasi-
drug products without data from animal testing. Given the current situation, JaCVAM
has attempted to promote the development of guidance for the use of alternatives to
animal testing. Unfortunately, there are still many types of testing for which non-
animal test methods are limited. In particular, there are as of yet no suitable non-animal
Table 2. Test methods proposed to the Ministry of Health, Labour and Welfare by JaCVAM
No. Test Method
1 In vitro skin corrosion testing: i.e. Human Skin Model Test: Vitrolife-Skin, EpiDerm,
Episkin, SKinEthics, EpiCS
2 In vitro skin corrosion testing: Transcutaneous Electrical Resistance Test Method (TER)
3 In vitro skin corrosion testing: In Vitro membrane barrier test method for skin corrosion
4 In vitro skin irritation testing: i.e. Reconstructed Human Epidermis Test Method, Episkin,
Epiderm, SkinEthics and LabCyte EPI-Model
5 Bovine corneal opacity and permeability (BCOP) test for identifying ocular corrosives
and severe irritant
6 Isolated chicken eye (ICE) test for identifying ocular corrosives and severe irritants
7 Fluorescein leakage (FL) assay for identifying ocular corrosives and severe irritants
8 Short Time Exposure In Vitro Test Method for assessing ocular irritation
9 Reconstructed human Cornea-like Epithelium Eye Irritation Test Method
10 Acute Eye irritation/Corrosion
11 Local lymph node assay (LLNA) and reduced LLNA for identifying skin sensitising
substances
12 LLNA:DA, a non-radioactive modification of the LLNA method, which quantifies
adenosine triphosphate (ATP) content via bioluminescence, as an indicator of
lymphocyte proliferation for identifying skin sensitising substances
13 LLNA:BrdU-enzyme linked immunosorbent assay (ELISA), a non-radioactive
modification of the LLNA method, which utilises non-radiolabelled 5-bromo-2-
deoxyuridine (BrdU) in an ELISA-based test system, to measure lymphocyte
proliferation for identifying skin sensitising substances
14 Direct Peptide Reactivity Assay for skin sensitisation Testing
15 ARE-Nrf2 Luciferase Test Method assay for skin sensitisation testing
16 h-CLAT (human Cell Line Activation Test) for skin sensitisation testing
17 Skin absorption in vitro method
18 Reactive Oxygen Species (ROS) assay for photosafety assessment
19 In vitro cytotoxicity test for estimating starting doses for acute oral systemic toxicity tests
20 BG1Luc estrogen receptor transactivation assay (ETRA), for identifying oestrogen
receptor agonists and antagonists
21 Stably transfected Transcriptional Activation Assay to Detect ER mediated activity
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test methods available as alternatives to the LLNA, LLNA:DA, LLNA:BrdU-ELISA,
or Draize eye test, and the time has come to accelerate the development of and
guidance for the use of in vitro test methods for new cosmetic ingredients.
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Abstract. Globally cancer is a major public health issue and is a second biggest
cause of deaths. Although animal models have limitations in terms of predictive
and translational value to humans, they have played a major role in under-
standing this disease and anticancer drug discovery. In cancer research the most
commonly used animal species are mice, rats, hamsters, rabbits, Guinea pigs,
fish and amphibians. Use of different cell lines in tissue culture system offers a
great relief from use of animals at the same time provide important clues before
embarking the animal experiments. Use of spontaneously developing tumor
models are encouraged rather producing diseases in the animals. Beside the
alternatives, refinement also plays important role in reducing the animal usage in
cancer research. However, cancer research use whole body system to evaluate
the new strategies for diagnosis and treatment of cancer. This paper highlights
the available alternatives and refinements for animal experimentation. A positive
note is that if coupled with the refinements, even a minimised number of animal
usage shall also yield the meaningful and acceptable results.
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Introduction
Cancer researcher plays an important role in investigating new modalities of diagnosis
and treatment. This includes discovering the faulty genes and molecules that cause
cancer, investigating how the disease grows and spreads, developing and testing new
treatment and tests, and exploring how our immune system can help fight tumours.
Literature surveys indicate that amongst various species, rodents have been extensively
used in biomedical research. The laboratory mouse and rat is a common experimental
model, in part because of well-defined strain genealogies, standardized mapping tools,
and the availability of sophisticated genetic monitoring technologies. When animals are
used for research, it is the moral duty of the scientist to avoid or minimize discomfort,
distress, and painful situations. The regulations and policies help to ensure animals are
treated humanely. If a procedure involves more than momentary or slight pain or
distress, it must be performed using appropriate pain relieving drugs (e.g. sedatives,
analgesia or anesthesia) [1].
Knowledge gained through use of animals in research is still improving the life of
not only humans but domestic as well as pet and wild animals too. Discovery of
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antibiotics like penicillin, erythromycin, tetracyclin etc. would have not been possible
without involvement of animal testing.
Further the discovery of Nude and SCID mice model have made significant
improvement in these models and have made it possible to identify clinically effica-
cious agents through anticancer research and testing. These models are said to be a
‘Workhorse’ of the pharmaceutical industry. These models have not only helped in
characterization of cancer cell lines but also helped us in understanding metastatic
processes and efficacy of the newly developed anticancer drugs [2].
Cancer researchers need predictive and cost effective preclinical models that more
accurately predict the response of human cancer to chemotherapy. Experimental
models of human cancers are important in reconstructing the events that occur in
human patients with cancers. A variety of factors decides the choice of tumor and
model.
Alternatives in Cancer Research
Scientists use many ways to try to replace animals used in research. These include
using cell cultures, computer modelling and human studies. Researchers must attempt
using these techniques if they would be as effective as using animals.
Responses to chemicals are complex and difficult to accurately assess using only
biochemical or cell-based (in vitro) systems or computer models. No single in vitro test
method can be employed to serve all regulatory needs for a specific testing area.
Mechanistically based alternative approach may provide promising opportunity for
assessing hazards of regulatory concern. Adverse outcome pathways (AOPs) are
expected to provide insight into the biological relevance, reliability, and uncertainties
associated with the results from in silico, in chemico and in vitro approaches for
regulatory use. This provides the biological context and supporting weight of evidence
to facilitate the interpretation of such alternative data [3]. Severe eye irritants and
substances that could cause allergic contact dermatitis is the only option where major
progress has been made in reducing and replacing animal use [4]. For other hazards that
can cause cancer or birth defects, development of in vitro tests that reliably identify
hazards is more difficult because of the number of different mechanisms involved in
these complex biological processes. However, some lower vertebrate offers the best
alternatives in cancer research.
Zebrafish, Danio rerio have become a popular model for studying developmental
processes and human diseases. Fish and human solid tumors share a high degree of
histological similarity and therefore have been used extensively as model for human
cancers. Zebrafish also form spontaneous tumors with similar histopathological and
gene expression profile as human tumors [5]. Zebrafish have proved to be useful for use
in cancer research over the last decade. There are several long-standing methods for
establishing a cancer model in zebrafish, including carcinogenic treatment, transgenic
regulation, and the transplantation of mammalian tumor cells. Some of the analysis of
metastasis pathway is conducted in tightly controlled in vitro cell system usually
involving up-regulation or down-regulation of genes. These assays include trans-well
motility, wound healing, invasion and hanging drop assays. These assays do not answer
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issues of intravasation of tumor cells into blood vessels or extravasation in to distant
organs. In order to study these processes, there is no alternative to in vivo systems.
However, zebrafish can offer these assays as an alternative to rodents or other verte-
brates animals to study the human tumor angiogenesis or metastasis. Because of the
transparent in nature, Zebrafish offer excellent features to study tumor angiogenesis as
well as metastasis [6, 7]. Reports have also shown that primary human cancer cells can
metastasize in fish and this ability can be used to predict metastatic potential in a
clinical setting. Zebrafish has been used to study the metastasis of lymphoblastic
leukemia, melanoma, breast tumor, prostate cancer, rhabdomyosarcoma, testicular
cancer, colon cancer, neuroblastoma and pancreatic tumors [8–13].
Organisms like Hydra have been used as a model for regeneration, embryogenesis,
testing the water pollutant eco-pollutant and environmental genomics [14, 15]. How-
ever, it remains to be seen whether they can also be used explored for studying the
carcinogenesis.
Efforts are also targeted towards use of ‘artificial tumor’ tissue grown from stem
cells or a combination of tumor cells and tumor stromal cells etc. [16, 17]. Full-
thickness skin models can be used to test the effect of substance in question on the skin
tissues. However, since cancer research needs a complete body system for testing, this
model may be of little hopes.
Use of spontaneously developing tumor models like leukemia, lung cancer, brain
cancer and breast cancer caused by MMTV or any other aetiology are encouraged in
lieu of producing these diseases in the animals.
3R’s
WMS Russell and RL Burch originated the concepts of replacement, reduction, and
refinement, which they published in their book in 1959 entitled “The Principles of
Humane Experimental Technique” [18]. Russell and Burch proposed that if animals
were to be used in experiments, every effort should be made to ‘Replace’ them with
non-sentient alternatives, to ‘Reduce’ to a minimum number of animals used, and to
‘Refine’ the experiments so that they caused the minimum pain and distress.
Replacement alternatives advocate methods to be used in achieving scientific
results without conducting experiments on animals. There is a direct correlation
between larger number of animals used to higher overall costs and animal suffering.
Therefore, the number of animals used should be kept to a minimum that would be
consistent with the research objectives. Refinement alternatives include methods that
alleviate or minimize potential pain and distress thus emphasizing on animal well-
being.
CPCSEA
The Institutional Animal Care and Use Committee (IACUC) or Institutional Animal
Ethics Committee (IAEC) is legally required to oversee all animal care and use
activities conducted at their institution. IACUC/IAEC is also required to set high
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ethical and welfare standards for using the animals. In India the Committee for the
Purpose of Control and Supervision of Experiments on Animals (CPCSEA), estab-
lished under the Ministry of Environment, Forests and Climate Change has been
instrumental in avoiding the animal usage or if not possible, to reduce the number of
animals used in experimentation. At the local level, IACUC/IAEC are mandated to
ensure that: the number of animals used for the research in each groups are enough to
yield statistically valid results; appropriate species of animal is used for the project;
humane experimental endpoints have been established and appropriate methods of
euthanasia are being utilized [19]. The CPCSEA integrate the 3R’s in all R&D pro-
cesses and procedures. It gives emphasis on review of animal models on a continuous
basis for replacement with alternatives. It also promotes use of human cells and tissues
instead of living animals, wherever possible. The CPCSEA is charged with reviewing
and approving all research and testing activities in India that involve animals before
scientists begin their experiments to ensure that there are no alternatives to using
animals, that research is not being unnecessarily duplicated, and the experiment is
relevant to human or animal health and will be for the betterment of the society.
Refinement in Cancer Research
For more than a half century mice have been the primary species in which experimental
cancer chemotherapy have been tested [20]. Cancer drug screening program of the US
National Cancer Institute (NCI) started with the ascitic and then with solid tumors. This
program used conventional mouse models like C57BL/6, Swiss, BALB/c and DBA/2
strains. After the discovery of the Nude and SCID mice, widespread use of human tumor
transplantation for anticancer research and testing was made possible [21, 22]. Mice and
rats often develop benign and malignant cancers spontaneously. The incidence may vary
from strain to strain. These spontaneous tumors do not always metastasize to different
organs or have mild local tissue invasion and therefore the incidence is very rare.
However, majority of the data generated on the metastatic behavior of cancer is reported
to be derived from studies in rodent models only [23, 24].
‘Specialized’ models like transgenic, knock out, Nude, SCID and hairless SCID
mouse models have played a central role in cancer research. Models like SCID beige,
NIH-III, NOD-SCID, SCID beige, NSG, NOG and Rag-1 and 2 mutation mouse model
which lack T-, B- as well as NK cell activity are the next level of ‘super specialized’
models, which supports not only the hetero-transplantation but also the metastasis
studies.
Use of T- and B-cell deficient animals as shown by the use of flow cytometry; use
of rodent pathogen-free animals; use of genetically proven animal models; use of
appropriate number of cells and volume for injection; use of appropriate route of
injection; and use of properly genotyped/phenotyped animal models helps to reduce the
number of animals used for the respective research and also yield authentic and
reproducible results. Use of spontaneously developing tumor models such as mammary
gland tumors in C3H/J mice, leukemia in AKR mice, lung cancer in A/J mice and brain
tumor in Ptch or Smo knockout mice is one of the refinements. New tumors or tumor-
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like growth found in the laboratory animals can be a potential material to study the
disease processes. Spontaneously developing papilloma incidence has been reported in
Nude mice by Ingle et al., 2011 [25]. These are characterized to be caused by mouse
papillomaviruses. This model has been exploited and characterized fully for its cause,
genomic analysis, molecular diagnosis and sequencing of the virus. [26–29].
In order to ascertain the absence of T- and B-cells in the immune-compromised
animals, assessment of these cells by flow cytometry is the best method [30]. This can
be done by measuring the CD3 antibodies for T-cells and CD19 antibodies for B-cells.
Additionally, subsets of CD3 can also be checked by including CD4 and CD8
antibodies.
Conclusion
Use of animals remains unavoidable for the time being for the development of new and
more effective methods for diagnosis and treating diseases that affect both humans and
animals. However, it is our moral duty to see that the use of animals is either replaced
or atleast minimized to the extent to get the meaningful as well as reproducible and
acceptable results. With its own advantages and disadvantages, the zebrafish embryo as
well as zebrafish tumor xenograft model can be very well used as a tool for investi-
gating the cancer biology including neovascularization for drug discovery and gene
targeting in tumor angiogenesis. With refinement of the quality of animals through
genetic & microbiological testing, refining the volume and route of injection and use of
spontaneously available tumor models, it is possible to achieve the same results in
cancer research.
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Abstract. The 3Rs principles – Replacement, Reduction, Refinement – were
established in 1959 and since then have been adopted widely and particularly in
Europe with the European Directive 2010/63/EU. The vaccine industry in
Europe has been committed to the 3Rs principles for several years, including
animal welfare as well as for reducing and replacing animal use in research, non-
clinical safety and analytical testing.
Whereas animal testing has been successfully removed from lot release
testing of well-characterized human vaccines, large numbers of laboratory ani-
mals continue to be used for safety and potency quality control testing for
established inactivated vaccines such as rabies, pertussis, diphtheria, and tetanus
vaccines.
Moreover, specifications for human vaccine batch approval often differ
between various parts of the world, resulting in either duplication of animal
testing or partial implementation of 3Rs for some vaccines when distributed
worldwide. This reinforces the need for enhancing international harmonization
and cooperation efforts.
In this chapter, we review the use of laboratory animals in human vaccines
research and quality control and describe the vaccine manufacturing industry
commitments and its concrete programs for implementing 3Rs principles in
R&D and industrial operations processes. We highlight the successes as well as
the barriers that are encountered when implementing 3Rs principles, as well as
the ongoing efforts that include international collaborations with other indus-
tries, public organizations and Health Authorities for the acceptance of alter-
native methods.
Animal Use in Vaccine Quality Control
Vaccine quality control tests have their roots in the 19th century with the work of L.
Pasteur, R. Koch, E. von Behring, P. Ehrlich and others. Test design based on multi-
dilutions assays and using a reference preparation in parallel to the vaccine to be tested
was introduced in the 30–50 s of past century by Prigge [1]. The current in vivo quality
control tests have been developed in the 50 s–70 s of the previous century (for
example: the Kendrick test for Pertussis vaccine, the NIH test for Rabies vaccine).
A sharp increase in animal numbers used for vaccine quality control has been observed
since the 50 s.
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Today, testing of biologicals has the highest proportion of experiments causing
severe pain and distress to animals out of various types of experiments (basic research,
non-clinical testing, and quality control). The vaccine industry accounts for a high
proportion of these animals. Animals are used for vaccine development (research, non-
clinical evaluation of safety & efficacy), production as well as batch control testing for
safety and potency. Vaccines quality control is responsible for the vast majority of
animal used by vaccine manufacturers. Moreover, in addition to animals used for batch
control testing by vaccine manufacturers, there are additional animals used by National
Control Laboratories when duplicating some of the control tests.
3Rs History and Vaccine Context
The principles of Humane Experimental Technique were first described by William
Russel and Rex Burch in 1959 [2]. An important step in international coordination of
3Rs efforts for vaccines quality control was achieved at the conference organized by
IABS in London in 1985. The concept of 3Rs in vaccine research and testing translates
as follows:
– Replacement means implementing methods which avoid or replace the use of
animals
– Reduction, means changing the test design in order to minimize the number of
animals per experiment
– Refinement: means moving to methods that minimize suffering and improve animal
welfare (e.g. replacing challenge tests by immunogenicity assays)
There are four main drivers that justify implementing 3Rs in vaccine quality control.
The first driver is animal welfare: Animals are sentient beings, large number of
animals is used for vaccine quality control and a large proportion of those animals are
exposed to severe pain and distress, and there is a growing societal concern regarding
the use of animals for scientific purposes.
The second driver is Science: In vivo models act as a black box and their relevance
to human is sometimes questionable; they often show poor robustness and high vari-
ability inherent to the use of live individuals. The technologies and the scientific
knowledge have evolved over the past years and state of the art in vitro technologies
are now more performant and relevant than animal in vivo assay to evaluate the
consistency of a vaccine.
The third driver is Economics: In vivo tests are time consuming and human
resource demanding; in vivo tests are expensive due to the animals themselves, and
have long cycle times (several weeks for most in vivo potency assays as well as some
safety tests). Moreover, the high variability can lead to rejection of safe and efficacious
vaccines, thus inducing delays to market release and vaccine shortages.
The fourth driver is the regulatory context: 3Rs have now become legal requirement
in Europe; it started with EMA guidance in 1997 [3], followed by a first directive in
2001 for medicinal as well as veterinary products [4]. The key directive on the pro-
tection of animals used for scientific purposes was issued in June 2010 [5] with the
following statement: “Member States shall ensure that, wherever possible, a
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scientifically satisfactory method or testing strategy, not entailing the use of live ani-
mals, shall be used…”
In addition, the 3Rs offer an opportunity for harmonization. There is today no
worldwide harmonized framework, leading to many divergent local regulatory
requirements. As a vaccine may be registered in more than 100 countries for which
there are different release requirements, this translates into having to apply various
in vivo methods for one product, which leads to additional complexity for supply chain,
for testing and regulatory submissions, as well as more animals used per batch release
(in practice we may end up with 4 repeat testing between manufacturer and the different
National Control Laboratories involved in batch release). The ultimate impact is
increased costs and timelines with no added value on the quality of the product, a risk
of vaccine shortage, and finally a negative impact on public health.
3Rs Successes
Table 1 presents the current status for the use of alternative methods, in the European
Pharmacopeia and in vaccine industry respectively.
For all vaccines, the European Pharmacopeia has waived the General Safety Test
from routine testing. In practice, this test is omitted for all new vaccines, but not yet for
all existing vaccines due to local requirements, as well as time needed to submit
variations in all countries.
For the test for specific toxicity for diphtheria vaccines, the European Pharmacopeia
allows performing a cell-based method at Drug Substance stage, and to waive the test at
Drug Product stage, and this is partially implemented again due to local requirements.
For the test for specific toxicity for Pertussis vaccines, the European Pharmacopeia
allows performing a cell-based method at Drug Substance stage, and this is partially
implemented depending on the product; applying the cell-based assay as well as
omitting the test at Drug Product stage is under evaluation at European Pharmacopeia.
For oral Polio vaccine neurovirulence test, switching from non-human primates to
transgenic mice is described in European Pharmacopeia and implemented. For inac-
tivated Polio vaccine (IPV) inactivation test, the European Pharmacopeia allows
replacing the primary monkey kidney; the L20B cell line is routinely used.
For testing of adventitious agents, the removal of tests on guinea pigs and eggs is
applicable in European Pharmacopeia since January 2017, and the implementation is
ongoing. Moreover, the replacement of in vivo tests by broad molecular methods is
described in European Pharmacopeia since January 2017, and developments to support
implementation are ongoing.
For potency assay for diphtheria and tetanus vaccines, the European Pharmacopeia
allows using serological instead of lethal endpoints, and allows moving to single
dilution assays and this is partially implemented, depending on product and market.
For IPV, the European Pharmacopeia allows replacing the in vivo assay by an
immunochemical assay (ELISA), and this is implemented for most products but not all
due to local requirements.
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For the potency assay for inactivated rabies vaccines, the European Pharmacopeia
allows using an immunochemical method and such assay has been developed at Sanofi
Pasteur [6] and is under validation in the frame of an international working group [7].
Table 1. Use of alternative methods to in vivo safety and potency tests for vaccines
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For the potency assays for hepatitis A and B respectively, haemophilus Influenzae
and human papilloma vaccines, the European Pharmacopeia allows using immuno-
chemical methods and this is implemented for both vaccines.
Barriers to 3Rs
There are two main barriers to 3Rs implementation: one is regulatory and the other is
scientific.
The main regulatory hurdles are:
– the lack of harmonization of regulatory requirements, worldwide
– the prudence of health authorities to accept deviations from established guidelines
– the complexity of regulatory changes that discourage and slow development and
implementation of alternatives to animal testing; this is one of the main reasons why
industry has not been able to fully implement alternative tests described in Euro-
pean Pharmacopeia.
The key scientific hurdles are:
– The inherent variability of in vivo assays
– The fact that the in vivo assays are not validated as per ICH requirements [8]
– The fact that the product quality attributes will likely be assessed differently when
changing from an in vivo to an in vitro method.
Therefore, a one-to-one comparison is often challenging and not necessarily
justified.
Perspectives for the Future
This is the time for moving from the concept of test replacement to the concept of test
substitution that is based on demonstrating the scientific relevance of the new test.
For potency tests, this means demonstrating the capability of new test to control key
quality attributes and maintain link with batches found efficacious through clinical
studies or through routine use as well as the capability of the in vitro test to detect
differences that are relevant to the control of the production process.
For safety tests, the in vitro method should be specific and at least as sensitive as
in vivo assay. Where possible, a functional assay should be used; otherwise, the
alternative method should be based on the detection of parameter(s) reflecting the mode
of action of the toxic component.
Moving from one-to-one replacement or substitution to an integrated approach aims
at implementing the “consistency approach” that was described by de Mattia et al. in
2011 [9] and is based on the strict application of GMP rules and guidelines, process
validation, in process and final product tests, and is aimed at verifying that a manu-
facturing process produces final batches which are consistent with one that fulfils all the
criteria of Quality, Safety and Efficacy as defined in the marketing authorization,
ultimately resulting in replacement of routinely used in vivo tests.
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Concluding Remarks
3Rs acceptability is based on full implementation of GMP, reliable, standardized and
validated processes, in process monitoring, consistent product demonstrated safe &
efficacious, relevant science and validated tests (as per ICH Q2(R1)).
Regulatory acceptance of 3Rs is easier for new vaccines. For existing vaccines,
manufacturers need help in order to facilitate post-approval changes based on:
– a mutual understanding, recognition and implementation of the change by all
stakeholders in a timely manner
– a global harmonization of regulatory requirements endorsed by an international
organization
– involvement of all stakeholders (regulators, scientists, animal welfare organizations,
the public and decision makers) for communication of best practices.
International collaboration is a key element for the implementation of 3Rs princi-
ples and the European vaccine industry is involved in several international projects or
working groups such as:
– European Partnership for Alternative to Animals (EPAA) and more specifically in a
project dedicated to the replacement of NIH potency assay for human Rabies
Vaccine [7] as well as in another project working on harmonization of 3Rs in
Biologicals which is currently focusing on the deletion of GST worldwide [10]
– An international working group sponsored by NIH, ICCVAM, NC3Rs and EDQM
that has been working on the replacement of the histamine test for Pertussis specific
toxicity at Drug Product stage from 2010–2015, that may lead to the introduction of
a cell-based method in European Pharmacopeia
– The Vac2Vac project which is supported by the European Innovative Medicines
initiative (IMI), which is a public-private partnership between the European Union
and the European Federation of Pharmaceutical Industries and Associations
(EFPIA). Vac2Vac is a 5-year project with a total budget around 16 M euros, and
involves 21 partners, 15 public, 6 vaccines manufacturers, from veterinary and
human vaccine industries. The objective of the project is to provide the proof of
concept to support use of the “consistency approach” for quality control of estab-
lished vaccines using sets (toolbox) of in vitro analytical methods.
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Abstract. New streamlined approaches that use fewer resources and animals
are needed for the safety assessment of chemicals. Data gathering should be
streamlined to fit regulatory need and the specific properties of the chemicals
being assessed. Toward this goal, the Organization for Economic Cooperation
and Development (OECD) has introduced the concept of integrated approaches
to testing and assessment (IATA) to inform hazard or risk assessment. An IATA
is designed to address a specific question, and may include exposure or regu-
latory considerations, depending on the context. IATA can be informed by
mechanistic information about the chemical and related biology. OECD’s of
Adverse Outcome Pathways (AOPs) framework is designed to gather biological
information related to adverse outcomes of regulatory significance. An AOP is
the collected chemical and biological information about a particular biological
pathway. The OECD has developed guidance for building and assessing AOPs,
and is coordinating development of the AOP Knowledge-base (AOP-KB) for
collecting and using this information. The AOP-KB also accepts information
about the perturbations of these pathways caused by chemical exposure –
information can be used to design prediction models. AOPs can form the logical
basis for the integration of information and the design of integrated testing
strategies (ITS), within the context of an (IATA), to more effectively and effi-
ciently inform hazard or risk determination.
Keywords: Adverse Outcome Pathway (AOP)  Integrated Approach to
Testing and Assessment (IATA)  Chemical safety assessment
New Approach Methodologies (NAM)
Introduction
There are scientific, social, economic, practical and regulatory pressures stimulating the
development and use of streamlined chemical testing and assessment approaches,
including increased reliance on non-animal approaches [also called new approach
methodologies (NAM)]. Advances in biological understanding as well as in experi-
mental technologies (e.g. ‘omics tools, cell culturing, reconstructed tissues) have
allowed the consideration of dramatically different approaches to chemical safety
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assessment than those traditionally practiced. Increasingly, combinations of non-testing
and non-animal test methods are replacing apical animal tests.
For example, there are perhaps tens of thousands of industrial chemicals already in
use and in the environment about which there is little toxicological information, and
many new chemicals are developed each year, necessitating implementation of a new
approach that can broadly assess a large number of chemicals relatively quickly.
Another driver comes from the personal care product sector where consumers and
regional laws are increasing pressure to develop products without testing on animals.
To build a more efficient process, a 2007 National Research Council (NRC) report
recommends “Transform(ing) toxicity testing from a system based on whole animal
testing to one founded primarily on in vitro methods that evaluate changes in biologic
processes using cell, cell lines, or cellular components, preferably of human origin”
(NRC 2007).
The Adverse Outcome Pathway (AOP) Framework
In order to be able to make decisions using this new type of information, we need to
understand how changes at the molecular level in cells and tissues are related to the
apical adverse outcomes (such as tumor development, changes in organ size or his-
tology, or death) that toxicologists are more familiar with Fig. 1). The Organization of
Economic Cooperation and Development (OECD) has created the Adverse Outcome
Pathway framework to collect, organize and evaluate the biological information that
links upstream molecular changes with downstream organ, organism and population
changes (Fig. 1). According the OECD AOP handbook, AOPs “can be viewed as a
sequence of events commencing with initial interactions of a stressor with a biomo-
lecule in a target cell or tissue (i.e., molecular initiating event), progressing through a
dependent series of intermediate events and culminating with an adverse outcome…
AOPs are typically represented sequentially, moving from one key event to another, as
compensatory mechanisms and feedback loops are overcome” (OECD 2018).
Every AOP consists of a variable number and arrangement of a few key elements: a
molecular initiating event (MIE), the adverse outcome (AO) of regulatory relevance,
any number of intermediate Key Events (KE) and the relationships between these
elements (key event relationships or KERs). Five general principles are involved in
AOP development: (1) AOPs are not chemical specific, (2) AOPs are modular (con-
sisting of KEs and KERs) that can be shared between two or more pathways, (3) An
individual AOP is a pragmatic unit of development and evaluation; (4) for most real-
world applications, AOP networks are the functional unit of prediction, and (5) AOPs
are living documents, and, as more information is discovered, will be continuously
updated and never really finished (Villeneuve et al. 2014). OECD is coordinating the
development of the software (the AOP knowledge-base or AOP-KB) as well as a
number of guidance documents to facilitate the development, evaluation and use of
AOPs. In addition, the Human Toxicology Project Consortium (which is coordinated
by the Humane Society of the United States), in collaboration with OECD’s AOP
program, has created a training course that is freely available to anyone. These
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documents are available from the OECD website, and the training course is available
from the HTPC website or at https://aopwiki.org.1
The main element of the AOP-KB is currently the AOP Wiki (https://aopwiki.org).
The AOP wiki is designed to capture all of the information about AOP elements in text
form, via standardized drop-down menus (to keep a standard format and consistent
ontology) and free text fields (to accommodate data, explanations and references). As
of this writing, there are more than 200 AOPs and more than 1000 KEs and KERs
described in the wiki linked to 340 different stressors (metrics available on the AOP
Wiki). As more pathways are described, connections between KEs that are common to
different pathways are identified, and in this way, biological networks, which are the
basis for predicting AOs from MIEs, are discovered.
The AOP Wiki also supports evaluation of the consistency, quantity and quality of
the information supporting the KERs and AOP overall (Table 1). The criteria for
evaluating KERs and AOPs, modified from the Bradford-Hill criteria for evaluating
causal linkages are described in the OECD guidance and in Meek et al. 2014. AOPs
that are published in the OECD program series are evaluated in two stages. The first
review is by members of the OECD AOP program to make sure the information has
been entered in compliance with OECD guidance. The second stage is an independent
scientific review by a subject matter expert group that can be a combination of OECD
Fig. 1. Linking upstream molecular changes to adverse outcomes: the Adverse Outcome
Pathway (AOP) project of the Organization for Economic Cooperation and Development
(OECD). (Diagram from “Pathways to a Better Future” video series, © The Human Toxicology
Project Consortium).
1 OECD AOP Program: http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-mole
cular-screening-and-toxicogenomics.htm; HTPC training course: https://humantoxicologyproject.
org/about-pathways-2/aop-online-course/.
The Use of Adverse Outcome Pathways (AOPs) to Support Chemical 85
and outside experts - this is similar to peer review of a scientific publication. Once the
authors and reviewers are satisfied, a “snapshot” of the AOP at that time is published on
the OECD website and is considered the current state of knowledge about that pathway.
The Use of AOPs to Support Hazard and Risk Assessment
The AOP framework has been developed to facilitate the use of molecular and cell-
based information to inform regulatory decisions. AOPs on their own are nothing more
than organized and, in some cases, evaluated information; however, they can be used in
several different ways to support chemical assessment. For example, AOPs can be used
to support weight-of-evidence (WoE) evaluation of new or existing information (as is
current performed during hazard and risk evaluations), they can be used to generate
hypothesis to develop new information for answering a specific regulatory question (as
in the context of an integrated approach to testing and assessment, IATA, described in
more detail below), or if enough quantitative information is available, they can be used
to create predictive models.
To streamline AOP-supported chemical assessment, OECD has also provided
guidance for developing and assessing IATA.2 OECD guidance on developing IATA
defines IATA as “pragmatic, science-based approaches for chemical hazard or risk
characterization that rely on an integrated analysis of existing information in a weight
of evidence assessment coupled with the generation of new information using testing
strategies…IATA follow an iterative approach to answer a defined question in a
specific regulatory context…” (Sachana and Leinala 2017; OECD 2016b). The IATA
framework is flexible and allows streamlining of the testing and assessment process to
generate exactly the information needed to make a decision. IATA can be as simple or
as complex as needed to answer the specific question, depending on the amount of
certainty needed.
AOPs can support IATA development and implementation in a number of ways
(Fig. 2). AOPs can support WoE evaluation of existing data and, in cases where more
Table 1. Biological plausibility: between KE upstream and KE downstream?
High (strong): Extensive
understanding of KER
Moderate: KER is plausible Low (weak): some empirical
support
Essentiality: are downstream KEs prevented if upstream KE’s blocked?
High (strong): direct evidence
from experimental studies
Moderate: indirect evidence Low (weak)
No or contradictory evidence
Empirical Evidence: amount, quality, consistent, inconsistent?
High (strong): extensive
evidence for temporal, dose-
response
Moderate: multiple reports of
consistent evidence, some
inconsistent
Low (weak): limited or no studies
and/or significant inconsistencies
Extracted from OECD (2018), Annex I.
2 OECD Integrated Approaches to Testing and Assessment: http://www.oecd.org/chemicalsafety/risk-
assessment/iata-integrated-approaches-to-testing-and-assessment.htm.
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information is needed, identify what information would decrease uncertainty and suggest
the method by which to obtain that information. AOPs can be consulted iteratively until
sufficient information is obtained to answer the question with the required certainty.
While IATA are designed to be flexible, tailored approaches to address regulatory
needs, the potential variability in IATA can cause uncertainty for regulators as well as
the regulated community. If there are several different ways to answer the same reg-
ulatory question, how do regulators know that each are equally reliable, and how can
the submitters of the data be assured of regulatory acceptance? To address this potential
regulatory issue, individual standardized IATA, with defined methods and interpreta-
tion procedures can be evaluated for regulatory application. OECD has published
guidance to facilitate standardization and evaluation of IATA (OECD 2016b).
According to this guidance, there are six general principles that are included in every
IATA: the defined approach should be associated with the following set of information:
(1) a defined endpoint, (2) a defined purpose, (3) a description of the underlying
rationale, (4) a description of the individual information sources used, (5) a description
of how data from the individual information sources are processed, (6) a consideration
of the known uncertainties (and in each case, a description of the magnitude of each
source of uncertainty).
Fig. 2. AOPs can support Integrated Approaches to Testing and Assessment (IATA).
(Diagram reprinted from OECD (2016a).
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AOP-Supported IATA Case Study: Skin Sensitization
The AOP for skin sensitization has been well-described, and several assays have been
identified that can query the MIE and upstream KEs, and there is quite a bit of evidence
substantiating the prediction of the AO by measuring various combinations of these
KEs (OECD 2012a, b). There are also a number of different IATA that have been
developed to assess skin sensitization (e.g. Natsch et al. 2013; Ramirez et al. 2016;
OECD 2016c) (Fig. 3). Nearly all sensitizers are molecules that are or can become
electrophiles and will react covalently with proteins. If these substances are exposed to
and can penetrate skin, they are likely to cause allergic reactions in humans. Several
computer models exist that relate the structure of a molecule to its potential to become
an electrophile (Quantitative Structure Activity Relationships or QSARs), and for many
molecules, can accurately predict skin sensitizing potential. Several QSARs and
in vitro test methods exist to look at the MIE (covalent reaction with proteins) and two
early KE (dendritic cell and keratinocyte activation). IATA using combinations of one
or more of these assays have been evaluated for regulatory application, some of which
outperform animal tests to predict human skin sensitization (Bauch et al 2012; Natsch
et al. 2013; OECD 2016c).
To facilitate regulatory uptake of IATA for skin sensitization, the International
Cooperation onAlternative TestMethods (ICATM), in collaboration with OECD and the
European Commission’s Joint Research Centre, held a workshop on the International
Regulatory Applicability and Acceptance of Alternative Approaches to Skin Sensitiza-
tion Assessment of Chemicals (Kleinstreuer et al. 2017). Attendees, which included 40
regulators and scientists from 12 countries, concluded that in vitro methods are available
that are adequate for use within an IATA to predict skin sensitization for regulatory
purposes, but that a number of barriers remain to be surmounted, including: a lack of
Fig. 3. Skin sensitization AOP and validated methods to assess various KEs (pink outlined
boxes).
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familiarity and need for training in the methods and development of clear guidance for
application of multiple IATA. A recommendation was for OECD to develop a
performance-based test guideline for skin sensitization IATA. To follow on this work-
shop, the OECD is coordinating a project, led by the US ICCVAM and Environmental
Protection Agency and the EC JRC, to evaluate the 12 IATA described in OECD
Guidance Document 256 (OECD 2016c). A special OECD workshop was held in Dec
2017 to review the progress and obtain input from the OECD national coordinators of the
test guideline program. Results of the study are expected in mid 2018.
Summary
AOPs can support decision making, including for regulatory application, and in several
ways. AOPs can: support WoE evaluations; form the basis for integrated approaches to
testing and assessment; provide the basis for biological hypothesis to identify what
information would be most helpful for decreasing uncertainty in a given situation; provide
transparent communication of the information and uncertainty that underlie decisions;
form the basis for development of predictive models. The OECD is coordinating an
AOP KB for collecting and assessing information related to AOPs. The AOP Wiki is a
crowd-sourcing platform that is open to all interested parties and guidance materials and
training courses to assist in use are freely available. Participation in the wiki should be
promoted as the more expert input into the wiki, the more useful the knowledgebase will
become. IATA are designed to streamline regulatory decision making. OECD has created
a number of guidance documents to assist with the development and review of IATA.
Development of IATA begin with problem formulation that includes consideration of the
regulatory context and gathering of all existing relevant information. IATA are
hypothesis-driven and can be supported by AOPs. There can be more than one IATA to
answer a given question, and that necessitates the development of specific cases of IATA,
or defined approaches, that consist of defined methods and data interpretation procedures,
for regulatory application. OECD and member organizations are developing case studies
of defined approaches, beginning with skin sensitization.
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Abstract. We have been developing a carcinogenicity prediction system based
on gene expression profiles focusing on omics technology to enable mechanism-
based evaluations of toxicity to reduce the numbers of animals and toxicological
endpoints required by animal studies. Here, we report the development of a
mechanism-based evaluation system focused on chemically induced hepato- and
nephrotoxicity or hepatic and renal carcinogenicity using a gene expression
analysis with a DNA microarray. As a case study, the mode-of-action (MoA)/
adverse outcome pathway (AOP) was constructed from the gene expression
profiles and histopathological findings of carbon tetrachloride and cisplatin for
hepatotoxicity and nephrotoxicity, respectively. Consequently, we developed an
advanced toxicity evaluation system for hepato- and nephrotoxicity or hepatic
and renal carcinogenicity based on the toxicity mechanisms. We also developed
a new prediction system named “CARCINOscreen®” for evaluating the car-
cinogenic potentials of chemicals using the gene expression profiles of liver and
kidney tissues from rats after a 28-day repeated administration. The prediction
system could predict the carcinogenicity potential of a training chemical set
including carcinogens and non-carcinogens with an accuracy of more than 90%.
The marker genes established in this study are promising for the development of
new effective in vitro testing methods in the future.
Keywords: Adverse outcome pathway (AOP)  Gene expression
profiles  Hepatotoxicity  Nephrotoxicity  Carcinogenicity
CARCINOscreen®
Introduction
Of the more than 80,000 chemicals in commerce, rigorous safety testing and risk
assessment has been carried on relatively few. As an example, rodent carcinogenicity
test data available for less than 1,000 compounds in the US National Toxicology Pro-
gram database. The carcinogenicity of chemicals in our environment is an important
health hazard to humans. Carcinogenicity studies using rodents have long been the
standard for evaluating the carcinogenic potential of chemicals [1]; however, such
studies are time-consuming, expensive, and require large numbers of experimental
animals. Therefore, the carcinogenic potential of many important chemicals remains
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untested. In addition to the carcinogenic potential, the hepatotoxicity and nephrotoxicity
of xenobiotics, which include classical drugs, herbal medicines, and chemical products,
represents a significant cause of liver and kidney diseases [2, 3]. To evaluate hazards of a
compound, various toxicity studies are needed, leading to problems such as a high cost
and long test period in regulatory sciences. The test guideline known as the “repeated
dose 28-day oral toxicity study in rodents” (TG 407) adopted by the Organization for
Economic Co-operation and Development (OECD) is used mainly in Japan and Europe
as a screening toxicity test. If an initial response, such as a change in a gene expression
level associated with toxic effects, could be detected, a single animal study might be
capable of predicting various toxicity endpoints, including long-term toxicity. Under
these circumstances, the development of an efficient hazard assessment system for
chemicals is needed. Moreover, the promotion of a “3Rs” policy and the development of
promising in vitro alternative test methods, are both progressing in toxicological studies.
Omics technology, such as gene expression analyses, can be used effectively for the
identification and prediction of hazards. Toxicogenomics has been established as a
powerful tool for elucidating the mechanisms of chemical toxicity, such as carcino-
genicity [4–6], hepatotoxicity [7, 8] and nephrotoxicity [9, 10]. However, numerous
unknown pathways or gene networks that lead to toxicity exist. For a better under-
standing of adverse outcome pathways (AOPs) and the expansion of mode of action
(MoA) applications, the elucidation of pathways/networks or biomarkers to detect or
predict in vivo toxicity is needed.
We participated in a 5-year ARCH-Tox project conducted by the Ministry of
Economy, Trade and Industry (METI) in Japan with the aim of developing a new testing
approach that would enable the evaluation of multiple endpoints (hepatotoxicity/
nephrotoxicity, carcinogenicity and neurotoxicity) in a single 28-day repeated dose
toxicity study using sets of marker genes selected based on toxicity mechanism such as
MoAs or AOPs.Mechanism-based analysis using omics technology is expected to reveal
new MoAs or AOPs, leading to the development of new in vitro assays.
Chemicals, Animal Test and Microarray Analysis
A total of 100 chemicals, consisting of 68 chemicals used in prediction systems
examining hepatic carcinogenicity and 32 chemicals commonly used in prediction
systems examining renal carcinogenicity and detection systems for hepatotoxicity and
nephrotoxicity, were selected from among chemicals used in previous studies [11–13].
The number of test compounds used in each experiment is shown in Fig. 1a.
Four-week-old specific-pathogen-free (SPF) male Crl:CD (SD) rats and Fischer 344
(F344) rats were obtained from Charles River Laboratories Japan, Inc. (Kanagawa,
Japan). The rats were treated with the test compounds in a suitable vehicle by gavage
for 28 days. The animals were then sacrificed by exsanguination under anesthesia with
CO2–O2 (4:1) or isoflurane gas inhalation 24 h after the final administration, and the
livers were immediately excised and weighed. Then, the left lateral lobe of the liver
was sliced and immediately placed in RNAlater® (Ambion, Austin, TX, USA) for
RNA extraction; the remaining liver sample was submitted for histopathological
examination. All the animals were treated in compliance with the applicable animal
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welfare regulations (Declaration of Helsinki [2000] and guidelines for animal experi-
ments at CERI according to LABORATORY ANIMAL SCIENCE [1987] published
by the American Association for Laboratory Animal Science). The experimental design
and the results of histopathological findings is shown in Fig. 1b and Tables 1 and 2,
respectively.
Fig. 1. Number of test compounds used in each experiment and animal study design a Test
compounds: Sixty-eight chemicals were used to develop a prediction system for hepatic
carcinogenicity, and 32 chemicals were used to develop prediction systems for renal
carcinogenicity and detection systems for hepatotoxicity and nephrotoxicity. b Animal study:
The gene expression profiles of liver and kidney tissues were detected after a 28-day repeated
dose toxicity study in male Crl:CD (SD) rats
Table 1. Histopathological findings of liver (CCl4)
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Total RNA was extracted from the liver samples using QIAzol (Qiagen, Hilden,
Germany) and the RNeasy Mini Kit or miRNeasy Mini Kit (Qiagen), in accordance
with the manufacturer’s protocol. The quality of the RNA samples was examined using
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and
undegraded RNA samples were used for the experiments; for this study, we used RNA
samples with RIN values of > 7.0 as an index of the high purity and integrity of the
RNA samples.
Microarray analysis was performed as described previously [12]. Briefly, three
types of custom arrays, Toxarray III ver.2 and Agilent Whole Rat Genome Microarrays
8  60 K Toxplus ver.1 and ver.2, and the gene-expression-based carcinogenicity
prediction system CARCINOscreen® were used for the microarray analysis. Global
normalization was applied to one-color microarray data using GeneSpring GX 10
(Agilent Technologies). Lowess normalization was applied to two-color microarray
data using Feature Extraction Software 9.5.3.1 (Agilent Technologies). The signal log2
ratio of the administration group vs. the vehicle control group was calculated using the
mean normalized signal intensity in each group. The pathway or functional analysis for
the DNA microarray data was performed using Ingenuity Pathways Analysis
(IPA) software (Qiagen).
Table 2. Histopathological findings of kidney (cisplatin)
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AOP-Based Mechanism of Hepatotoxicity Suggested by Case
Study with Carbon Tetrachloride
The liver has long been considered the major target organ for most of the chemicals
implicated in eliciting toxic effects following environmental exposure. Hepatotoxicity
represents a major regulatory issue, and the pathophysiologic mechanisms of hepato-
toxicity are still being explored and include both hepatocellular and extracellular
mechanisms. We investigated the mechanism of hepatotoxicity induced by carbon
tetrachloride (CCl4), which is a well-known hepatotoxin. CCl4 reportedly damages
liver cell mitochondria and causes the failed transport of fatty acids as phospholipids
[14]. We attempted to create an AOP for liver fibrosis induced by CCl4 using gene
expression data and histopathological data obtained in our studies as well as previously
reported information [14]. A previous study reported that CCl4 was biotransformed by
the cytochrome P450 system in the endoplasmic reticulum to produce trichloromethyl
free radical (CCl˙3) [15]. This CCl˙3 then combined with cellular lipids and proteins to
form trichloromethyl peroxyl free radical, which attacks lipids on the membrane of the
endoplasmic reticulum as a molecular initiating event (MIE). Thus, trichloromethyl
peroxyl free radical is thought to lead to lipid peroxidation [15]. In the results of our
case study using CCl4., Cyp2c12 and Cyp4f5 were upregulated and cholesterol
biosynthesis appeared to be activated, while fatty acid b-oxidation appeared to be
downregulated in association with a 1-day treatment with CCl4. A functional analysis
using IPA software of significantly downregulated genes in the liver after the admin-
istration of CCl4 showed that these genes were strongly correlated with fatty acid
metabolism, transport of lipid and cleavage of lipid became with the severity depending
on the administration period (Fig. 2). After 7 days of administration or thereafter, the
significantly upregulated genes were strongly correlated with increases in the synthesis
of DNA, DNA replication and chromosomal congression as well as the p63 signaling
pathway and the G2/M DNA damage checkpoint pathway (data not shown).
Histopathologically, fatty degeneration and centrilobular hydropic degeneration were
observed by macroscopic examination on the first day of administration. Furthermore,
Fig. 2. Histopathological changes and functional analysis of DNA microarray data obtained
after the oral administration of carbon tetrachloride (CCl4). The red and blue arrows indicate a
significant functional analysis using IPA software for the up- and downregulated genes,
respectively. The number of arrows shows the degree of relevance of these function and gene
expression changes
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microgranuloma, mitosis and single cell necrosis in the centrilobular area were
observed, and the degree of severity increased with the dose and administration period
(Table 1). We constructed AOP-based hepatotoxicity mechanisms of CCl4 using these
multifaceted considerations, and the mechanism map is shown in Fig. 3.
AOP-Based Mechanism of Nephrotoxicity Suggested by Case
Study with Cisplatin
Recent studies have demonstrated that the kidney is also an important target of injury
after chemical exposure, although substantial gaps in knowledge remain regarding the
effects of environmental chemicals on specific aspects of kidney function [16, 17].
Cisplatin is a potent anticancer drug that is widely used in chemotherapy. However,
adverse effects in normal tissues and organs, notably nephrotoxicity in the kidneys,
limit the use of cisplatin and related platinum-based therapeutics. Recent research has
shed significant new light on the mechanism of cisplatin nephrotoxicity, especially on
the signaling pathways leading to tubular cell death and inflammation [18]. As a case
study of nephrotoxicity, we administered cisplatin to male rats for 28 days; kidney
samples were then obtained and anatomically separated into the papilla, inner medulla,
outer medulla, and cortex, which have different structures and functions, and gene
expression analyses were performed for each of these renal anatomic regions, since the
marked morphological, functional and biochemical heterogeneity of the kidney
accounts for the site-specific toxicity of several drugs and xenobiotics [19]. In our
Fig. 3. AOP-based mechanisms of hepatotoxicity of carbon tetrachloride (CCl4). MIE:
molecular initiating event, KE: key event, GEx: Gene expression data. The red and blue arrows
indicate the significance of a functional analysis using IPA software for the up- and
downregulated genes, respectively. The number of arrows shows the degree of relevance of
these function and gene expression changes
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previous DNA microarray study, no significant variations for each renal anatomic
region were seen between the left and right kidneys or among individuals (data not
shown). Nevertheless, the gene expression profiles differed in each renal anatomic
region, and the DNA microarray data of the outer medulla and cortex were used to
analyze the nephrotoxicity of cisplatin. The major focus in renal damage research is on
proximal tubule toxicity, where the majority of the reabsorption of drug metabolites
occurs, and the proximal tubules of the nephron in animals including the proximal
convoluted tubules, which are situated in the cortical labyrinth and are connected
directly to the proximal straight tubules in the inner cortex and outer stripe of the outer
medulla [19]. Cisplatin has been suggested to produce reactive oxygen species
(ROS) via NADPH oxidase activation [20]. ROS are highly reactive molecules that can
damage cell structures such as carbohydrates, nucleic acids, lipids, and proteins and
alter their functions [21]. In this gene expression data, Nrf2, Gpx2, Ho-1, Scarb1,
Gstm3, and Mgst2, which are concerned with the NRF2-mediated oxidative stress
response, were significantly upregulated, supporting the MIE of cisplatin, i.e. the
oxidation of DNA, proteins, lipids, and co-factors (data not shown). A functional
analysis using IPA software of significantly upregulated genes in the outer medulla of
the kidney after the administration of cisplatin showed that these genes were strongly
correlated with cell death and survival, inflammatory disease, cellular growth and
proliferation, organismal injury and abnormalities, and apoptosis (data not shown). The
downregulated genes were involved in amino acid metabolism, lipid metabolism,
vitamin and mineral metabolism, drug metabolism, and molecular transport, which is
involved in basic renal function (data not shown). In particular, many genes expressed
in the outer medulla and cortex related to oxidative phosphorylation, were downreg-
ulated, resulting in mitochondrial dysfunction (Fig. 4). The proximal tubule of the
kidney has three morphologically distinct segments, S1, S2, and S3, which can be
distinguished as the pars convoluta and the pars recta of the proximal tubule [22].
Epithelial cells in the S1 segments possess a tall brush border, a well-developed vac-
uolar lysosomal system, and many long mitochondria that fill the basal portion of the
cell. The S2 segments are not as tall as the S1 segments. The S3 cells have rare apical
vacuoles and fewer and smaller mitochondria than the S1 and S2 cells [22]. These
observations suggest that the administration of cisplatin leads to kidney injury and
abnormalities. Histopathologically, after 7 days of administration or longer, single cell
necrosis of the proximal tubule in the cortico-medullary junction or the inner medulla
was observed microscopically. Furthermore, degeneration, karyomegaly, dilation, and
regeneration were observed, and the degree of severity increased with the dose and
administration period (Table 2). We constructed an AOP-based hepatotoxicity mech-
anism for cisplatin using these multifaceted considerations, as shown in Fig. 5.
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Fig. 5. AOP-based mechanisms of nephrotoxicity of cisplatin. MIE: molecular initiating event,
KE: key event. The red and blue arrows indicate the significance of a functional analysis using
IPA software for the up- and downregulated genes, respectively. The number of arrows shows
the degree of relevance of these function and gene expression changes
Fig. 4. An example of a pathway analysis of DNA microarray data obtained after the
intraperitoneal administration of cisplatin. The red and green colored objects indicate the up- and
downregulated genes, respectively
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Detection System for Hepato- and Nephrotoxicity
We attempted to develop a detection system for hepato- and nephrotoxicity using DNA
microarray data; the strategy used to construct the detection system is shown in Fig. 6.
We focused on frequently listed toxicity findings in the Hazard Evaluation Support
System Integrated Platform database (HESS-DB: http://www.nite.go.jp/en/chem/qsar/
hess-e.html), which contains information on toxicity and metabolism released in Japan.
We then chose five toxicological findings for each toxicity: centrilobular fatty
Fig. 6. Strategy of a detection system for hepato- and nephrotoxicity. To discover biomarker
candidates, microarray data was analyzed using hierarchical clustering to group compounds
based on gene expression profiles, and common gene sets among the compounds that were
grouped in the same cluster were selected and used in a Venn diagram. Furthermore, marker
genes based on toxicity mechanisms were selected based on the results of an AOP-based
mechanisms analysis of hepato- and nephrotoxicity, and toxicity detection systems were
constructed for each toxicological finding
Table 3. Toxicological findings and number of detection genes for hepato- and nephrotoxicity
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Fig. 7. Detection results for hepato- and nephrotoxicity. a Radar chart model of the detection
system: The detection score was calculated using a support vector machine with the detection
genes. Each detection score for the five toxicological findings in the liver and kidney was plotted
in the upper and lower areas of the radar chart, respectively. b Results of training data (25 tests/22
compounds), c Results of validation data (10 tests/10 compounds): Liv-1: centrilobular fatty
degeneration, Liv-2: periportal fatty degeneration, Liv-3: cell death, Liv-4: centrilobular
hypertrophy, Liv-5: hypertrophy (diffuse). Kid-1: vacuolization of proximal tubule, Kid-2:
anisonucleosis of proximal tubule, Kid-3: pyknosis of proximal tubule, Kid-4: cell death of
proximal tubule, Kid-5: necrosis of papilla
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degeneration, periportal fatty degeneration, cell death, centrilobular hypertrophy, and
hypertrophy (diffuse) for hepatotoxicity, and vacuolization of the proximal tubule,
anisonucleosis of the proximal tubule, pyknosis of the proximal tubule, cell death of the
proximal tubule, and necrosis of the papilla for nephrotoxicity. The detection formula
was generated using a support vector machine with detection genes selected from 22
training chemicals (25 tests) datasets, and a predictive score was then calculated to
detect the hepato- or nephrotoxicity potentials of the tested chemicals. The detection
genes were selected for each toxicological finding: 8–36 genes for hepatotoxicity and
3–10 genes for nephrotoxicity (Table 3). The potential score for each toxicological
finding was shown in a radar chart model that allowed the visualization of multiple
toxicity findings at a glance (Fig. 7a). In the training data, the potential score for each
toxicological finding was 96%–100%, resulting in a 99.2% total concordance (Fig. 7b).
In the validation data for ten chemicals, the potential score for each toxicological
finding was 80%–100%, resulting in a 96.7% total concordance (Fig. 7c).
Prediction System for Hepatic and Renal Carcinogenicity:
CARCINOscreen®
Carcinogenicity is one of the most serious toxic effects of chemicals, and highly
accurate methods for predicting carcinogens are strongly desired for the assessment on
human health. We previously developed a prediction system named “CARCINOsc-
reen®” for evaluating the carcinogenic potentials of chemicals using the gene
expression profiles of liver tissues from rats after a 28-day repeated dose toxicity study
[12]. The prediction formula was generated using a support vector machine with
predictive genes selected from 68 training chemical datasets; a predictive score was
then calculated to predict the carcinogenic potentials of the tested chemicals. To ensure
the accuracy of the prediction system, the chemicals were divided into three groups
(Groups 1 to 3) according to the resulting hepatic gene expression profiles, and a
prediction formula was generated for each group. The prediction system was capable of
predicting the carcinogenicity of the training carcinogens and the non-carcinogens with
an accuracy of 92.9%–100%. The final prediction result was determined based on the
maximum prediction value obtained with three independent prediction formulas to
establish the CARCINOscreen®. The system was able to accurately predict carcino-
genicity in rats in 94.1% of the 68 training chemicals [12]. Furthermore, we attempted
to develop a quantitative PCR (qPCR)-based system as an alternative to the microarray-
based CARCINOscreen® [23]. The prediction accuracies of the qPCR-based alternative
for training- and validation-phase trials were 82.8% and 86.4%, respectively [23].
Recently, we reported a renal carcinogenicity prediction system to predict chemical
carcinogenicity in rats; a 28-day repeated-dose test was performed using male Crl:CD
(SD) rats with 12 carcinogens and 10 non-carcinogens as the training dataset and five
carcinogens and five non-carcinogens as the validation dataset [13]. In this prediction
system, the prediction accuracies for the training and the validation datasets were
calculated to be 100% and 90%, respectively, while 4-hydroxy-m-phenylenediammo-
nium dichloride (AMIDOL), a known non-renal carcinogen, was judged as being
positive. Among the predictive genes, Hamp and Ranbp1 are known to be important
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for cell growth and cell cycle regulation, which are important events in carcinogenesis.
Given our current limited knowledge of the genes responsible for renal carcinogenesis,
the identification of candidate genes for chemical-induced renal carcinogenicity using
this gene expression-based prediction method represents a promising advance in renal
carcinogen identification [13].
Concluding Remarks
In hepatotoxicity and nephrotoxicity, marker genes can be selected based on toxicity
mechanisms such as MoA or AOP, enabling a detection accuracy of more than 90% for
five kinds of toxicity findings in both the liver and kidney. For carcinogenicity, the
CARCINOscreen® system predicted the carcinogenic potential of a training compound
set that included non-carcinogens with a more than 90% accuracy for the liver and
kidney. Furthermore, we developed a qPCR-based prediction system as an alternative
to the microarray-based CARCINOscreen® for rat liver carcinogenicity. The prediction
performance of the qPCR-based CARCINOscreen®, as well as its user-friendliness and
cost effectiveness, suggests that this method is promising for application in primary
health hazard assessments. These results suggested that omics technology, such as gene
expression analysis, can be used effectively for hazard identification and prediction.
From now on, the application of urine and blood samples, which are non- or semi-
invasive to animals, might be more important as a contribution to the 3Rs policy. Blood
and urine samples are used in metabolomics and proteomics approaches with a high
frequency, and these techniques may also be powerful tools for the identification of
toxicity mechanisms and to resolve issues in which changes in gene expression levels
are not always correlated with the phenotypes.
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Abstract. Development of an organism is accompanied by rapid and complex
changes within a relatively short period, and embryotoxic chemicals adminis-
tered to a mother during pregnancy can result in persistent lesions, general
growth retardation, or delayed organ growth. In vitro toxicity tests are useful for
evaluating the safety or hazards of small quantities of chemicals. Since cell
death and inhibition of differentiation in mouse embryonic stem cells (ESCs) can
occur within different concentration ranges of compounds, depending on the
toxic potency of the compound, these cell properties can be used as guides for
classifying the embryotoxicity of a compound. The use of multiple endpoints,
such as assessing the inhibition of viability in ESCs (IC50ESC) and 3T3 cells
(IC503T3), and reduction in embryoid body (EB) area (ID50EB), has the
advantage of providing a detailed baseline for the classification of a compound’s
toxicity level and for establishing a prediction model that utilizes those end-
points. The EB area-based toxicity test (EBT) is an animal-free, novel drug
screening system that can be useful in evaluating of various embryotoxic
chemicals within a short time.
Keywords: Embryonic stem cell test  Embryoid bodies
Developmental toxicity  Prediction model
Introduction
Toxicity tests are necessary for assessing the safety or hazard levels of substances in
various fields. Alternative tests based on the 3R principles (reduction, refinement, and
replacement of animal use) have been proposed to overcome some of the drawbacks of
animal experiments and to avoid unethical procedures [1]. Developmental toxicology is
an important field in which undesirable effects on the development of an organism,
including malformation, growth retardation, embryo lethality, and malfunction are
assessed [2]. In vitro systems for testing developmental toxicity of compounds are
capable of providing rapid, precise, and relevant information compared to that provided
by some animal-based studies, and they are an economical approach as they are
characterized by a low compound requirements and a short testing duration [3].
Embryonic stem cells (ESCs) have the capacity to self-renew and the ability to generate
differentiated cells. Embryoid bodies (EBs) act at the onset of differentiation and are
useful for the evaluation of developmental toxicity. The mouse embryonic stem cell test
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(EST) can be used to evaluate the 50% inhibitory concentration of chemicals at three
endpoints: viability of undifferentiated mouse ESCs (IC50ESC), viability of mouse
fibroblasts (3T3 cells; IC503T3), and differentiation of ESCs into cardiomyocytes
(CMs; ID50CM) (Fig. 1A green line). In our study, we used EB area to replace the
assessment of cardiomyogenesis of ESCs in order to reduce the need for time-
consuming and laborious processes. The replacement of CM assessment with that of
EB area shortened the assessment period from 10 days to 3 days (Fig. 1A orange line).
The EB area test is also referred to as the embryoid bodies test (EBT).
Materials and Methods
Twenty-one compounds (Table 1), including non-embryotoxic and embryotoxic or
teratogenic chemicals, were evaluated. Cell viabilities of ESCs and 3T3 cells were
measured using a cell counting kit (CCK) assay. Sectional image of EBs were pho-
tographed by a phase-contrast microscope and the EB area was analyzed by using
image analysis software. The 50% inhibitory concentrations were derived from loga-
rithmic graphs.
Fig. 1. Endpoints and reduction in EB area, dependent on the toxic potency of chemicals.
(A) The EST evaluates the developmental toxicity of chemicals at three endpoints: Cytotoxicity
in (i) ESCs. (ii) 3T3 cells, and (iii) inhibition in cardiac differentiation of ESCs at 10 days of
treatment (green line). The EBT replaces cardiac differentiation endpoint with a new endpoint
based on EB cross-sectional area (orange line). (B) EBs were formed over three days via the
hanging drop method with 10−6, 10−5, or 10−4 M of non-toxicant (isoniazid) or toxicants (aspirin,
indomethacin, or dexamethasone). Scale bars indicate 300 lm. The isoniazid-treated group
maintained a EB size in 10−4 M treatment similar to that in the control group. Toxicant-treated
groups markedly reduced the EB area at 10−4 M.
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Results
Exposure to toxicants resulted in increased cell death and reduced EB area in mouse
ESCs. Tested chemicals were roughly categorized based on their typical concentration-
response curves obtained for EB area and the viability of ESCs and 3T3 cells over the
tested concentration range of each test chemicals. Strongly embryotoxic chemicals
including methotrexate, ochratoxin-A, and retinoic acid inhibited growth and differ-
entiation of EBs and showed a high cytotoxicity to 3T3 cells and ESCs at very low
concentrations. As the toxic potency of the chemical increased, the concentration at
Table 1. 21 chemicals tested in a developmental toxicity test using mouse ESCs (N, non-
toxicant; W, weak toxicant; M, moderate toxicant; S, strong toxicant)
No Chemicals CAS No. Mw Class Function
1 Sodium
bicarbonate
144-55-8 84.01 N Food additive (EU, E500)
2 Sodium gluconate 527-07-01 218.14 N Chelating agent
3 Saccharin 82385-42-
0
205.17 N artificial sweetener
4 Penicillin G 113-98-4 372.48 N Antibiotic
5 Isoniazid 54-85-3 137.14 N Antibiotic, Initial therapy of active
tuberculosis
6 Ascorbic acid 134-03-2 198.11 N Antioxidant
7 Doxylamine
succinate
562-10-7 388.46 W Antihistamine, Antiallergy
8 Pravastatin 81131-70-
6
446.51 W Hypocholesterolemic drug
9 Caffeine 58-08-2 194.19 W Psychoactive drug, natural pesticide
10 Aspirin 50-78-2 180.16 W Non-steroidal, Anti-inflammatory
11 Diphenhydramine 147-24-0 291.82 M Antihistamine, Antiallergy, Antiemetic
12 Diphenylhydantoin 57-41-0 252.27 M Anti-seizure
13 Indomethacin 53-86-1 357.79 M Non-steroidal, Anti-inflammatory
14 Dexamethasone 50-02-2 392.46 M Steroidal, Anti-inflammatory, Anti-
Rheumatic
15 Papaverine 61-25-6 375.85 M Opium alkaloid antispasmodic drug
16 Lovastatin 75330-75-
5
404.54 M Hypocholesterolemic drug




454.44 S Abortifacient, Anti-Rheumatic,
Antitumor
19 D-Penicillamine 52-67-5 149.21 S Chelating agent
20 Ochratoxin A 303-47-9 403.81 S Toxin produced by Aspergillus
ochraceus
21 Retinoic Acid 302-79-4 300.44 S Metabolite of vitamin A (retinol)
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which cellular viability, growth, and differentiation rapidly decreased. The EB area was
reduced in a dose-dependent manner by the tested chemicals (Fig. 1B), and a decrease
in EB area resulted in a decline in beating ratio during cardiac differentiation. The 50%
inhibitory concentration of EB area (ID50EB) was highly correlated with the ID50CM
(correlation coefficient, 0.8842). Thus, the EBT can reflect not only the cytotoxicity of
a chemical but also the differentiation toxicity. The developmentally toxic levels of
various chemicals were evaluated and classified by using a prediction model
(PM) based on IC50ESC, IC503T3, and ID50EB (Fig. 2A–C). To classify the chemical
results into four classes, the EBT-PM included four linear functions that could best
divide groups with different characteristics along a plane. Among the results of func-
tions I, II, III, and IV of the EBT-PM, if the value of linear function I is the largest, the
group is classified as non-embryotoxic. If the value of function II is largest, the toxicity
is weak. If function III is largest, toxicity is moderate, and if function IV is largest,
toxicity is strong (Fig. 2D).
Fig. 2. Relationship between endpoints and classification for 21 chemicals. On the log scale, the
correlation coefficients between (A) ID50EB and IC50ESC, (B) IC503T3 and IC50ESC, and
(C) ID50CM and ID50EB were 0.9613, 0.9463, and 0.8842, respectively. (D) Non-, weak,
moderate, and strong toxicants were classified according to the highest value among functions I,
II, III, and IV.
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Discussion
The EBT assesses the developmental toxicity of chemicals at three endpoints: viability
of ESCs, viability of 3T3 cells, and reduction in EB area. The three EBT endpoints
were verified by performing experiments independently and repeatedly (three or more
times in triplicate; 3  3). In comparison with the toxicity classification according to
in vivo data, the EBT-PM showed a prediction accuracy of 90.5%. Developmental
toxicants at toxicity-inducing concentrations resulted in a reduction in EB area and a
deterioration of EB quality, which indicate the potential for growth retardation and
abnormal differentiation in embryos. Chemical treatments resulted in dose-dependent
decreases in the EB area via epigenetic inhibition of differentiation and arrest of the cell
cycle. To determine the reliability and relevance of the EBT, a validation process is
required. In this study, the initial evaluation determined that EB area assessment could
be used instead of CM assessment to indicate the differentiation-related toxicity of
chemicals. The EBT is a novel toxicological screening system that can facilitate rapid
evaluation of embryotoxicants.
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Abstract. The use of mammalian models for toxicological risk assessment of
chemicals has been a widespread practice for well over 50 years. This has
remained controversial in view of the species differences. Further, the advances
in molecular biology techniques have revolutionized the toxicological risk
assessment scenario by creating demand for rapid, less expensive and highly
relevant methods to risk-evaluate chemical substances quickly. In order to take
advantage of these advances the US EPA funded the National Research Council
to develop a strategy and vision for toxicity testing in 21st century (Tox21).
Tox21 envisions a paradigm shift in toxicity testing and proposes the use of
emerging technologies based on non-animal methods for better understanding of
chemical-environment interaction, and also emphasizes the adoption of animals
belonging to lower levels of taxonomic hierarchy, which are less sentient, in
in vivo toxicity testing. Adoption of this shift would perhaps benefit translation
of the REACH Legislation, which otherwise greatly relies on animal experi-
ments for chemical risk assessment. We aimed at establishing Hydra, a simple
organism belonging to Phylum Cnidaria, as a model organism for toxicity
testing of environmental chemicals. Besides, Hydra offers advantages such as
easy to culture, reproduces fast, cost-effective and highly sensitivity to inorganic
pollutants. Moreover, the whole genome sequence of hydra revealed that most
of the genes are conserved in which sense it offers advantage over even in the
most routinely used other invertebrate model organisms. We standardized sev-
eral assay methods which formed the nucleus of several publications. Herein we
show that Hydra can be used as a viable bio-indicator for early warning of
aquatic pollutants.
Keywords: Hydra model  Invertebrate  Toxicity testing  Budding
Regeneration  ROS  Apoptosis
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Introduction
Chemicals are the basic constituents of living as well as non-living things. Many
chemicals naturally occur and many are synthesized. Production and/or
consumption/utilization of chemical substances has increased manifold over the per-
iod of time, resulting in humans and animals getting exposed to large varieties and
volumes of chemical entities directly and/or indirectly. The toxicities of many chem-
icals are known although thorough risk assessment has not been done for most of the
chemicals. This is particularly true of many chemicals belonging to the categories such
as nanoparticles and pesticides. Their fate, behavior and adverse effects are not ade-
quately understood, particularly when they exist as mixtures (Geissen et al. 2015).
These chemicals, released from the sites of industrial production and/or domestic
applications and storage, are carried into the environment through contaminated water,
landfill leakage and sewage effluents, and ultimately arrive at the aquatic bodies which,
therefore, need special attention (Quinn et al. 2008; Patwardhan and Ghaskadbi 2013;
Marchesano et al. 2015). Many chemical substances may degrade as they arrive at the
aquatic environment or soon thereafter, whereas the others do not break down easily, so
would enter the aquatic organisms and move up the food chain to the higher tropic
levels and bio-accumulate, which is a serious threat to the aquatic biota and to the
terrestrial animals, including man, which have access to the aquatic ecosystems through
the food chain (Murugadas et al. 2016). In view of the adverse effects these chemical
substances produce in animals and humans, the lack of knowledge about their behavior
and fate, which in turn is due to paucity of sampling and/or analytical techniques, is a
big issue. Therefore, multiple actions are required at various levels for risk assessment
of chemical pollutants in the aquatic environment (Geissen et al. 2015).
It is generally agreed that health of the ecosystem is measured not only in terms of
chemical and physical qualities of water but also in terms abundance and health of
biota of the ecosystem (Herricks and Schaeffer 1985). The latter calls for testing of
chemical substances per se or the polluted waters in organisms that would in their
natural habitat be exposed to such chemicals. In other words, it is better that testing is
done in an environmentally related species. However, while fish would fit into this slot,
invertebrates should be of preference in the light of uptake of chemical entities from the
aquatic environment, by direct ingestion, contaminated preys, water filtration, surface
contact and inhalation (Cattaneo et al. 2009). Among the aquatic invertebrates, ones
with unlimited supply, small size, simple body plan, and short life cycle, together with
that are easy to maintain and cost-effective, and can better be groomed into a suitable
model organism. From a regulatory perspective this is highly pertinent and relevant
since the US Tox21 vision envisaged adoption of mechanistic models, including non-
vertebrate organisms for hazard assessment of chemical substances (Krewski et al.
2010). More recently, the Toxic Chemical Substances Act (TSCA) 1976 of USA has
been amended as the “Frank R. Lautenburg Chemical Safety for the 21st Century Act
2016.” This revised law includes a new section [4 (h)], entitled Reduction of Testing on
Vertebrates has been added, according to which EPA must “develop a strategic plan to
promote the development and implementation of alternative test methods and strategies
to reduce, refine or replace vertebrate animal testing…”, implying encouragement of
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use of non-vertebrate models. Under these circumstances, extensive research has been
undertaken in our laboratory to standardize the cnidarian polyp Hydra as a model
organism for evaluating the aquatic eco-toxicity of chemical substances and emerging
pollutants. Hydra is a small diploblastic organism. It is available in abundance in fresh
water bodies. It reproduces profusely by budding, thereby producing identical twins.
Hydra has also the remarkable capability to regenerate its amputated body region,
making it virtually immortal. It is not known to feel pain and, therefore, does not need
an ethical clearance. All cells in Hydra are in close proximity to and contact with the
aquatic environment, which facilitates permeation of chemical substances into the
animal (Beach and Pascoe 1998). In this paper we present an overview of the assay
methods encompassing morpho-physiological features, feeding behavior, growth rate,
regeneration, nuclear morphology, cell cycle analysis, apoptosis, and changes at
molecular level endpoints for aquatic toxicity testing of chemical entities including
nanomaterials.
Hydra-Systematics
Hydra is a fresh water eumetazoan diploblastic organism belonging to Phylum Cni-
daria, Class Hydrozoa, Order Anthomedusae/Anthoathecata, and Family Hydroidea.
The body is a cylindrical polyp which is radial. It is essentially a sedentary organism
living attached to stones, pebbles and water plants, but can get released from the
substratum and swim.
Physiology and Anatomy
Hydra measures about 10–15 mm long when fully extended. It is cylindrical and
tubular. The oral end of the body column consists of conical hypostome, surrounded by
3–10 tentacles which play role in prey capture, and the aboral end consists of basal disc
with which it attaches to the substratum. The body column is divided into four dis-
tinctive regions, (i) the gastric region which extends between the tentacle and the first
apical bud, where it digests the prey; (ii) the budding section, which produces the bud;
(iii) the peduncle, located between the lowest bud and the basal disc; and (iv) the foot
region (Hecker and Slobodkin 1976) (Fig. 1). The body wall is comprised of an outer
ectoderm or epidermis and an inner endoderm or gastrodermis, both of which are
formed of epithelio-muscular cells, separated by a non-cellular jelly-like mesoglea.
There is a primitive form of nervous system consisting of a net of neurons underlying
the epidermis, as well as gastrodermis. Cells unique to cnidarians – the cnidoblasts or
nematocytes, with a toxin-laden nematocyst inside – are very specialized, and engage
in offence and defense, playing a role in feeding by paralyzing the prey. Hydra consists
of three different stem cell lineages, including ectodermal and endodermal epithelial
cell lineages, which self-renew by continuous division and migrate towards both the
extremities and terminally differentiate. The third stem cell lineage consists of inter-
stitial cells which are multipotent and can differentiate into neurons, secretory cells and
112 A. Murugadas et al.
gametes. In view of the effectively dividing and expanding stem cell lineages, Hydra is
practically an immortal organism.
Reproduction
Hydra can reproduce by both sexual and asexual methods. The primary form of
reproduction is asexual, by budding, which happens as long as conditions are favor-
able. Budding results in rapid production of a large number of genetically identical
Hydras. This genetic identity enables the researchers to reproduce experimental results
with less statistical difference (Beach and Pascoe 1998). Growth rate in Hydra is in
equilibrium state between cell proliferation and removal of excess cell by phagocytosis
or bud formation (Bosch and David 1984). However, during unfavorable condition or
in the context of environmental contamination, the growth rate is affected, and the
animal engages in sexual reproduction resulting in cysts that can endure adverse
conditions (Ambrosone et al. 2014).
Regeneration
Hydra is known for its remarkable capability of regeneration. Amputation of Hydra
into any number of pieces other than hypostome and basal disc can result in each such
piece regenerating the missing parts. It has been stated that Hydra undergoes mor-
phallactic regeneration to restore its unique structure after amputation (Bode 2003). In
Fig. 1. Morphology of Hydra
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case of head regeneration, wound healing occurs in 3–6 h, the tentacles begin to
emerge within 30–36 h, and complete head regeneration occurs within 48–72 h of
amputation. Similarly, in case of foot regeneration, epithelial cells extend to heal the
wound site and the foot regenerates approximately in 30 h. This dynamic process of
regeneration in Hydra is tightly regulated by specific genes. Methods have been
developed to quantify the abnormal morphologies as well as alterations in gene
expression in Hydra following exposure to an environmental stress, which render
Hydra recognized as the ideal model organism to test teratogenicity of environmental
pollutants (Wilby 1988; Ambrosone et al. 2014).
End Point Analysis
Morphological Observation in Hydra Following Exposure to Chemicals
Toxicity testing in Hydra is manifested by alterations in its morphology, starting with
contraction of tentacles and shortening of body column and ending up in animal
disintegration. The scoring system for Hydra’s morphology was originally designed by
Johnson and Gabel (1983), and later improved by Wilby (1988). Thereafter, Wilby’s
scale of toxicity testing has served as the basis for the determination of toxicity of
chemical compounds in Hydra from the perspective of morphological changes. As
toxicant concentration increases, progressive changes occur in Hydra’s morphology.
A score of 10 was assigned to highly intact and healthy polyps, 8 to clubbed tentacles,
6 to shortened tentacles, 5 to tulip phase, 3 and 2 to osmoregulation loss, and 0 to
animals that had undergone disintegration (Table 1; Fig. 2). Recently, Ambrosone
et al. (2014) observed different phenotypic variations in Hydra when treated with SiO2
nanoparticles, based on which a new scaling system to assess the detrimental effects of
nanoparticles in Hydra was devised (Table 2).
Table 1. Scoring system devised by Wilby (1988) for assessing the morphological damage
following toxicant exposure.












Extended tentacles; body reactive
Partially contracted; slow reactions
Clubbed tentacles; body slightly contracted
Shortened tentacles; body slightly contracted
Tentacles and body shortened
Totally contracted; tentacles visible
Totally contracted; no visible tentacles
Expanded; tentacles visible
Expanded; no visible tentacles
Dead but intact
Disintegrated
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Methodology
For aquatic eco-toxicity testing, Hydra is placed at one per mL of medium (1 mM
CaCl2, 1 mM NaCl, 0.1 mM MgSO4, 0.1 mM KCl, and 1 mM Tris-HCl; pH 7.8).
Depending on the container capacity, a minimum of 10–25 animals are taken for each
experiment, and care is taken to pick those animals which do not possess bud or with
only slightly developed bud, to avoid increase in the number of animals at the end of
the experiment. For a controlled laboratory experiment, the polyps should be main-
tained at 18 ± 1 °C under 12 h dark-light cycle. The experiment can be initiated by
adding varying concentrations of the chemical substance to the culture dishes and
monitoring continuously in a stereo-zoom microscope throughout the study period (72
or 96 h). The morphological variations are recorded at regular time intervals. Animals
that respond in a specific time are assigned with a median score for determination of
median lethal concentration. A score of 5 or less is considered to be lethal and the
change is irreversible; in the case of score above 5 the change is reversible, wherein the
animal becomes healthy when healthy environment is restored. For a concentration-
and/or time-dependent toxicity, the median score is indirectly proportional to the
incubation time and concentration tested.
Fig. 2. Representation of Wilby’s (1988) scale of toxicity testing for assessing the morpho-
logical damage following toxicant exposure. (Adopted from: Murugadas et al. 2016).
Table 2. Scoring system devised by Ambrosone et al. (2014) to measure the morphological
traits in hydra following nanoparticle exposure
Score Morphology Vital state
7 Normal hydra Active
6 Bumped gastric regions, normal tentacles Active
5 Inverted-cone gastric regions,
shortened tentacles
Whitening of gastric region;
paralyzed, slow tentacles
4 Inverted-cone gastric regions, short tentacles Paralyzed, rigid tentacles
3 Gastric region reduced in size, crushed tentacles Permanently damaged to death
2 Further reduced gastric region, without tentacles Abundant cell death
1 Irregular shape Death
0 Dispersed cell clamps and debris Disintegrated
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Impact of Chemicals on Hydra Growth Rate
Hydra primarily reproduces by budding, which is an asexual method of reproduction.
The extent of budding is directly related to food intake. A regular diet maintains the cell
proliferation and budding process, whereas budding ceases when starved. In view of a
regular feeding regime, the epithelial cell lineage that migrates towards both extremities
contributes to bud formation in the gastric region. Thus, growth rate of Hydra is a
balance between length of epithelial cell cycle, phagocytosis of the excess cells, and/or
bud formation (Bosch and David 1984). Quality of the environment, including
chemical contamination, affects the growth rate in Hydra (Lenhoff and Brown 1970).
Methodology
To measure the growth rate of Hydra, four Hydras each with one bud are exposed to
sub-lethal doses of chemical entities for a study period (24 h in case of acute toxicity),
and then washed and placed in multi-well plates, preferably as one Hydra per well.
Control polyps at the same developmental stage are left untreated and maintained
separately. Both treated and untreated Hydras are fed regularly atleast for two weeks
and monitored every day for bud detachment. The growth rate constant (K) is measured
using the formula K = ln (n/n0)/T, where n is the number of animals at time T (day of
experiment), n0 is the number animals at time t0, i.e., starting day of the experiment;
budding rate is calculated as the average number of buds detached per Hydra per day;
T2, the population doubling time, is calculated by linear regression (Ambrosone et al.
2012).
Impact of Chemicals on Hydra’s Regeneration Ability
Hydra is known for remarkable capability of regenerating missing body parts. Hydra
undergoes morphallactic regeneration where the tissue left over in a bisected region is
remodeled to regenerate the missing body structure. Though Hydra has three different
cell lineages, regeneration is taken care by the two epithelial cell lineages. Head
regeneration is rapid after bisection of the tubular body column, wherein complete
regeneration occurs within 72 h.
Teratogenicity testing in Hydra was initially described by Johnson and Gabel
(1983) using dissociated cells of Hydra. Later, Wilby (1988) recommended a new scale
to measure the regeneration of Hydra using gastric region. More recently, Ambrosone
et al. (2012) proposed a new scale to measure head regeneration in Hydra in the
presence of nanoparticles. Here, in the present review, we have summarized the
methods of Ambrosone et al. (2012), and Wilby (1988) to measure the regeneration
capability of Hydra.
Methodology
(i) Ambrosone et al. (2012): To measure the effect of toxicant on Hydra’s head
regeneration capability, groups of polyps are bisected in the upper gastric region and
the body column is allowed to regenerate the missing head region in the presence of
sub-lethal concentrations of the toxicant. Polyps that undergo head regeneration are
examined in a stereo-zoom dissecting microscope at regular time intervals for 72 h, and
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score is assigned based on the regeneration. As seen in Fig. 3a and Table 3, score 0
stands for no regeneration, 1 for emergence of tentacles, 2 for complete head regen-
eration; lethal and disintegration can also be observed.
(ii) Wilby (1988): To measure the chronic toxic effect of a toxicant on Hydra
regeneration, groups of polyps are cut below the hypostome and above the budding
Fig. 3. a. Hydra images representing the scoring system devised by Ambrosone et al. (2012) to
measure the head regeneration in hydra (Adopted from Murugadas et al. 2016). b. Hydra images
representing the scoring system devised by Wilby (1988) for assessing the toxicant induced
inhibition of regeneration of gastric region. (Adopted from Zeeshan et al. 2016)
Table 3. Scoring system devised by Ambrosone et al. (2012) to measure the head regeneration
in hydra
Score Degree of regeneration
0 Lethal or disintegrated
1 No regeneration
2 Emergence of tentacles
3 Complete head regeneration
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region to separate the gastric region, and allowed to regenerate the missing body
portion in the presence of sub-lethal concentrations of the chemical to be tested and the
medium is renewed daily. Initially, the wound healing occurs within 3–6 h and the
emergence of tentacles and basal disc occurs within 36–48 h. The regeneration is
recorded at every 24 h until 72 h of amputation. Score of 10 indicates complete
regeneration and 0 represents mortality; scores from 9 to 1 express various stages of
regeneration (Fig. 3b; Table 4).
However, in most cases, impairment of regeneration in Hydra at sub-lethal con-
centrations is due to the general toxicity as the chemicals/nanoparticle (NPs) can easily
gain access into the Hydra cells via nick at either ends and induce toxicity by
increasing the ROS level or sudden exposure of amputated region to a high concen-
tration of chemicals/NPs can induce cell death.
Impact of Chemicals on Hydra Cell Cycle
Hydra as a whole organism possesses different cell types from three different lineages
(Siebert et al. 2008). The cell cycle of interstitial cells is shorter than that of the
epithelial cells. However, both cell lineages exhibit a similar regulation of cell cycle
with a pause in G2 phase and lack of G1 phase (Buzgariu et al. 2014). Pausing of G2
makes Hydra a potential model to study the impact of pausing of G2 impinging on
regenerative competence. Two major challenging tasks in analyzing the cell cycle of a
multicellular organism are, (i) to dissociate the complex cell types into individual cells,
and (ii) to sort the cells of a similar type based on the marker genes. Cell cycle analysis
overcoming these challenges is still possible, taking advantage of the latest advance-
ments in technologies, and it helps in determining the detrimental effects of chemical
entities and also in designing new drugs.
Table 4. Scoring system of Wilby (1988) for assessing the toxicant-induced inhibition of
regeneration of gastric region
Score Degree of regeneration
10 Mouth, 4–6 tentacles and peduncle
9 Mouth, 4–6 tentacles
8 Mouth, <4 tentacles and basal disc
7 Mouth and <4 tentacles
6 Tentacle buds and basal disc
5 Tentacle buds only
4 Basal disc only
3 Normal wound healing at both ends of gastric region
2 Healed but body expanded
1 Open ends of gastric region/dissected region; not healed or dead
0 Disintegrated
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Methodology
The simplest and most convenient way to dissociate Hydra is to adopt trypsin diges-
tion. After incubation with the toxicant Hydras are rinsed in fresh medium and dis-
sociated in 250 lL of trypsin-EDTA for 5–7 min at 37 °C. Trypsin is inactivated by
addition of 100 lL of fetal calf serum (FCS) to the cell suspension. The cells, at
5 * 105/mL, are fixed in 4% paraformaldehyde and permeabilized using 70% ethanol.
Cells are then stained with 500 lL of hypertonic NP-40 buffer [Propidium Iodide (PI)]
40 lg/mL, RNase A 200 lg/mL, 0.5% NP-40 in PBS), for 15–30 min. The fluores-
cence emission is measured (Buzgariu et al. 2014) on a FACS Calibur II System
(Becton–Dickinson) using an argon-ion laser at 488 nm, together with the forward
scattered (FSC) and side scattered (SSC) parameters. The emitted PI fluorescence is
collected by a 585 nm band pass filter in the FL2 channel. Typically 10,000 events per
sample are collected using the Cell Quest software, and analyzed with FlowJo software
(Tree Star Inc) after excluding debris, clumps (FSC versus SSC) and doublets (signal
area FL2-A versus signal width FL2-W).
Assessment of Cell Death in Hydra by ROS Generation and Apoptosis
Owing to the continuous proliferation of stem cells, excess or dead cells from Hydra
are sloughed off by the programmed cell death, i.e. “apoptosis”. It is well established
that in Hydra apoptotic mode of cell death is conserved (Böttger and Alexandrova
2007). Therefore, Hydra is emerging as an appropriate model organism for drug dis-
covery and biomedical applications. Apoptosis is induced by treatment with chemical
substances or under stressful conditions. Oxidative stress sets in as a consequence of
imbalance between generation of ROS triggered by external factors and the counter-
acting antioxidants in the biological system. Excess ROS cause DNA damage and
failure of DNA repair mechanism and finally ends up in cell death.
Determination of ROS Generation in Hydra by H2-DCFDA Staining
Groups of 6 animals per 6 mL are incubated in medium containing sub-lethal concen-
trations of the chemical substance to be tested, for the defined period, after which the
animals are washed in fresh Hydra medium and incubated with 10 lMH2-DCFDA dye
for 1 h in dark as described by Jantzen et al. (1998). After incubation the polyps are rinsed
in Hydra medium, mounted on 2% urethane, and the green punctae are observe imme-
diately in a fluorescent microscope. For quantification of intracellular ROS level, cell
lysate is prepared by homogenizing the Hydra in PBS. Protein concentration of the cell
lysate is determined using Bradford reagent, with bovine serum albumin (BSA) as the
standard. Intracellular ROS level is determined by incubating the cell lysate with 10 lM
H2-DCFDA dye for 20 min in dark and the fluorescence is read in a fluorometer.
Determination of Apoptosis by Acridine Orange and DAPI Staining
Acridine Orange Staining
Induction of apoptosis at whole animal level can be identified by acridine orange
staining as described by Cikala et al. (1999). Groups of 6 animals per 6 mL are
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incubated in medium containing sub-lethal concentrations of the toxicants to be tested,
for the defined period. After incubation polyps are rinsed in Hydra medium and
incubated with acridine orange (3.3 lM) for 15 min in dark. Polyps are washed ade-
quately with Hydra medium, relaxed in 2% urethane and the green punctae as apoptotic
cells are observed in fluorescent microscope.
4′-6-Diamidino-2-Phenylindole (DAPI) Staining
Apoptosis as single cells in Hydra can be enumerated following DAPI staining as
described by Ambrosone et al. (2012). Groups of 6 animals per 6 mL are incubated in
medium containing sub-lethal concentrations of chemicals for the defined period.
Single cell suspensions are prepared by macerating the Hydras and spreading them on
gelatin-coated microscopic slides. After adequate wash in PBS the cell suspensions are
stained with DAPI for 2 min and washed in PBS. Cells are examined in a phase
contrast fluorescent microscope. Cells, 300–500, are examined for each treatment and
the percentage of apoptosis is calculated for both the untreated and treated cells. The
comparison is necessary since cells in untreated Hydra also would undergo apoptosis
towards maintenance of cell number.
Genotoxicity Assessment in Hydra Following Chemical Exposure
Genotoxicity assessment in an aquatic invertebrate organism would take it to the level
of a good bio-indicator. Chemical substances that affect DNA have serious implications
in many pathological conditions such as carcinogenesis and impairment of reproduc-
tion. Genotoxicity assessment in a multicellular organism is a challenging task as the
organism contains many cell types of different origins. We embarked on dissociation of
toxicant-exposed Hydra into individual cells and address the implications of
chemical/nanoparticle on DNA in individual cells.
Methodology
Hydras are treated with sub-lethal concentrations of the intended chemical for the
specific period. Hydra could be dissociated into individual cells using trypsin-EDTA or
homogenization using a micropipette. In our experience, effective dissociation is
possible in trypsin-EDTA digestion (Murugadas et al. 2016). The resulting cell sus-
pension is mixed with low melting agarose in PBS, and placed on microscopic slides
coated with normal melting agarose. The slides are placed in pre-chilled lysis buffer
(2.5 M NaCl, 100 mM Na2-EDTA, 10 mM Tris, 0.2 mM NaOH [pH 10], 10% DMSO
and Triton X-100) and incubated overnight at 4 °C. Alkaline denaturation and gel
electrophoresis are performed in cold under dim light in freshly prepared elec-
trophoresis buffer (300 mM NaOH, 1 mM Na2-EDTA, [pH > 13]) for 20 min at 20 V.
Then the slides are washed with neutralization buffer (0.4 M Tris, pH 7.5) and
observed in fluorescent microscope. Three hundred cells from each treatment group are
captured and analyzed using CASP software. The extent of DNA damage is measured
according as depicted in Fig. 4 and Table 5.
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Transcriptional Alterations in Hydra Following Chemicals Exposure
It is well demonstrated that chemicals/heavy metals/nanoparticles can interact with
nucleic acids and induce DNA damage and point mutations and alter transcriptional
regulation of important genes governing antioxidant defense system and cell death
(Woo et al. 2012; Murugadas et al. 2016; Zeeshan et al. 2016, 2017). The whole
genome sequencing of Hydra has revealed that it has conserved sequences and sig-
naling pathways of divergent organisms and makes it comparable with the other model
organisms. Thus, toxicant-exposed Hydras can be subjected to RNA isolation, cDNA
synthesis and qPCR to assess the transcriptional alterations, which we intend to
standardize and bring out in our next review.
Conclusion
In view of varied manifestations of emerging pollutants, risk assessment of the
chemical entities before releasing them into the environment is necessary. Hydra as a
model organism is easy to culture, multiplies rapidly by asexual reproduction, cost-
effective, sensitive to inorganic substances, morphological changes can be easily
monitored and classified, and genetically identical twins can be made use of for
reproducible results at transcriptional levels. Its robust nature of whole body regen-
eration from the dissociated cells or gastric region or body column makes Hydra a
suitable organism for teratogenicity testing. A comprehensive study including various
Fig. 4. Images representing the extent of DNA damage as assessed by Comet assay. (Adopted
from Zeeshan et al. 2017)
Table 5. Allocation of empirical scores to cells (categorization of DNA damage and score
allocation)
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end point analyses and expression of biomarker genes can explain the underlying
mechanism of toxicity induced by various chemical substances. Thus, Hydra is an
organism highly suited for aquatic eco-toxicity testing.
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Abstract. The Lush Prize is now in its fifth year and awards a total of
52,000,000 JPY (approx.) annually to initiatives working to end the use of
animals in toxicology testing. There are six categories of award: Science;
Training; Young Researcher; Lobbying and Public Awareness. The sixth cate-
gory is the Lush Black Box Prize which offers, in any one year, a further
38,000,000 JPY (approx.) for a key breakthrough in human toxicology. Many
initiatives are directed at the ‘3Rs’: reduction, refinement, and replacement of
the use of animals. The Lush Prize seeks only to support projects working on the
genuine replacement of animal tests and is the largest reward in its field [1].
In 2016, the Prize is very pleased to announce the launch of its Young
Researcher Asia awards, to welcome young scientists from across Asia, up to 35
years old at time of application, who wish to pursue a career in animal-free
toxicology. Applicants complete a nomination explaining their research pro-
posals, including how they would use a bursary of approx. 1,400,000 JPY. To
date in 2016, a total of 37,800,000 JPY has been awarded to nineteen interna-
tional young researchers for 21st century human-relevant toxicology projects.
The Lush Prize continues to welcome nominations from across the Asia
region, not only for Young Researcher awards, but all other prize categories.
This report aims to provide an overview of the Prize, the categories of award
available, achievements to date and further background information.
Introduction
The Lush Prize was developed to address two urgent goals; firstly, to fund the
development of modern, more reliable methods of human-relevant safety testing and
secondly but equally importantly, to replace unreliable and inhumane animal tests.
Many scientists find that access to funding for research into non-animal tech-
nologies can be a barrier. The Lush Prize wants to change this and encourage young
researchers to develop a career in toxicology without harming animals, by offering
bursaries to allow them to advance in this area. The Lush Prize is now in its fifth year
and awards an annual total of 52,000,000 JPY (approx.) to initiatives working to end
the use of animals in toxicology testing. There are six categories of award: Science;
Training; Young Researcher; Lobbying and Public Awareness. The sixth category is
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the Lush Black Box Prize which offers, in any one year, a further 38,000,000 JPY
(approx.) for a key breakthrough in human toxicology. An overview of the different
categories is provided below.
The Lush Prize Categories
1. Science - For individuals, research teams or institutions for work conducted on
relevant toxicity pathways. Outstanding research producing an effective non-animal
safety test based on an approach other than toxicity pathways, where none existed
before, may also be considered.
2. Young Researchers - Open to scientists (up to 35 years of age at the time of
application) with a desire to fund the next stage of a career in animal free toxi-
cology. (The annual YR prize fund is usually divided between five winners, each
awarded approx 1,400,000 JPY). The Young Researcher prizes are distinct from
other categories as they awarded on the basis of future research proposals, intended
to replace the use of animals. All other categories of prize are awarded on the basis
of past activities and achievements, over the previous 12–18 months.
The Science and Young Researcher Prizes are designed to advance direct research
into non-animal technologies. The Lush Prize is pleased to launch the Young
Researcher Asia Awards at the 2016 JSAAE Congress.
3. Training - For individuals, teams or organisations involved in training others in
non-animal methods. There remains an ongoing, urgent need for education and
training in the use of widely available, human-relevant, non-animal technologies;
communication on this is vital and remains an obstacle to change. Many estab-
lishments or individuals may not have been trained in available, animal-free
methods or might not even be aware of them, while future scientists and students
need to be provided with education in alternative methods, in order to be able to
pursue further research in this area. This prize recognises the importance of relevant
information and hands-on training among commercial scientists, researchers and
students.
The Training Prize is designed to aid resource for projects training scientists or
regulators in non-animal methods.
4. Lobbying - The Lobbying prize rewards exceptional individuals, groups or
organisations pushing for change, focusing on policy interventions promoting the
replacement or end of animal tests. These may include science-based lobbying at
national or international level, for example to recognise non-animal testing methods
in national or international (e.g. Organisation for Economic and Cooperative
Development (OECD) programmes of test guidelines [2], removal of animal tests
and achieving mandatory requirements for non-animal methods in legislation,
regulatory policies and testing guidelines.
5. Public Awareness - Organisations and individuals working to raise awareness on
both the ongoing suffering associated with animal testing and the scientific need for
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its replacement are recognised by the Public Awareness prize. Winners are awarded
for their work in ensuring that these issues remain high on the public agenda.
The Public Awareness and Lobbying Prizes are designed to maintain pressure and
influence, to ensure regulation is updated to reflect advances in 21st-Century toxicology.
The Black Box Prize
A special sixth category of prize is the Black Box Prize. It may offer a full 38,000 000
JPY (approx.) in any one year, for a key breakthrough in research into pathways of
human toxicity in response to chemicals, replacing the use of animals.
The first Black Box prize was awarded in 2015, to several individuals and
organisations for their achievements in the development of new in-vitro test methods
which elucidated the Adverse Outcome Pathway (AOP) for skin sensitisation, now
accepted at OECD level [3].
The Lush Prize Is a ‘1R’ Initiative
Many funding schemes are devoted to ‘the 3Rs’; Reduction, Refinement, Replacement
of the use of animals in experiments. However, as ‘reduction’ and ‘refinement’
methods still involve animals, the Lush Prize only supports projects working towards
the ‘1R’- the complete replacement of animal tests. It is the largest prize fund in the
world devoted to this initiative.
Launch of Lush Prize ‘Young Researcher Asia’ Awards
in 2016
In 2016, the Prize is very pleased to announce the launch of its Young Researcher Asia
Awards and welcomes young scientists from across Asia, up to 35 years old at time of
application, whowish to pursue a career in animal-free toxicology. Applicants complete a
nomination explaining their research proposals, including how they would use a bursary
of approx. 1,400,000 JPY. To date in 2016, a total of 37,800,000 JPY has been awarded to
nineteen international young researchers for human-relevant toxicology projects. Our
2016 Young Researcher Award winning projects [4] include research themes of;
• Development of innovative 3D human skin models to test cosmetics
• Human tissue-derived test methods to assess how chemicals cause hepatotoxicity
• Establishment of human based in vitro methods to test dental and medical devices.
Projects Funded by the Lush Prize to Date
• 8 international scientific organisations for projects including human lung cancer
tissue culture models, body-on-a chip systems, ‘omics’ technology-derived data
126 R. Ram
from analysis of human in-vitro and in-silico models, QSARs (Quantitative
Structure Activity Relationships) and work on toxicity pathways in heptatoxicity
and developmental toxicity.
• 32 young researchers and early career scientists from across the world, with bur-
saries totalling more than 40,000,000 JPY.
• 8 outstanding Training prize winning organisations, for projects including prepa-
ration and delivery of training workshops and webinars, outreach and communi-
cation in universities and educational establishments across the world and direct
delivery of ‘hands-on’ training in non-animal methods in China.
• 11 Public Awareness projects (total more than 45,000,000 JPY) for breakthrough
investigational campaigns highlighting the suffering of non-human primates, cats
and dogs; initiatives to end toxicity testing in the USA, Switzerland, China, Russia,
Canada and Japan and finally, campaigns on banning animal tested cosmetics in
Taiwan, Australia and New Zealand.
• 10 Policy makers, political figures and scientific organisations devoted to alterna-
tives to animal testing from the USA, Sweden, Germany, New Zealand, Brazil and
India have been awarded more than 45,000,000 JPY in Lobbying Prize funding to
date.
Since its launch in 2012, the Lush Prize has awarded over 210,000,000 JPY to
bring forward the day when safety testing takes place using only human- based
methods, without animals.
Past nominations have been welcomed from across Japan, South Korea, China,
Taiwan, Singapore and Malaysia. In 2016, a record number of nominations 55
projects/scientists from 21 countries, including Japan, South Korea, China and Sin-
gapore [5]. The prize welcomes many future nominations from across the Asia region
and worldwide.
Many initiatives are directed at the ‘3Rs’: reduction, refinement, and replacement of
the use of animals. The Lush Prize seeks only to support projects working on the
genuine replacement of animal tests and is the largest reward in its field.
Nominations open for the Lush Prize open in March each year. Any individual(s) or
organisation who wish to apply must submit a full nomination form by the June
deadline. Judging is carried out by an independent panel of experts from around the
world – scientists, lobbyists and campaigners. Winners participate in a conference and
attend a prestigious awards ceremony. Full details of the Young Researcher Award [6]
and other award categories are available on the Lush Prize website [1].
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